Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
Phase: PHASE3
Conditions: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Sponsor: Hoffmann-La Roche

Official Title: 
RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL 
STUDY OF ALECTINIB VERSUS CRIZOTINIB IN ASIAN 
PATIENTS WITH TREATMENT-NAIVE ANAPLASTIC 
LYMPHOMA KINASE−POSITIVE ADVANCED NON−SMALL 
CELL LUNG CANCER  
NCT Number: 
NCT02838420 
Document Date: 
Protocol Amendment/Version 3: 23-Mar-17 

PROTOCOL AMENDMENT APPROVAL 
CONFIDENTIAL 
This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, 
Switzerland.  However, it may be implemented in individual countries by Roche’s local affiliates, 
including Genentech, Inc. in the United States.  The information contained in this document, especially 
any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
you, your staff, and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from Roche except to the 
extent necessary to obtain informed consent from persons to whom the drug may be administered. 
Alectinib—F. Hoffmann-La Roche Ltd 
Protocol YO29449, Version 3 
TITLE: 
PROTOCOL NUMBER: 
VERSION NUMBER: 
TEST PRODUCT: 
PROTOCOL 
RANDOMIZED, MULTICENTER, PHASE III, 
OPEN-LABEL STUDY OF ALECTINIB VERSUS 
CRIZOTINIB IN ASIAN PATIENTS WITH 
TREATMENT-NAIVE ANAPLASTIC LYMPHOMA 
KINASE−POSITIVE ADVANCED NON−SMALL CELL 
LUNG CANCER 
YO29449 
3 
Alectinib (RO5424802) 
MEDICAL MONITOR: 
, M.D. 
SPONSOR: 
F. Hoffmann-La Roche Ltd
DATE FINAL: 
22 January 2015
DATE AMENDED: 
Version 2:  4 February 2016
Version 3:  See electronic date stamp below.
23-Mar-2017 23:55:35
Title
Approver's Name
Company Signatory (Clinical)
Date and Time (UTC)

Alectinib—F. Hoffmann-La Roche Ltd 
2/Protocol YO29449, Version 3 
PROTOCOL AMENDMENT, VERSION 3: 
RATIONALE 
Protocol YO29449 has been amended to revise the primary analysis timepoint and the 
tumor and response assessment. 
The major changes to the protocol are as follows: 
•
Tumor and response assessment: deleted the requirement for confirmation of
response in Section 4.5.7, as described below:
An objective response should be confirmed by repeat assessments 4 weeks after
the initial documentation.  It is recommended that the confirmatory tumor
assessment not be left until the next scheduled CT scan, but be performed as soon
as possible following the 28-day interval from the initial documentation of response.
•
Safety-related changes:
In Section 4.4.2, restrictions related to concomitant medications known to prolong
the QT interval have been modified.  The restriction is no longer required for
alectinib-treated patients on the basis of the detailed evaluation of the pooled
electrocardiogram (ECG) data from the two pivotal Studies NP28761 and NP28673
and ECG data from the supportive Study AF-001JP, which showed no evidence that
alectinib caused any clinically relevant QTcF prolongation.  Furthermore, there was
no apparent correlation between the change in QTcF and alectinib plasma
concentration.  For crizotinib-treated patients, this restriction still applies.  For the
same reason, the guideline for management of specific adverse events related to
QT prolongation in alectinib-treated patients has been removed from Table 3.
In Section 5.1.2.3, the section title “Hematologic Abnormalities” has been changed
to “Anemia.”  This aligns with the alectinib Investigator’s Brochure (IB), Version 7.
The guideline for management of specific adverse events related to hematological
abnormalities in alectinib-treated patients has been removed accordingly.  Should
adverse events be categorized as “hematological abnormalities,” appropriate
management of the adverse events is already covered by the guideline “Other AEs
or Laboratory Abnormalities,” also included in Table 3.
•
In Section 6.1, the primary analysis timepoint was revised, as described below:
The primary objective of the study is to determine whether the benefit (in terms of
investigator-assessed progression-free survival [PFS]) of administrating alectinib in
this study is consistent with the benefit observed in the global Study BO28984
(ALEX).  Consistency is defined as maintaining ≥ 50% of risk reduction from
Study ALEX.  The number of PFS events required to show consistency depends on
the hazard ratio (HR) observed in the ALEX trial.  The primary analysis of PFS will
occur when as early as required PFS events show that consistency has occurred.  If
the number of PFS events is not enough for the estimation of median PFS, an
updated PFS analysis will be done when approximately 55% of patients have had
PFS events.  The first survival analysis will be performed together with the primary
PFS analysis.  A survival follow-up analysis will be performed when approximately
55% of patients have died.

Alectinib—F. Hoffmann-La Roche Ltd 
3/Protocol YO29449, Version 3 
Other minor changes have been made to improve clarity and consistency and/or to align 
language with the updated model document (Sections 5.3.5.7, 5.3.5.10, 9.2, and 9.5).  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol. 

Alectinib—F. Hoffmann-La Roche Ltd 
4/Protocol YO29449, Version 3 
 
PROTOCOL AMENDMENT, VERSION 3: 
SUMMARY OF CHANGES 
GLOBAL CHANGES 
The Medical Monitor was changed from 
 M.D., Ph.D. to 
 
M.D., throughout. 
PROTOCOL SYNOPSIS 
The protocol synopsis has been updated to reflect the changes to the protocol, where 
applicable. 
SECTION 2.1:  EFFICACY OBJECTIVES 
This objective is to reliably determine whether the benefit (in terms of PFS) of 
administrating alectinib in this study is consistent with the benefit observed in the global 
Study ALEX (BO28984). 
SECTION 2.5:  EXPLORATORY OBJECTIVES 
The exploratory objectives for this study are as follows: 
• 
To investigate detection of mutations in ALK and other genes involved in cancer in 
plasma, refer to Appendix 12 for detailed information. 
 
SECTION 3.1:  DESCRIPTION OF STUDY 
Approximately 183 patients (122 in the alectinib treatment arm and 61 in the crizotinib 
treatment arm) will be enrolled into the study over a planned recruitment period of 14 
13 months.  Patients who are inappropriately randomized into the study will not be 
replaced.  With the current assumption that hazard ratio is 0.65, Tthe final 
primary analysis that will evaluate the primary endpoint of investigator-assessed PFS is 
expected to occur approximately 24 23 months after the first patient has been enrolled 
when approximately 97 PFS events have occurred. 
SECTION 3.1.1:  Independent Review Committee 
An IRC will be established to perform an independent review of all radiological scans for 
the final primary analysis and to determine the response and disease progression on 
the basis of the RECIST v1.1 in addition to the local investigator’s review of 
radiographs…. The IRC’s assessment will only be used in the final primary analysis. 
Sites will submit radiological files to the centrally located IRC’s data review facility during 
the study on an ongoing basis or at the Sponsor’s request for final primary analysis.  
For the final primary analysis, the IRC will perform an independent review of the 
computed tomography (CT) and magnetic resonance imaging (MRI) scans on the basis 
of a prespecified Charter to determine the response and disease progression on the 
basis of the RECIST v1.1. 

Alectinib—F. Hoffmann-La Roche Ltd 
5/Protocol YO29449, Version 3 
 
SECTION 3.2:  END OF STUDY 
This study is event driven, with a recruitment period of approximately 14 months.  The 
required number of 97 PFS events for the final analysis of the primary endpoint is 
expected to occur approximately 24 months after the first patient has been enrolled.  
Follow-up for survival information will continue until the survival follow-up analysis or the 
Sponsor decides to end the study, whichever occurs first.  A survival follow-up analysis 
will be performed when approximately 50% of the patients have died, which is estimated 
to occur approximately 40 months after the first patient has been enrolled. 
This is an event-driven study.  With the current assumption that the HR is 
0.65 and the recruitment period is 13 months, the required 97 PFS events for 
primary efficacy analysis is expected to occur 23 months after the first patient 
has been enrolled.  If the number of PFS events is not enough for the estimation 
of median PFS, an updated PFS analysis will be done when approximately 55% 
of patients have had PFS events.  A survival follow-up analysis will be 
performed when approximately 55% of patients have died, which is estimated to 
occur 41 months after the first patient has been enrolled. 
Only serious adverse events will be reported after the survival follow-up analysis has 
been completed.   
SECTION 3.3.4:  Rationale for Open-Label Design 
These include performing sensitivity analyses to demonstrate the robustness of the 
primary endpoint, defining disease progression with the use of established response 
evaluation criteria (RECIST v1.1), performing tumor assessment at the same frequency 
in both treatment arms, adhering to protocol-defined schedules, and finalizing the 
strategy for the final primary analysis of the primary endpoint before initiating this study, 
which include predefined methods for handling missing data and censoring rules.  
Efficacy analyses will be performed only at the prespecified analysis timepoints in the 
protocol (final primary analysis will be performed when 97 PFS events have occurred, 
and survival follow-up analysis will be performed when 92 101 OS events have occurred) 
SECTION 4.1.1:  Inclusion Criteria 
Patients must meet the following criteria for study entry: 
• 
… Examples of non-hormonal contraceptive methods with a failure rate of < 1% per 
year include tubal ligation, male sterilization, hormonal implants, established, proper 
use of combined oral or injected hormonal contraceptives, and certain intrauterine 
devices.… 
SECTION 4.1.2:  Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from study entry: 
• 
Administration of agents with potential QT-prolonging effects within 14 days prior to 
receiving the first dose of study drug and during treatment (see Section 4.4.2 for 
further details)… 

Alectinib—F. Hoffmann-La Roche Ltd 
6/Protocol YO29449, Version 3 
 
• 
Pregnant or lactating women 
 
SECTION 4.4.2:  Prohibited Therapy 
… Exceptions to the below listed concomitant therapies restrictions (e.g., prescription 
drugs, over-the-counter drugs, herbal or homeopathic remedies, nutritional supplements) 
may be made only if the rationale is discussed and documented between the 
investigator and the Sponsor’s Clinical Pharmacologist. 
• 
Any concomitant medications known to affect QT interval duration, including but not 
limited to the following drugs:  amiodarone, cisapride, clarithromycin, methadone, 
and quinidine within 2 weeks prior to the first dose of study drug treatment, during 
for all patients, and while on treatment with study drugs, and through the end of the 
study for crizotinib-treated patients only 
 
SECTION 4.5.7:  Tumor and Response Evaluations 
Disease burden must be documented at screening and re-assessed at each subsequent 
tumor evaluation.  Response will be assessed by the investigator based on physical 
examinations.  Clinical lesions will be, radiographic imaging, and other modalities, and 
documented by color photography (with caliper measurement for measurable lesions) or 
measurements by CT scans, and other modalities (e.g., MRI, brain scans), with the use 
of RECIST v1.1 (see Appendix 4).  An objective response should be confirmed by repeat 
assessments ≥ 4 weeks after the initial documentation.  It is recommended that the 
confirmatory tumor assessment not be left until the next scheduled CT scan, but be 
performed as soon as possible following the 28-day interval from the initial 
documentation of response. 
SECTION 4.5.8.1:  Laboratory Assessments 
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis: 
• 
Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, 
absolute differential count or percentage [neutrophils, eosinophils, lymphocytes, 
monocytes, basophils, other cells, etc.]) 
• 
Serum chemistry (sodium, potassium, chloride, bicarbonate or total CO2, fasting 
glucose… 
 
SECTION 4.5.8.2:  Pretreatment Tumor Samples (Mandatory) 
Tumor blocks (formalin-fixed, preferred 10% neutral-buffered formalin) are the preferred 
source, but if blocks are not available, 7 unstained 5-µm slides cut < 3 months before 
screening are also accepted. acceptable for ALK IHC testing.   
For cases where tumor blocks have been submitted, an additional 8 6 slides (optional 
sample collection) will be cut from blocks submitted for randomized patients.  For cases 
where slides have been submitted for screening, an additional 6 slides are desired for 
tumor nucleic acid sequencing. Pretreatment tumor samples may be used for DNA 
and/or RNA extraction to investigate mechanisms of enable Next Generation 

Alectinib—F. Hoffmann-La Roche Ltd 
7/Protocol YO29449, Version 3 
 
Sequencing (NGS) to identify somatic mutations that are associated with disease 
progression or acquired resistance to ALK inhibitors. alectinib and to add to researchers' 
understanding of disease pathobiology.  These samples will not be collected in countries 
/sites where the regulatory agency or the Institutional Review Board (IRB) does not 
allow this testing.  Any remaining tumor blocks of from screen-failed patients will be 
returned to the sites within 3-4 months of receipt at Sponsor-designated central 
laboratory, and any remaining tumor blocks from randomized screen-failed patients will 
be returned to the sites before the final closure of the clinical database; slides will not be 
returned.… 
Pretreatment tumor samples may be used for DNA and/or RNA extraction to enable 
Next Generation Sequencing (NGS) to identify somatic mutations that are associated 
with disease progression or acquired resistance to alectinib and to add to researchers' 
understanding of disease pathobiology. 
SECTION 4.5.8.3:  Post-Treatment Tumor Samples (Optional) 
These samples may allow a greater understanding of the molecular mechanisms of 
resistance to ALK inhibitors and genes involved in cancer.  Any remaining tumor blocks 
of randomized patients will be returned to the sites before the final closure of the 
clinical database.  Slides will not be returned. 
SECTION 4.5.8.4:  Blood and Plasma Samples 
Mandatory plasma samples for biomarker analysis will be obtained to determine: 
• 
ALK rearrangement determination by plasma ALK quantitative reverse transcription 
polymerase chain reaction.  This will require 20 mL of blood at screening from all 
screened patients. 
• 
Mutations Mutation status in ALK and other escape genes (e.g., EGFR, KRAS).  
This will require 20 mL of blood (two tubes of 10 mL each) to be collected at 
baseline, at Treatment Visit 7 (Week 16), and subsequently at every second 
treatment visit (every 16 weeks) [see Appendix 1 for detailed information] until and 
at disease progression (CNS and during treatment post-/or systemic disease 
progression in case of isolated, asymptomatic progression of disease in the CNS.  
For sample handling procedures, storage conditions, and shipment instructions, see 
the laboratory manual.  ) or treatment discontinuation for any reasons.  
• 
These samples will not be collected in countries/or sites where the regulatory 
agency or the IRB does not allow genetic testing. 
 
For biomarkers, a maximum of 20 mL of blood will be collected at screening (for 
determination of ALK rearrangement), and a maximum of 20 mL of blood will be 
collected at baseline, at Visit 7 (Week 16), subsequently at every second visit (every 
16 weeks), and at disease progression (CNS and/or systemic disease progression).  
These plasma samples (baseline and subsequent visits) will be used for determination of 
mutation status in ALK and other escape genes. 

Alectinib—F. Hoffmann-La Roche Ltd 
8/Protocol YO29449, Version 3 
 
All the biomarker samples described in Sections 4.5.8.2, 4.5.8.3, and 4.5.8.4 will be 
stored for 5 years after the date of final closure of the associated clinical database. 
SECTION 4.5.9:  Electrocardiograms 
To have a consistent approach for the RR and QTcF, it was decided that the calculation 
of RR and QTcF will be done by the Sponsor using the formulae provided in 
Appendix 11.  The results will be populated in the eCRF for use by the investigator. 
If any ECG abnormality is associated with an adverse event, it must be recorded and 
managed as described in Section 5.  Management of QT interval prolongation should be 
performed according to the guidance provided in Section 5.1.3. 
If considered appropriate by the Sponsor, ECG recordings may be analyzed 
retrospectively at a central laboratory.  Guidance for abnormal ECG test results 
(QT prolongation) is provided in Table 3. 
SECTION 5.1.2.3:  Hematologic Abnormalities Anemia 
Hematologic abnormalities Cases of neutropenia, leukopenia, thrombocytopenia, and 
anemia have been reported in patients treated with alectinib administration.  Neutrophil 
counts generally decreased early and remained stable thereafter; the majority of the 
events were Grade 1 or 2. 
SECTION 5.1.2.8:  Cardiovascular Effects Bradycardia 
QT interval prolongation appears to be an off-target class effect of some TKIs, 
including the ALK inhibitor crizotinib and ceritinib (Shah et al. 2013; 
XALKORI U.S. Package Insert; ZYKADIA U.S. Package Insert).  Many TKIs have 
been associated with bradycardia and hypertension. 
In an in vitro study of the cardiovascular system, alectinib inhibited the human 
Ether-a-go-go−Related Gene (hERG) current (IC20: 58 ng/mL; IC50: 217 ng/mL).  
Because plasma protein binding by alectinib is ≥ 99%, the plasma concentration of 
alectinib that is required to induce the same inhibition in vivo would be ≥ 100 times 
greater than the concentration required in vitro.  In the monkey telemetry study, there 
were no effects on the ECG or any of the other cardiovascular parameters or body 
temperature at doses of up to 15 mg/kg (mean Cmax: 279 ng/mL). 
SECTION 5.1.3:  Management of Specific Adverse Events with Alectinib 
Table 3:  Guidelines for Management of Specific Adverse Events with 
Alectinib 
Table 3 has been updated to reflect changes to the protocol. 
SECTION 5.3.5.7:  Deaths 
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 

Alectinib—F. Hoffmann-La Roche Ltd 
9/Protocol YO29449, Version 3 
 
reported.  The term "sudden death" should be used only for the occurrence of an 
abrupt and unexpected death due to presumed cardiac causes in a patient with or 
without preexisting heart disease within 1 hour after the onset of acute symptoms or, in 
the case of an unwitnessed death, within 24 hours after the patient was last seen alive 
and stable.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death" should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should 
be replaced by the established cause of death.  The term "sudden death" should not 
be used unless combined with the presumed cause of death (e.g., "sudden cardiac 
death"). 
SECTION 5.3.5.10:  Hospitalization or Prolonged Hospitalization 
The following hospitalization scenarios are not considered to be adverse events: An 
event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event:… 
The following hospitalization scenarios are not considered to be serious adverse events 
but should be reported as adverse events instead: An event that leads to hospitalization 
under the following circumstances is not considered to be a serious adverse event, but 
should be reported as an adverse event instead:… 
SECTION 5.4.1:  Emergency Medical Contacts 
Medical Monitor (Roche Medical Responsible) Contact Information 
Medical Monitor: 
, M.D., Ph.D. 
Email:   
 
Telephone No.: 
(office)
Mobile Telephone No.: 
SECTION 6:  STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN 
The primary objective of the study is to determine whether the benefit (in terms of 
investigator-assessed PFS) of administrating alectinib in this study is consistent with 
the benefit observed in global study ALEX.   Consistency is defined as 
maintaining ≥ 50% of risk reduction from ALEX.  The final analysis of number of PFS 
events required to show consistency depends on the HR observed in the ALEX trial.  
The required number of PFS events to achieve approximate 87% probability to meet 
consistency criteria is listed as below. 
The primary endpoint analysis of PFS will occur when as early as 97required PFS 
events to show consistency have occurred, based on the investigators’ assessments.  
On the basis of the assumptions outlined in Section 6.1, this is estimated to occur 
approximately 24 months after. If the number of PFS events is not enough for the 
estimation of median PFS, an updated PFS analysis will be done when approximately 
55% of patients have had PFS events.   

Alectinib—F. Hoffmann-La Roche Ltd 
10/Protocol YO29449, Version 3 
 
The first patient has been enrolled.  survival analysis will be performed together with 
the primary PFS analysis.  A survival follow-up analysis will be performed when 
approximately 50% of patients (i.e., 92 55% patients) have died, which is estimated to 
occur approximately 40 months after the first patient has been enrolled. 
Table 7:  Required Number of PFS Events to Show Consistency 
 Table 7 has been added to reflect changes to the protocol. 
SECTION 6.1:  DETERMINATION OF SAMPLE SIZE 
…The primary objective of the study is to reliably determine whether the benefit (in terms 
of PFS) of administrating alectinib in this study is consistent with the benefit observed in 
the global Study ALEX.  Consistency is defined as maintaining ≥ 50% of risk reduction 
from Study ALEX.  That is, assuming the estimated PFS HR for Study BO28984 the 
ALEX trial is 0.65 (i.e., 35% risk reduction), if the point estimate of HR from 
Study YO29449 this study is less than 0.83, then the study’s primary objective to 
demonstrate consistency is met. 
Based on the assumption of PFS HR = 0.65, a total of 97 PFS events are required to 
achieve approximately 87% probability to show consistency. In this study, 183 patients 
will be enrolled in a 2:1 randomization allocation.  Based on the assumption that the 
median PFS is 10.9 months for the crizotinib arm and 16.8 months for the alectinib arm 
(HR = 0.65) and patients are to be enrolled over approximately 14 13 months; the final 
PFS analysis is expected to occur approximately 24 23 months after the first patient is 
enrolled. 
The first survival analysis will be performed together with the primary PFS analysis.  A 
survival follow-up analysis will be performed once approximately 50 55% of patients 
have died.  The median OS in the crizotinib arm is assumed to be 24 months, and the 
expected median OS in the alectinib treatment arm is 30 months, equating to an HR 
of 0.8.  At the time of the final analysis of the primary endpoint of investigator-assessed 
PFS, on the basis of the above assumptions, 61 OS events are expected to have 
occurred.  The survival follow-up analysis is expected to occur approximately 40 41 
months after the first patient has been enrolled. 
SECTION 6.4.1:  Primary Efficacy Endpoint 
…The stratification factors are the randomization stratification factors:  ECOG PS (0/1 vs. 
2) and CNS metastases at baseline (yes vs. no), as recorded on the eCRF.  Point 
estimate of the adjusted HR will be compared with the consistency threshold (observed 
HR in Study BO28984 the ALEX trial). 
The treatment comparison of PFS will also be assessed and tested based on a stratified 
log-rank test at the 5% level of significance (two-sided) to demonstrate the strength of 
consistent trend.… 

Alectinib—F. Hoffmann-La Roche Ltd 
11/Protocol YO29449, Version 3 
 
SECTION 6.4.2:  Secondary Efficacy Endpoints 
PFS by IRC 
An analysis of PFS on the basis of the IRC assessments will be performed using the 
same methodology as specified for PFS on the basis of investigator assessment. 
SECTION 6.4.3:  Sensitivity Analyses 
The following sensitivity analyses analysis will be performed on the primary endpoint of 
PFS: 
• 
The effect of non−protocol-specified anti-cancer therapy before progression will be 
assessed by censoring patients at the last adequate tumor assessment before the 
start of non−protocol-specified anti-cancer therapy. 
• 
The effect of missing tumor assessments will be assessed if the number of missing 
assessments in either arm is > 5%.  For patients with progression determined 
following one or more missing tumor assessments, the progression will be 
backdated to the first missing tumor assessment. 
• 
The effect of patient’s loss to follow-up will be assessed depending on the number 
of patients who are lost to follow-up.  If > 5% of patients are lost to follow-up for PFS 
in either treatment arm, a “worst-case” analysis will be performed in which patients 
who are lost to follow-up will be considered to have progressed at the last date they 
were known to be progression-free. 
 
SECTION 6.7.1:  Time to Deterioration of Patient-Reported Lung Cancer 
Symptoms 
Additional details regarding the TTD analyses will be included within the SAP. 
SECTION 6.7.2:  Additional Patient-Reported Outcomes 
Additional details regarding the PRO analyses will be included within the SAP. 
SECTION 8.2:  INFORMED CONSENT 
The Informed Consent Form will contain a separate section that addresses the use of 
remaining mandatory samples for optional exploratory research.  The investigator or 
authorized designee will explain to each patient the objectives of the exploratory 
research.  Patients will be told that they are free to refuse to participate and may 
withdraw their specimens at any time and for any reason during the storage period.  A 
separate, specific signature will be required to document a patient's agreement to allow 
any remaining specimens to be used for exploratory research.  Patients who decline to 
participate will not provide a separate signature. 
SECTION 9.2:  PROTOCOL VIOLATIONS 
The Sponsor will review all protocol deviations and assess whether any represent a 
serious breach of Good Clinical Practice guidelines and require reporting to health 
authorities.  As per the Sponsor's standard operating procedures, prospective requests 
to deviate from the protocol, including requests to waive protocol eligibility criteria, are 
not allowed. 

Alectinib—F. Hoffmann-La Roche Ltd 
12/Protocol YO29449, Version 3 
 
 
SECTION 9.5:  PUBLICATION OF DATA AND PROTECTION OF TRADE 
SECRETS 
For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data 
at the following Web site: 
http://www.rochetrials.com/pdf/RocheGlobalDataSharingPolicy.pdfhttp://www.roche.com
/roche_global_policy_on_sharing_of_clinical_study_information.pdf 
APPENDIX 1:  Schedule of Assessments 
Appendix 1 has been modified to reflect the changes to the protocol. 
SAMPLE INFORMED CONSENT FORM 
The sample Informed Consent Form has been revised to reflect the changes to the 
protocol. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
13/Protocol YO29449, Version 3 
 
 
TABLE OF CONTENTS 
PROTOCOL AMENDMENT ACCEPTANCE FORM .......................................... 21 
PROTOCOL SYNOPSIS .................................................................................... 22 
1. 
BACKGROUND .......................................................................................... 33 
1.1 
Background on Anaplastic Lymphoma 
Kinase−Positive Non−Small Cell Lung Cancer ...................... 33 
1.2 
Background on Alectinib ........................................................ 36 
1.3 
Study Rationale and Benefit-Risk Assessment ...................... 41 
2. 
OBJECTIVES .............................................................................................. 43 
2.1 
Efficacy Objectives ................................................................ 43 
2.2 
Safety Objective .................................................................... 44 
2.3 
Pharmacokinetic Objective .................................................... 44 
2.4 
Patient-Reported Outcome Objectives .................................. 44 
2.5 
Exploratory Objectives ........................................................... 45 
3. 
STUDY DESIGN ......................................................................................... 45 
3.1 
Description of Study .............................................................. 45 
3.1.1 
Independent Review Committee ............................................ 47 
3.2 
End of Study .......................................................................... 48 
3.3 
Rationale for Study Design .................................................... 48 
3.3.1 
Rationale for Alectinib Dosage .............................................. 48 
3.3.2 
Rationale for Patient Population ............................................ 49 
3.3.3 
Rationale for Control Group ................................................... 50 
3.3.4 
Rationale for Open-Label Design .......................................... 51 
3.3.5 
Rationale for Primary Endpoint Selection .............................. 52 
3.3.6 
Rationale for Secondary Endpoint of Time to 
CNS Progression ................................................................... 53 
3.3.7 
Rationale for Alectinib Pharmacokinetic Sample 
Collection Schedule ............................................................... 54 
3.3.8 
Rationale for Biomarker Assessments ................................... 54 
3.3.9 
Rationale for Patient-Reported Outcome 
Assessments ......................................................................... 55 
3.4 
Outcome Measures ............................................................... 56 

 
Alectinib—F. Hoffmann-La Roche Ltd 
14/Protocol YO29449, Version 3 
 
3.4.1 
Efficacy Outcome Measures .................................................. 56 
3.4.2 
Safety Outcome Measures .................................................... 56 
3.4.3 
Pharmacokinetic Outcome Measures .................................... 57 
3.4.4 
Patient-Reported Outcome Questionnaires ........................... 57 
3.4.5 
Exploratory Outcome Measures ............................................ 58 
4. 
MATERIALS AND METHODS .................................................................... 58 
4.1 
Patients .................................................................................. 58 
4.1.1 
Inclusion Criteria .................................................................... 58 
4.1.2 
Exclusion Criteria ................................................................... 59 
4.2 
Method of Treatment Assignment and Blinding ..................... 61 
4.3 
Study Treatment .................................................................... 61 
4.3.1 
Formulation, Packaging, and Handling .................................. 61 
4.3.1.1 
Alectinib ................................................................................. 61 
4.3.1.2 
Crizotinib ................................................................................ 61 
4.3.2 
Dosage, Administration, and Compliance .............................. 62 
4.3.2.1 
Alectinib ................................................................................. 62 
4.3.2.2 
Crizotinib ................................................................................ 62 
4.3.3 
Investigational Medicinal Product Accountability ................... 62 
4.3.4 
Post-Study Access to Alectinib .............................................. 63 
4.4 
Concomitant Therapy ............................................................ 63 
4.4.1 
Permitted Therapy ................................................................. 63 
4.4.2 
Prohibited Therapy ................................................................ 65 
4.4.3 
Prohibited Food ..................................................................... 66 
4.5 
Study Assessments ............................................................... 66 
4.5.1 
Informed Consent Forms and Screening Log ........................ 66 
4.5.2 
Medical History and Demographic Data ................................ 66 
4.5.3 
Corticosteroid Use for CNS Metastases ................................ 66 
4.5.4 
Physical Examinations ........................................................... 67 
4.5.5 
Vital Signs .............................................................................. 67 
4.5.6 
Eastern Cooperative Oncology Group 
Performance Status ............................................................... 67 
4.5.7 
Tumor and Response Evaluations ......................................... 67 

 
Alectinib—F. Hoffmann-La Roche Ltd 
15/Protocol YO29449, Version 3 
 
4.5.8 
Laboratory, Biomarker, and Other Biological 
Samples ................................................................................. 69 
4.5.8.1 
Laboratory Assessments ....................................................... 69 
4.5.8.2 
Pretreatment Tumor Samples (Mandatory) ........................... 69 
4.5.8.3 
Post-Treatment Tumor Samples (Optional) ........................... 70 
4.5.8.4 
Blood and Plasma Samples ................................................... 70 
4.5.8.5 
Samples for Alectinib Pharmacokinetic 
Assessments ......................................................................... 71 
4.5.9 
Electrocardiograms ................................................................ 72 
4.5.10 
Patient-Reported Outcomes .................................................. 73 
4.6 
Patient, Treatment, Study, and Site 
Discontinuation ...................................................................... 73 
4.6.1 
Patient Discontinuation .......................................................... 73 
4.6.2 
Study Treatment Discontinuation ........................................... 73 
4.6.3 
Study and Site Discontinuation .............................................. 74 
5. 
ASSESSMENT OF SAFETY ....................................................................... 74 
5.1 
Safety Plan ............................................................................ 74 
5.1.1 
Adverse Events Collection ..................................................... 74 
5.1.2 
Adverse Events Relating to ALK Inhibitors and/or 
the Tyrosine Kinase Inhibitor Class and Alectinib 
Data ....................................................................................... 75 
5.1.2.1 
Interstitial Lung Disease ........................................................ 75 
5.1.2.2 
Hepatotoxicity ........................................................................ 75 
5.1.2.3 
Anemia .................................................................................. 75 
5.1.2.4 
Gastrointestinal Disorders ..................................................... 76 
5.1.2.5 
Skin Disorders ....................................................................... 76 
5.1.2.6 
Vision Disorders .................................................................... 76 
5.1.2.7 
Edema ................................................................................... 77 
5.1.2.8 
Bradycardia ........................................................................... 77 
5.1.2.9 
Abnormal Renal Function ...................................................... 77 
5.1.2.10 
Severe Myalgia and CPK Elevations ..................................... 78 
5.1.3 
Management of Specific Adverse Events with 
Alectinib ................................................................................. 79 
5.1.4 
Safety of Crizotinib and Management of Adverse 
Events.................................................................................... 84 

 
Alectinib—F. Hoffmann-La Roche Ltd 
16/Protocol YO29449, Version 3 
 
5.2 
Safety Parameters and Definitions ........................................ 86 
5.2.1 
Adverse Events ..................................................................... 87 
5.2.2 
Serious Adverse Events (Immediately Reportable 
to the Sponsor) ...................................................................... 87 
5.2.3 
Non-Serious Adverse Events of Special Interest 
(Immediately Reportable to the Sponsor) .............................. 88 
5.3 
Methods and Timing for Capturing and 
Assessing Safety Parameters ................................................ 88 
5.3.1 
Adverse Event Reporting Period ........................................... 88 
5.3.2 
Eliciting Adverse Event Information ....................................... 89 
5.3.3 
Assessment of Severity of Adverse Events ........................... 89 
5.3.4 
Assessment of Causality of Adverse Events ......................... 90 
5.3.5 
Procedures for Recording Adverse Events ............................ 91 
5.3.5.1 
Diagnosis versus Signs and Symptoms................................. 91 
5.3.5.2 
Adverse Events That are Secondary to Other 
Events.................................................................................... 91 
5.3.5.3 
Persistent or Recurrent Adverse Events ................................ 91 
5.3.5.4 
Abnormal Laboratory Values ................................................. 92 
5.3.5.5 
Abnormal Vital Sign Values ................................................... 93 
5.3.5.6 
Abnormal Liver Function Tests .............................................. 93 
5.3.5.7 
Deaths ................................................................................... 94 
5.3.5.8 
Preexisting Medical Conditions .............................................. 94 
5.3.5.9 
Lack of Efficacy or Worsening of Non−Small Cell 
Lung Cancer .......................................................................... 94 
5.3.5.10 
Hospitalization or Prolonged Hospitalization .......................... 95 
5.3.5.11 
Adverse Events Associated with an Overdose or 
Error in Drug Administration .................................................. 95 
5.3.5.12 
Patient-Reported Outcome Data ........................................... 95 
5.3.5.13 
Adverse Events in Individuals Not Enrolled in the 
Study ..................................................................................... 96 
5.4 
Immediate Reporting Requirements from 
Investigator to Sponsor .......................................................... 96 
5.4.1 
Emergency Medical Contacts ................................................ 96 
5.4.2 
Reporting Requirements for Serious Adverse 
Events and Non-Serious Adverse Events of 
Special Interest ...................................................................... 97 

 
Alectinib—F. Hoffmann-La Roche Ltd 
17/Protocol YO29449, Version 3 
 
5.4.2.1 
Events That Occur before Study Drug Initiation ..................... 97 
5.4.2.2 
Events That Occur after Study Drug Initiation ........................ 97 
5.4.3 
Reporting Requirements for Pregnancies .............................. 97 
5.4.3.1 
Pregnancies ........................................................................... 97 
5.4.3.2 
Pregnancies in Female Partners of Male Patients ................. 98 
5.4.3.3 
Abortions ............................................................................... 98 
5.4.3.4 
Congenital Anomalies/Birth Defects ...................................... 98 
5.5 
Follow-Up of Patients after Adverse Events .......................... 98 
5.5.1 
Investigator Follow-Up ........................................................... 98 
5.5.2 
Sponsor Follow-Up ................................................................ 99 
5.6 
Post-Study Adverse Events ................................................... 99 
5.7 
Expedited Reporting to Health Authorities, 
Investigators, Institutional Review Boards, and 
Ethics Committees ................................................................. 99 
6. 
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN ..................... 100 
6.1 
Determination of Sample Size ............................................. 101 
6.2 
Summaries of Conduct of Study .......................................... 101 
6.3 
Summaries of Treatment Group Comparability ................... 101 
6.4 
Efficacy Analyses ................................................................ 102 
6.4.1 
Primary Efficacy Endpoint .................................................... 102 
6.4.2 
Secondary Efficacy Endpoints ............................................. 102 
6.4.3 
Sensitivity Analyses ............................................................. 105 
6.4.4 
Subgroup Analyses ............................................................. 105 
6.5 
Safety Analyses ................................................................... 105 
6.6 
Pharmacokinetic Analyses ................................................... 106 
6.7 
Patient-Reported Outcome Analyses .................................. 107 
6.7.1 
Time to Deterioration of Patient-Reported Lung 
Cancer Symptoms ............................................................... 107 
6.7.2 
Additional Patient-Reported Outcomes................................ 107 
6.8 
Exploratory Analyses ........................................................... 107 
6.9 
Optional Interim Analyses .................................................... 108 
7. 
DATA COLLECTION AND MANAGEMENT ............................................. 108 
7.1 
Data Quality Assurance ....................................................... 108 

 
Alectinib—F. Hoffmann-La Roche Ltd 
18/Protocol YO29449, Version 3 
 
7.2 
Electronic Case Report Forms ............................................. 108 
7.3 
Source Data Documentation ................................................ 108 
7.4 
Use of Computerized Systems ............................................ 109 
7.5 
Retention of Records ........................................................... 109 
8. 
ETHICAL CONSIDERATIONS .................................................................. 110 
8.1 
Compliance with Laws and Regulations .............................. 110 
8.2 
Informed Consent ................................................................ 110 
8.3 
Institutional Review Board or Ethics Committee .................. 111 
8.4 
Confidentiality ...................................................................... 111 
8.5 
Financial Disclosure ............................................................ 111 
9. 
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION ................................................................................... 112 
9.1 
Study Documentation .......................................................... 112 
9.2 
Protocol Violations ............................................................... 112 
9.3 
Site Inspections ................................................................... 112 
9.4 
Administrative Structure....................................................... 112 
9.5 
Publication of Data and Protection of Trade 
Secrets ................................................................................ 113 
9.6 
Protocol Amendments ......................................................... 114 
10. REFERENCES ......................................................................................... 115 

 
Alectinib—F. Hoffmann-La Roche Ltd 
19/Protocol YO29449, Version 3 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES 
Table 1 
Response Rates from Patients Participating in Part 2 
of Study AF-001JP ...................................................................... 37 
Table 2 
Progression-Free Survival Results from Patients 
Participating in Part 2 of Study AF-001JP ................................... 38 
Table 3 
Guidelines for Management of Specific Adverse Events with 
Alectinib ...................................................................................... 79 
Table 4 
Crizotinib Dose ModificationHematologic Toxicities 
(Except Lymphopenia) ................................................................ 84 
Table 5 
Crizotinib Dose ModificationNon-Hematologic Toxicities ........ 85 
Table 6 
Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in the NCI CTCAE ......................................... 90 
Table 7 
Required Number of PFS Events to Show Consistency ........... 100 
 
 
LIST OF FIGURES 
Figure 1 
Duration of Dosing by Cohort for Patients in Part 1 
of Study NP28761/AF-002JG...................................................... 39 
Figure 2 
Maximum Percent Change from Baseline in Target Lesion 
Size as Assessed by the Investigator for Patients in Part 1 of 
Study NP28761/AF-002JG.......................................................... 40 
Figure 3 
Summary of Study Design .......................................................... 47 
 
 
LIST OF APPENDICES 
Appendix 1 
Schedule of Assessments ......................................................... 120 
Appendix 2 
Schedule of Alectinib Pharmacokinetic Assessments ............... 127 
Appendix 3 
List of Substrates, Inhibitors, and Inducers of Drug-
Metabolizing Enzymes and Transporters .................................. 128 
Appendix 4 
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication ............................... 130 
Appendix 5 
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication ............................... 142 
Appendix 6 
Eastern Cooperative Oncology Group Performance Status 
Scale ......................................................................................... 150 
Appendix 7 
EORTC Quality-of-Life Questionnaire−Core 30 ........................ 151 
Appendix 8 
EORTC Quality-of-Life Questionnaire−Lung Cancer 13 
Module ...................................................................................... 153 
Appendix 9 
Modification of Diet in Renal Disease Formula ......................... 154 
Appendix 10 Anaplastic Lymphoma Kinase Immunohistochemistry .............. 155 

 
Alectinib—F. Hoffmann-La Roche Ltd 
20/Protocol YO29449, Version 3 
 
Appendix 11 Formulae for the Calculation of QTcF and RR .......................... 156 
Appendix 12 FoundationOne Gene Panel ..................................................... 157 

 
Alectinib—F. Hoffmann-La Roche Ltd 
21/Protocol YO29449, Version 3 
 
PROTOCOL AMENDMENT ACCEPTANCE FORM 
TITLE: 
RANDOMIZED, MULTICENTER, PHASE III, 
OPEN-LABEL STUDY OF ALECTINIB VERSUS 
CRIZOTINIB IN ASIAN PATIENTS WITH 
TREATMENT-NAIVE ANAPLASTIC LYMPHOMA 
KINASE−POSITIVE ADVANCED NON−SMALL CELL 
LUNG CANCER 
PROTOCOL NUMBER: YO29449 
VERSION NUMBER: 
3 
TEST PRODUCT: 
Alectinib (RO5424802) 
MEDICAL MONITOR: 
 M.D. 
SPONSOR: 
F. Hoffmann-La Roche Ltd 
I agree to conduct the study in accordance with the current protocol. 
 
 
 
Principal Investigator’s Name (print) 
 
 
 
 
 
Principal Investigator’s Signature 
 
Date 
Please retain the signed original of this form for your study files.  Please return a copy of 
this form to your local study monitor. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
22/Protocol YO29449, Version 3 
 
PROTOCOL SYNOPSIS 
TITLE: 
RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY 
OF ALECTINIB VERSUS CRIZOTINIB IN ASIAN PATIENTS WITH 
TREATMENT-NAIVE ANAPLASTIC LYMPHOMA 
KINASE−POSITIVE ADVANCED NON−SMALL CELL LUNG 
CANCER 
PROTOCOL NUMBER: 
YO29449 
VERSION NUMBER: 
3 
TEST PRODUCT: 
Alectinib (RO5424802) 
PHASE: 
III 
INDICATION: 
Anaplastic lymphoma kinase−positive non−small cell lung cancer  
SPONSOR: 
F. Hoffmann-La Roche Ltd 
 
Objectives 
Efficacy Objectives 
The primary efficacy objective for this study is to evaluate and compare the efficacy of alectinib 
compared with crizotinib in Asian patients with treatment-naive anaplastic lymphoma kinase 
(ALK)-positive advanced non−small cell lung cancer (NSCLC), as measured by 
investigator-assessed progression-free survival (PFS).  This objective is to reliably determine 
whether the benefit (in terms of PFS) of administrating alectinib in this study is consistent with 
the benefit observed in the global Study ALEX (BO28984). 
The secondary efficacy objectives for this study are as follows: 
• 
To evaluate and compare the objective response rate (ORR) and duration of response 
(DOR) 
• 
To evaluate and compare the time to disease progression in the CNS on the basis of review 
of patient radiographs by an Independent Review Committee (IRC) with the use of 
Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and Response 
Assessment in Neuro Oncology (RANO) criteria, as well as: 
To evaluate the CNS objective response rate (C-ORR) in patients with CNS 
metastases who have measurable disease in the CNS at baseline 
To assess the CNS duration of response (C-DOR) in patients who have a CNS 
objective response 
To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the basis of 
cumulative incidence 
• 
To evaluate and compare the PFS assessment by an independent review committee (IRC) 
by treatment arm 
• 
To evaluate and compare the overall survival (OS) by treatment arm 
 
Safety Objective 
The safety objective for this study is to evaluate the safety and tolerability of alectinib compared 
with crizotinib. 
Pharmacokinetic Objective 
The pharmacokinetic (PK) objective for this study is to characterize the pharmacokinetics of 
alectinib (and metabolite[s], if appropriate). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
23/Protocol YO29449, Version 3 
 
 
Patient-Reported Outcome Objectives 
The patient-reported outcome (PRO) objectives for this study are as follows: 
• 
To evaluate and compare time to deterioration (TTD) with patient-reported lung cancer 
symptoms of cough, dyspnea (single item and multi-item subscales), chest pain, 
arm/shoulder pain, and fatigue as measured by the European Organization for the 
Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire−Core 
(QLQ-C30), the supplemental EORTC Quality-of-Life Questionnaire−Lung Cancer module 
(QLQ-LC13), and a composite of the following three symptoms cough, dyspnea, chest pain. 
• 
To evaluate and compare PROs regarding health-related quality of life (HRQOL), daily 
functioning, and side effects of treatment as measured by the EORTC QLQ-C30 and 
EORTC QLQ-LC13. 
 
Exploratory Objectives 
The exploratory objectives for this study are as follows: 
• 
To investigate molecular mechanisms of resistance to ALK inhibitors. 
• 
To investigate detection of mutations in ALK and other genes, refer to Appendix 12 for 
detailed information. 
Study Design 
Description of Study 
This is a randomized, active controlled, multicenter Phase III open-label study in Asian patients 
with treatment-naive ALK-positive advanced NSCLC.  All patients are required to provide a 
pretreatment tumor sample that will be used to confirm the presence of ALK rearrangement (by 
Ventana immunohistochemistry [IHC] test performed at a central laboratory).  Patients will be 
randomized 2:1 into one of the two treatment arms to receive either alectinib or crizotinib, 
respectively. 
This study will be conducted in approximately three other Asian countries in addition to China. 
The primary endpoint of the study is investigator-assessed PFS. 
Central randomization will be performed via an interactive voice/Web response system (IxRS) 
with stratification by Eastern Cooperative Oncology Group Performance Status (ECOG PS) 
(0/1 vs. 2) and CNS metastases at baseline (yes vs. no).  An IxRS information manual will be 
provided to each study site. 
The experimental arm will receive alectinib administered orally at 600 mg twice a day (BID) with 
food.  The control arm will receive crizotinib administered orally at 250 mg BID, taken with or 
without food.  The first dose of the study drug should be administered as soon as possible after 
randomization, preferably within 24 hours, and no later than 48 hours after randomization. 
Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, 
or death.  Patients should discontinue the study medication once progression of disease has 
been determined based on the use of RECIST v1.1 and subsequent treatments will be decided 
at the discretion of the investigator according to local practice.  Information regarding the nature 
and the duration of subsequent therapies will be collected. 
In the case of isolated asymptomatic disease progression in the CNS (e.g., new CNS 
oligometastases) localized treatment (e.g., stereotactic radiotherapy or surgery) may be 
provided followed by the continuation of patient’s study treatment (either alectinib or crizotinib) 
until systemic disease progression or symptomatic disease progression in the CNS.  The 
decision to continue the study treatment beyond the isolated, asymptomatic disease 
progression in the CNS is at the investigator’s discretion for patients who may continue to 
benefit from respective treatment. 
Patients who discontinue study drug treatment before disease progression (e.g., because of 
unacceptable toxicity) will continue to be followed to collect information regarding disease 
progression and OS information regardless of whether the patient subsequently received any 
non-study anti-cancer therapy.  Data regarding subsequent anti-cancer therapy will be collected 
for the analysis of OS. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
24/Protocol YO29449, Version 3 
 
Approximately 183 patients (122 in the alectinib treatment arm and 61 in the crizotinib treatment 
arm) will be enrolled into the study over a planned recruitment period of 13 months.  Patients 
who are inappropriately randomized into the study will not be replaced.  With the current 
assumption that hazard ratio is 0.65, the primary analysis that will evaluate the primary 
endpoint of investigator-assessed PFS is expected to occur approximately 23 months after the 
first patient has been enrolled when approximately 97 PFS events have occurred.  Data 
collection will continue for each patient until death or study closure, whichever occurs first. 
Number of Patients 
Approximately 183 patients will be randomly assigned in a 2:1 allocation ratio to the two 
treatment arms (122 in the alectinib treatment arm and 61 in the crizotinib treatment arm) via a 
block stratified randomization procedure and over a planned recruitment period of 13 months. 
Randomization will guard against systematic selection bias and should ensure the comparability 
of treatment groups.  To assist the balance of important prognostic factors, randomization will 
be stratified by ECOG PS (0/1 vs. 2) and CNS metastases at baseline (yes vs. no). 
Target Population 
Inclusion Criteria 
Patients must meet the following criteria for study entry: 
• 
Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not 
amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive 
as assessed by the Ventana IHC test.  Sufficient tumor tissue available to perform ALK IHC 
is required.  Ventana IHC testing will be performed at the designated central laboratory. 
• 
Age ≥ 18 years 
• 
Life expectancy  ≥ 12 weeks 
• 
ECOG PS of 0−2 
• 
No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not amenable 
for multimodality treatment) or metastatic (Stage IV) NSCLC 
• 
Adequate hematologic function: 
Platelet count ≥ 100 × 109/L 
ANC ≥ 1500 cells/µL 
Hemoglobin ≥ 9.0 g/dL 
• 
Adequate renal function: 
An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet 
in Renal Disease (MDRD) formula of ≥ 45 mL/min/1.73 m2 
• 
Patients must have recovered from effects of any major surgery or significant traumatic 
injury at least 28 days before receiving the first dose of study treatment. 
• 
Measurable disease (by RECIST v1.1) before administration of study treatment. 
• 
Previous brain or leptomeningeal metastases are allowed if the patient is asymptomatic 
(e.g., diagnosed incidentally at study baseline).  Asymptomatic CNS lesions may be treated 
at the discretion of the investigator as per local clinical practice.  If patient has neurological 
symptoms or signs because of CNS metastasis, the patient must complete whole-brain 
radiation or gamma knife irradiation treatment.  In all cases, radiation treatment must be 
completed ≥ 14 days before enrollment and disease must be clinically stable. 
• 
For all females of childbearing potential, a negative serum pregnancy test result must be 
obtained within 3 days before starting study treatment. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
25/Protocol YO29449, Version 3 
 
• 
For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) 
or surgically sterile (absence of ovaries and/or uterus), agreement to remain abstinent or 
use single or combined contraceptive methods that result in a failure rate of < 1% per year 
during the treatment period and for at least 3 months after the last dose of study drug.  
Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the 
patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.  Examples of 
contraceptive methods with a failure rate of < 1% per year include tubal ligation, male 
sterilization, hormonal implants, established, proper use of combined oral or injected 
hormonal contraceptives, and certain intrauterine devices.  Alternatively, two methods 
(e.g., two barrier methods such as a condom and a cervical cap) may be combined to 
achieve a failure rate < 1% per year.  Barrier methods must always be supplemented with 
the use of a spermicide. 
• 
For men, agreement to remain abstinent or use a condom plus an additional contraceptive 
method that together result in a failure rate of < 1% per year during the treatment period and 
for at least 3 months after the last dose of study drug.  Abstinence is acceptable only if it is 
in line with the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not 
acceptable methods of contraception. 
• 
Able and willing to provide written informed consent before performing any study-related 
procedures and to comply with the study protocol. 
 
Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from study entry: 
• 
A malignancy within the previous 3 years (other than curatively treated basal cell carcinoma 
of the skin, early gastrointestinal [GI] cancer by endoscopic resection, in situ carcinoma of 
the cervix, or any cured cancer that is considered to have no impact in PFS or OS for the 
current NSCLC). 
• 
Any GI disorder that may affect absorption of oral medications, such as malabsorption 
syndrome or status post-major bowel resection. 
• 
Liver disease characterized by: 
ALT or AST > 3 × the upper limit of normal (ULN; ≥ 5 × ULN for patients with concurrent 
liver metastases) confirmed on two consecutive measurements 
OR 
Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or other 
conditions of decompensated liver disease such as coagulopathy, hepatic 
encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices 
OR 
Acute viral or active autoimmune, alcoholic, or other types of hepatitis 
• 
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 
Grade 3 or higher toxicities because of any previous therapy (e.g., radiotherapy) (excluding 
alopecia), which have not shown improvement and are strictly considered to interfere with 
current study medication. 
• 
History of organ transplant 
• 
Co-administration of anti-cancer therapies other than those administered in this study 
• 
Baseline QTc > 470 ms or symptomatic bradycardia 
• 
Administration of strong/potent cytochrome P4503A inhibitors or inducers within 14 days 
prior to the receiving the first dose of study treatment and during treatment with alectinib or 
crizotinib 
• 
Administration of agents with potential QT-prolonging effects within 14 days prior to 
receiving the first dose of study drug. 
• 
History of hypersensitivity to any of the additives in the alectinib drug formulation 

 
Alectinib—F. Hoffmann-La Roche Ltd 
26/Protocol YO29449, Version 3 
 
• 
History of hypersensitivity to any of the additives in the crizotinib drug formulation 
• 
Pregnant or lactating women 
• 
Known HIV positivity or AIDS-related illness 
• 
Any clinically significant concomitant disease or condition that could interfere with, or for 
which the treatment might interfere with, the conduct of the study or the absorption of oral 
medications or that would, in the opinion of the Principal Investigator, pose an unacceptable 
risk to the patient in this study 
• 
Any psychological, familial, sociological, or geographical condition that potentially hampers 
compliance with the study protocol requirements or follow-up procedures; those conditions 
should be discussed with the patient before study entry 
 
Length of Study 
The time from first patient screened to end of study, defined below, will be approximately 
43 months. 
End of Study 
This is an event-driven study.  With the current assumption that the HR is 0.65 and 
the recruitment period is 13 months, the required 97 PFS events for primary efficacy 
analysis is expected to occur 23 months after the first patient has been enrolled.  If 
the number of PFS events is not enough for the estimation of median PFS, an 
updated PFS analysis will be done when approximately 55% of patients have had 
PFS events.  A survival follow-up analysis will be performed when approximately 
55% of patients have died, which is estimated to occur 41 months after the first 
patient has been enrolled. 
Outcome Measures 
Efficacy Outcome Measures 
The efficacy outcome measures for this study are as follows: 
• 
PFS, defined as the time from randomization to the first documentation of disease 
progression, as determined by the investigators (primary endpoint) or IRC (secondary 
endpoint) with the use of RECIST v1.1 or death from any cause, whichever occurs first.  
Patients without an event will be censored at the last tumor assessment either during 
follow-up or during study treatment.  Patients without any assessments performed after 
baseline will be censored at the date of randomization. 
• 
ORR, defined as the percentage of patients who attain complete response (CR) or partial 
response (PR) as assessed by the investigator with the use of RECIST v1.1.  Patients 
without any assessments will be regarded as non-responders. 
• 
Time to progression of disease in the CNS, defined as the time from randomization to the 
first occurrence of disease progression in the CNS as determined by an IRC with the use of 
RECIST v1.1 and RANO (separate assessments and analyses), as well as C-ORR in 
patients with CNS metastases who have measurable disease in the CNS at baseline, 
C-DOR in patients who have a CNS Objective Response, and C-PR at 6, 12, 18, and 24 
months. 
• 
DOR, defined as the time from the initial documentation of response (CR or PR with the use 
of RECIST v1.1) to first documentation of disease progression with the use of RECIST v1.1 
or death (whichever occurs first).  This will be calculated only for patients who have a best 
overall response of CR or PR.  Patients who do have disease progression or die after they 
have had a response will be censored at the date of their last tumor measurement. 
• 
OS, defined as the time from randomization to death from any cause.  Patients without an 
event will be censored at the last date known to be alive.  Patients without any follow-up 
information will be censored at the date of randomization. 
 
Safety Outcome Measures 
The safety outcome measures for this study are as follows: 
• 
Serious and non-serious adverse events 

 
Alectinib—F. Hoffmann-La Roche Ltd 
27/Protocol YO29449, Version 3 
 
• 
Safety laboratory test results 
• 
Vital signs (blood pressure, heart rate), ECG 
• 
Physical examination findings 
 
Pharmacokinetic Outcome Measures 
The PK outcome measures for this study are as follows: 
• 
Sparse blood sampling will be performed in all patients receiving alectinib treatment to 
characterize the pharmacokinetics of alectinib (and metabolite[s], if appropriate). 
• 
Frequent blood sampling will be performed in the first 20 consenting Chinese patients 
enrolled to receive alectinib treatment. 
• 
PK parameters will be determined as appropriate and where data allow. 
• 
Non-compartmental analysis for alectinib (and metabolite[s], if appropriate) will be 
conducted in patients undergoing frequent blood sampling, as appropriate and where data 
allow. 
The sparse and frequent pharmacokinetics of alectinib (and metabolite[s], if 
appropriate) will be described, and the between-patient variability will be estimated 
with the use of a population PK approach.  The potential influence of covariates that 
contribute significantly to the between-patient differences in PK parameters of alectinib 
will also be explored and quantified.  If necessary, data may be pooled with data from 
other studies. 
 
Patient-Reported Outcome Questionnaires 
The PRO questionnaires for this study are as follows and will be administered to patients every 
4 weeks until disease progression and during disease progression while receiving study drug 
treatment in the case of isolated, asymptomatic disease progression in the CNS at the 
Post-Treatment Visit (4 weeks after treatment discontinuation), and every follow-up visit 
(every 8 weeks) after the Post-Treatment Visit for 6 months: 
• 
EORTC QLQ-C30 and the EORTC QLQ-LC13 will be used to determine the impact of 
alectinib compared with crizotinib as measured by TTD with patient-reported lung cancer 
symptoms (e.g., cough, dyspnea [single item and multi-item scales], pain in chest, pain in 
arm/shoulder, fatigue). 
• 
The EORTC QLQ-C30 and EORTC QLQ-LC13 will be used to measure PROs of HRQOL, 
patient functioning, and side effects of therapy compared between patients treated with 
alectinib and those treated with crizotinib. 
• 
For patients who discontinue treatment for reasons other than disease progression and who 
progress within the first 6 months of survival follow-up, PRO questionnaires will be 
administered every 4 weeks until disease progression.  Upon disease progression, PRO 
questionnaires will be provided every 8 weeks until 6 months post-treatment. 
• 
For patients who discontinue treatment for reasons other than disease progression and who 
have not yet progressed at 6 months post-treatment, PRO questionnaires will be 
administered every 4 weeks until disease progression and will no longer be required 
thereafter.  
 
Exploratory Outcome Measures 
The exploratory outcome measures for this study are as follows: 
• 
Baseline and post-progression tumor mutation status to study molecular mechanisms of 
resistance to ALK inhibitors 
• 
ALK and other genes involved in cancer mutation and rearrangement status in 
plasma-circulating tumor nucleic acids to monitor efficacy, resistance, and disease 
progression 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
28/Protocol YO29449, Version 3 
 
Investigational Medicinal Products 
Test Product 
Alectinib comes in a hard capsule dosage form containing the following active ingredient: 
Chemical name: 9-Ethyl-6, 6-dimethyl-8-[4-(morpholin-4-yl) piperidin-1-yl]-11-oxo-6, 
11-dihydro-5H-benzo[b]carbazole-3-carbonitrile hydrochloride 
Each capsule contains 150 mg of alectinib (as free base) along with lactose monohydrate, 
carmellose calcium, hydroxypropyl cellulose, SLS, and magnesium stearate. 
Alectinib capsules should be stored in accordance with the storage instructions on the label. 
Alectinib capsules should be administered orally BID with food in the morning and evening. 
Comparator 
Crizotinib comes in a hard capsule dosage form.  Each capsule contains 250 mg or 200 mg 
crizotinib.  Crizotinib hard capsules should be stored in accordance with the storage instructions 
on the label.  Crizotinib capsules should be administered orally BID. 
For further details, see the local prescribing information for crizotinib 
(XALKORI, U.S. Package Insert). 
Non-Investigational Medicinal Product 
Concomitant therapy includes any medication (e.g., prescription drugs, over-the-counter drugs, 
herbal or homeopathic remedies, nutritional supplements) used by a patient from 28 days prior 
to screening to the Study Completion and Study Treatment Discontinuation Visit.  All 
concomitant medications should be reported to the investigator and recorded on the 
Concomitant Medications electronic case report form (eCRF). 
All therapy and medication administered to manage adverse events should be recorded on the 
Concomitant Medications eCRF. 
Permitted medications and treatments are listed below: 
• 
Anticoagulants and anti-thrombotic agents (i.e., warfarin-derived anticoagulants, 
unfractionated heparin or low-molecular heparins, aspirin [≤ 325 mg/day], and clopidogrel). 
• 
Acetaminophen up to 2 g/day 
• 
Gastric pH− elevating medications (such as proton pump inhibitors, H2 blockers, or 
antacids) 
• 
Local therapy (e.g., stereotactic radiotherapy or surgery) may be given to patients with 
isolated asymptomatic CNS progression (e.g., new CNS oligometastases). 
 
Statistical Methods 
Primary Analysis 
PFS is defined as the time from date of randomization to the date of first documented disease 
progression or death, whichever occurs first.  The primary endpoint of PFS will be determined 
based on investigator assessment of progression with the use of RECIST v1.1.  Patients who 
have not experienced disease progression or death at the time of analysis will be censored at 
the last tumor assessment date either during study treatment or during follow-up.  Patients 
without tumor assessments after baseline will be censored at the date of randomization. 
Patients who discontinue treatment before disease progression (e.g., because of toxicity) will 
continue in the study and will be followed until disease progression and for OS regardless of 
whether they subsequently receive anti-cancer therapy. 
The Kaplan-Meier method will be used to estimate the median PFS for each treatment arm with 
95% confidence limits, and a Kaplan-Meier curve will be constructed to provide a visual 
description of the difference between the treatment arms.  A stratified Cox proportional 
regression model will be used including treatment in order to provide an estimate of the 
treatment effect expressed as a hazard ratio (HR) (alectinib vs. crizotinib), as well as a 95% CI.  
The stratification factors are the randomization stratification factors:  ECOG PS (0/1 vs. 2) and 
CNS metastases at baseline (yes vs. no), as recorded on the eCRF.  Point estimate of the 
adjusted HR will be compared with the consistency threshold (observed HR in the ALEX trial). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
29/Protocol YO29449, Version 3 
 
The treatment comparison of PFS will also be assessed and tested based on a stratified 
log-rank test to demonstrate the strength of consistent trend.  However, this hypothesis testing 
is limited because statistically negative outcomes do not necessarily rule out clinically significant 
treatment effects. 
Determination of Sample Size 
The primary endpoint of investigator-assessed PFS was used to determine the sample size of 
the study.  The primary objective of the study is to reliably determine whether the benefit (in 
terms of PFS) of administrating alectinib in this study is consistent with the benefit observed in 
the global Study ALEX.  Consistency is defined as maintaining ≥ 50% of risk reduction from 
Study ALEX.  That is, assumed the PFS HR for the ALEX trial is 0.65 (i.e., 35% risk reduction), 
if the point estimate of HR from Study YO29449 is less than 0.83, then the study primary 
objective to demonstrate consistency is met. 
Based on the assumption of PFS HR = 0.65, a total of 97 PFS events are required to achieve 
approximately 87% probability to show consistency.  In this study, 183 patients will be enrolled 
in a 2:1 randomization allocation.  Based on the assumption that median PFS is 10.9 months for 
the crizotinib arm and 16.8 months for the alectinib arm (HR = 0.65) and patients are to be 
enrolled over 13months; the final PFS analysis is expected to occur approximately 23 months 
after the first patient is enrolled. 
Interim Analysis 
No interim analysis for efficacy or futility is planned. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
30/Protocol YO29449, Version 3 
 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
ALK 
anaplastic lymphoma kinase 
ALP 
alkaline phosphatase 
ASCO 
American Society of Clinical Oncology 
AUC 
area under the concentration−time curve 
BID 
twice daily 
Cmax 
maximum plasma concentration observed 
C-DOR 
CNS duration of response 
C-ORR 
CNS objective response rate 
C-PR 
CNS progression rate 
CR 
complete response 
CT 
computed tomography 
CYP 
cytochrome P450 
DLT 
dose-limiting toxicity 
DOR 
duration of response 
DOT 
duration of treatment 
EC 
Ethics Committee 
eCRF 
electronic Case Report Form 
ECOG PS 
Eastern Cooperative Oncology Group Performance Status 
EDC 
electronic data capture 
eGFR 
estimated glomerular filtration rate 
EGFR 
epidermal growth factor receptor 
EML4 
echinoderm microtubule-associated protein-like 4 
EORTC  
European Organization for the Research and Treatment of Cancer 
FDA 
U.S. Food and Drug Administration 
FISH 
fluorescence in situ hybridization 
GGT 
gamma-glutamyl transferase 
GI 
gastrointestinal 
HR 
hazard ratio 
HRQOL 
health-related quality of life 
ICH 
International Conference on Harmonisation 
IHC 
immunohistochemistry 
ILD 
interstitial lung disease 
IMP 
investigational medicinal product 
IRB 
Institutional Review Board 
IRC 
Independent Review Committee 

 
Alectinib—F. Hoffmann-La Roche Ltd 
31/Protocol YO29449, Version 3 
 
Abbreviation 
Definition 
ITT 
intent-to-treat 
IxRS 
interactive voice/Web response system 
KRAS 
Kirsten rat sarcoma viral oncogene homolog 
MDRD 
modification of diet in renal disease 
MET 
mesenchymal-epithelial transition factor 
MRI 
magnetic resonance imaging 
MTD 
maximum tolerated dose 
NCA 
non-compartmental analysis 
NCCN 
National Comprehensive Cancer Network 
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for 
Adverse Events 
NE 
not evaluable 
NSCLC 
non-small cell lung cancer 
NGS 
Next Generation Sequencing 
ORR 
objective response rate 
OS 
overall survival 
P-gp 
P-glycoprotein 
PD 
progressive disease 
PET 
positron emission tomography 
PFS 
progression-free survival 
P-gp 
P-glycoprotein 
PK 
pharmacokinetic 
PR 
partial response 
PRO 
patient-reported outcome 
QD 
once daily 
QLQ-C30 
Quality-of-Life Questionnaire−Core 
QLQ-LC13 
Quality-of-Life Questionnaire−Lung Cancer module 
QOL 
quality of life 
QTcF 
Fridericia’s formula 
RANO 
Response Assessment in Neuro Oncology 
RECIST 
Response Evaluation Criteria in Solid Tumors 
RON 
recepteur d’origine nantais 
ROS1 
c-ros oncogene 1 
SAP 
Safety Analysis Population 
SD 
stable disease 
TKI 
tyrosine kinase inhibitor 
TTD 
time to deterioration 

 
Alectinib—F. Hoffmann-La Roche Ltd 
32/Protocol YO29449, Version 3 
 
Abbreviation 
Definition 
UGT 
uridine 5′-diphospho-glucuronosyltransferase 
ULN 
upper limit of normal 

 
Alectinib—F. Hoffmann-La Roche Ltd 
33/Protocol YO29449, Version 3 
 
1. 
BACKGROUND 
1.1 
BACKGROUND ON ANAPLASTIC LYMPHOMA 
KINASE−POSITIVE NON−SMALL CELL LUNG CANCER 
Non−small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality 
worldwide.  Lung cancer was estimated to cause 160,300 deaths in the United States 
in 2012, accounting for 28% of all cancer-related deaths according to a report from the 
American Lung Association (2014).  In China, lung cancer is also the leading cause of 
cancer-related mortality, accounting for 25.2% of all malignant tumors in 2009 
(Chen et al. 2013); the prevalence and mortality rate are 53.6 and 45.6 per 100,000, 
respectively.  Survival rates for lung cancer tend to be much lower than other common 
cancers because of the late diagnosis and limited effective therapy of lung cancer in the 
advanced stage.  The expected 5-year survival rate for all patients who receive a 
diagnosis of lung cancer is 16.3% compared with 65.2% for colon cancer, 90.0% for 
breast cancer, and 99.9% for prostate cancer (Siegel et al. 2012).  Conventional 
anti-cancer therapies are far from satisfactory, and there is an unmet medical need for 
the development of new therapies for NSCLC. 
Recent progress in the identification of genetic mutations or chromosomal 
rearrangements in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral 
oncogene homolog (KRAS), mesenchymal-epithelial transition factor (MET), and other 
genes has provided new opportunities to use targeted therapeutic agents for the 
treatment of NSCLC, when the tumor is identified as having these mutations 
(Katayama et al. 2011; Doebele et al. 2012). 
Approximately 5% of NSCLC cases have been shown to harbor the echinoderm 
microtubule-associated protein-like 4 (EML4)−anaplastic lymphoma kinase (ALK) fusion 
gene as a result of a chromosomal inversion at 2p21 and 2p23 (Choi et al. 2010; 
Ou et al. 2012).  The formation of the ALK fusion protein results in activation and 
dysregulation of the gene’s expression and signaling, which may contribute to increased 
cell proliferation and survival in tumors that express these genes.  The formation of the 
ALK fusion protein is further supported by reports that the TFG and KIF5B genes may 
also serve as ALK fusion partners in some patients with NSCLC.  Expression of these 
ALK fusion genes in mouse 3T3 fibroblasts causes their transformation and enhanced 
proliferation.  ALK gene alterations are generally in a mutually exclusive relationship with 
mutations in EGFR or KRAS (Soda et al. 2007; Inamura et al. 2008; Inamura et al. 2009; 
Wong et al. 2009), although EGFR mutations may develop as a resistance mechanism 
after treatment with crizotinib (XALKORI, U.S. Package Insert) (Doebele et al. 2012).  
Inhibition of ALK activity in Ba/F3 cells that were transfected with the EML4-ALK fusion 
protein resulted in inhibition of cell growth (Ou et al. 2012), whereas a small molecule 
inhibitor of ALK demonstrated anti-tumor efficacy in two xenograft models in athymic 
mice, namely, the H3122 NSCLC and Karpas299 anaplastic large cell lymphoma models 
harboring the EML4-ALK and nucleophosmin-ALK fusion proteins, respectively.  Hence, 

 
Alectinib—F. Hoffmann-La Roche Ltd 
34/Protocol YO29449, Version 3 
 
ALK appears to be a suitable therapeutic target for NSCLC with ALK gene 
rearrangements. 
Wild-type ALK is hardly expressed at all in most normal human tissues, being expressed 
at higher levels in a few limited types of tissue such as developing and mature nervous 
system tissue (glial cells, neurons, endothelial cells, and pericytes) (Pulford et al. 1997).  
By contrast, an aberrant ALK with constitutively active kinase results from the formation 
of the EML4-ALK fusion gene by chromosomal translocation. 
Currently, the first approved medicine for treatment-naive ALK-positive NSCLC is 
crizotinib, an inhibitor of receptor tyrosine kinases including ALK, hepatocyte growth 
factor receptor (HGFR; also known as c-Met), recepteur d’origine nantais (RON), and 
c-ros oncogene 1 (ROS1) (Sahu et al. 2013). 
Crizotinib was first granted accelerated approval by the U.S. Food and Drug 
Administration (FDA) in August 2011 for the treatment of patients with locally advanced 
or metastatic NSCLC that is positive for ALK as detected by an FDA-approved test.  The 
approval was based on two single-arm studies.  The primary endpoint for both studies 
was the objective response rate (ORR) as assessed by the investigator.  In one study, 
the ORR was 50% (95% CI: 42%, 59%) with a median response duration of 42 weeks, 
and in the other study, the ORR was 61% (95% CI: 52%, 70%) with a median response 
duration of 48 weeks (Camidge et al. 2012; Kim et al. 2012).  In November 2013, the 
FDA granted regular approval for crizotinib on the basis of the demonstration of superior 
progression-free survival (PFS) and ORR for crizotinib compared with chemotherapy in 
patients with ALK-positive NSCLC whose disease progressed after platinum-based 
doublet chemotherapy (Study PROFILE 1007).  Study PROFILE 1007 was an 
open-label active-controlled multinational randomized study that enrolled 347 patients 
with ALK-positive metastatic NSCLC.  Patients were required to have disease 
progression following platinum-based chemotherapy.  The study demonstrated 
significantly prolonged PFS in patients who were treated with crizotinib compared with 
patients who received chemotherapy (hazard ratio [HR] = 0.49 [95% CI: 0.37, 0.64], 
p < 0.0001).  Median PFS was 7.7 months for patients treated with crizotinib and 
3.0 months for patients treated with chemotherapy.  The ORR was significantly 
higher for patients treated with crizotinib compared with patients who received 
chemotherapy (65% vs. 20%, respectively), with median response durations of 
7.4 months for patients treated with crizotinib and 5.6 months for patients treated with 
chemotherapy.  No difference in overall survival (OS) was noted between the two groups 
in a planned interim analysis (HR = 1.02 [95% CI: 0.68%, 1.54%]) (Shaw et al. 2013a).  
Common adverse reactions in clinical studies with crizotinib, occurring at an incidence of 
25% or higher, included visual disorders, nausea, diarrhea, vomiting, constipation, 
edema, elevated transaminases, and fatigue (National Cancer Institute 2013).  Study 
PROFILE 1014, a Phase III study of crizotinib compared with standard 
pemetrexed−platinum−based chemotherapy, met its primary objective of prolonging PFS 
in patients with ALK-positive non-squamous NSCLC who were previously untreated, with 

 
Alectinib—F. Hoffmann-La Roche Ltd 
35/Protocol YO29449, Version 3 
 
a median PFS of 10.9 and 7.0 months (HR: 0.45; 95% CI: 0.35, 0.60; p<0.0001) for 
crizotinib and pemetrexed-platinum-based chemotherapy, respectively 
(Solomon et al. 2014).  Objective response rates were 74% and 45%, respectively 
(P<0.001).  Median OS was not reached in either group (HR for death with crizotinib: 
0.82; 95% CI: 0.54, 1.26; P = 0.36) (Solomon et al. 2014). 
These results showed that an ALK inhibitor is effective in patients with NSCLC whose 
disease harbors ALK fusion genes.  Crizotinib has subsequently been approved in other 
countries, such as Japan, Korea, Canada, Switzerland, and China.  In the European 
Union, crizotinib was conditionally approved in October 2012 for the treatment of adults 
with previously treated ALK-positive NSCLC. 
Although substantial benefit has been observed with crizotinib therapy, relapse typically 
occurs.  Studies with patients who had disease progression while receiving crizotinib 
treatment reveal two main reasons for treatment failure:  the development of resistance 
to treatment because of secondary (e.g., gatekeeper) mutations (predominantly in ALK 
or occasionally in other genes, such as EGFR, cKIT, or KRAS) (Katayama et al. 2011; 
Doebele et al. 2012; Kim et al. 2013) and CNS relapse (crizotinib has impaired control of 
brain metastases in comparison with other sites of systemic disease).  The CNS is the 
primary site of initial treatment failure in 46% of patients with ALK-positive NSCLC who 
are treated with crizotinib (Costa et al. 2011; Chun et al. 2012).  Significant morbidity is 
associated with brain metastases as a function of brain involvement and because of the 
treatment required for disease control (e.g., corticosteroids, surgery, and radiation). 
The second approved treatment for ALK-positive NSCLC (approved in the United States, 
currently under development in China) is ceritinib (ZYKADIA, U.S. Package Insert), 
which is an inhibitor of receptor tyrosine kinases that include ALK and insulin-like growth 
factor 1.  Ceritinib was granted accelerated approval by the FDA in 2014 for the 
treatment of patients with ALK-positive metastatic NSCLC who experienced disease 
progression while receiving crizotinib treatment or whose disease was intolerant to 
crizotinib therapy.  This indication was approved on the basis of tumor response rate and 
duration of response (DOR) in a Phase I single-arm study (Shaw et al. 2013b). 
One hundred thirty-one patients were enrolled in the ceritinib Phase I study (38% male, 
median age 53 years), including 59 patients in the dose-escalation phase 
(Shaw et al. 2013b).  The maximum tolerated dose (MTD) of 750 mg administered once 
daily (QD) was established, and 72 patients in an expanded cohort received the MTD.  
Among the 88 evaluable patients with NSCLC who received 400−750 mg ceritinib QD, 
the ORR was 70%, with 40 confirmed and 22 unconfirmed responses.  In the subset of 
64 crizotinib-resistant patients, the ORR was 73%, with 31 confirmed and 
16 unconfirmed responses.  As of 8 November 2012, 50% of patients with unconfirmed 
responses continued to receive ceritinib treatment.  Responses were observed in 
patients with different crizotinib-resistance mutations as well as in patients without a 
detectable mutation.  Responses were also observed in patients with untreated CNS 

 
Alectinib—F. Hoffmann-La Roche Ltd 
36/Protocol YO29449, Version 3 
 
metastases.  Among patients with NSCLC who had a confirmed response, the median 
DOR was 7.4 months (95% CI: 6.7, not reached) and 78% had a DOR of ≥ 6 months.  In 
all of the 123 patients with NSCLC, the median PFS was 8.6 months 
(95% CI: 4.3, 19.3 months).  In the subset of 83 crizotinib-naive patients, the ORR was 
72.3% (95% CI: 61.4%, 81.6%), median PFS was 18.4 months (95% CI: 11.1, non-
estimable) and median DOR was 17.0 months (95% CI: 11.3, non-estimable) 
(Felip et al. 2014).  The most common adverse events that were reported were nausea 
(72%), diarrhea (69%), vomiting (50%), and fatigue (31%).  The most common Grade 3 
or Grade 4 adverse events that were reported were ALT elevation (12%), diarrhea (7%), 
and AST elevation (6%). 
A new generation of ALK inhibitors may have the potential to overcome these two major 
limitations of crizotinib treatment to offer patients a better chance of prolonged remission 
and to minimize the development of CNS metastases and the attendant comorbidity. 
1.2 
BACKGROUND ON ALECTINIB 
Alectinib (also known as RO5424802, CH5424802, or AF802) is a newly developed 
small molecule, highly selective, and potent oral next-generation ALK inhibitor with a 
benzo[b]carbazole scaffold.  In enzyme inhibition assays performed in vitro, this 
compound has been shown to selectively inhibit ALK.  The compound also shows high 
anti-tumor activity both in vitro and in vivo against tumor cell lines with some type of ALK 
gene alteration, including NSCLC and anaplastic large cell lymphoma lines harboring an 
ALK translocation and a neuroblastoma line harboring an amplified ALK gene. 
Nonclinical pharmacology studies showed that alectinib is efficacious in a model of 
tumors that express an ALK fusion and bear the L1196M mutation, which is associated 
with resistance to crizotinib, and alectinib is effective in mouse NCI H2228 NSCLC 
xenografts that are already maximally suppressed by crizotinib.  Alectinib also prolongs 
survival in an intracerebral NCI H2228 implantation model, and it reduces tumor growth 
in an intracranial model monitored with the use of bioluminescence. 
To date, the clinical development program for alectinib is comprised of three ongoing 
Phase I/II studies in patients with ALK-positive NSCLC.  The ongoing Phase I/II studies 
consist of the following:  Study AF-001JP, which is being conducted in Japan; 
Study NP28761/AF-002JG, which is being conducted in North America; and 
Study NP28673, which is being conducted globally. 
The first-in-human Study AF-001JP is an open-label Phase I/II study being conducted in 
Japan.  This study’s objective is to assess the pharmacokinetics, safety, and efficacy of 
alectinib in Japanese patients with ALK-positive NSCLC who are crizotinib-naive and 
have had disease progression after receiving at least one line of chemotherapy.  This 
study has completed enrollment, but it is still ongoing.  A total of 70 patients were 
enrolled in the study (24 patients in the Part I portion and 46 patients in the Part 2 
portion of the study).  In the Part 1 portion of the study, at the data cutoff date of 14 

 
Alectinib—F. Hoffmann-La Roche Ltd 
37/Protocol YO29449, Version 3 
 
February 2014, 24 patients were treated with alectinib doses ranging from 20 to 300 mg 
administered twice daily (BID).  No dose-limiting toxicities (DLTs) or adverse events of 
Grade 4 severity were observed at up to the highest dose tested (i.e., 300 mg BID); the 
dosage of 300 mg BID was further evaluated in the Part 2 portion of the study without 
further dose escalation.  In the Part 2 portion of the study, 46 patients were treated with 
the highest evaluated alectinib dosage of 300 mg BID, of whom 43 patients achieved an 
objective response (93.5%; 95% CI: 82.1%, 98.6%) and 9 patients (20%) experienced a 
complete response (CR) based on the review and assessment of patient radiographs by 
an Independent Review Committee (IRC) for the 12-month follow-up analysis (data 
cutoff date for response data, 31 January 2013).  The median PFS was 27.7 months 
(95% CI: 26.9−not evaluable) based on the 31 January 2014 data cutoff date 
(Tamura et al. 2014). 
Table 1 and Table 2 show the ORR and PFS results from patients participating in Part 2 
of Study AF-001JP.  The majority of patients (86%) had a time to response of  ≤ 6 weeks 
after administration of the first dose. 
Table 1 
Response Rates from Patients Participating in Part 2 
of Study AF-001JP 
 
Response 
IRC Assessment (%) 
(n = 46) 
Complete response 
9 (20) 
Partial response 
34 (74) 
Stable disease 
1 (2) 
Progressive disease 
0 (0) 
Not evaluable 
2 (4.3) 
Complete and partial responses [95% CI] 
43 (93.5 [82.1, 98.6]) 
IRC = Independent Review Committee; RECIST v1.1 = Response Evaluation Criteria in Solid 
Tumors version 1.1. 
Note:  Radiographs reviewed and assessed by an IRC with the use of RECIST v1.1 (data cutoff 
date, 2 April 2014). 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
38/Protocol YO29449, Version 3 
 
Table 2 
Progression-Free Survival Results from Patients Participating 
in Part 2 of Study AF-001JP 
Result 
No. (%) of Patients 
n = 46 
Median duration of treatment, months 
22.4 
No. (%) of patients with PFS events 
12 (26) 
Median PFS, months (95% CI) 
27.7 (26.9, not estimable) 
Percent of patients with 2-year PFS (95% CI) 
76 (60, 86) 
IRC = Independent Review Committee; PFS = progression-free survival; RECIST v1.1 = Response 
Evaluation Criteria in Solid Tumors version 1.1. 
Notes:  Radiographs reviewed and assessed by an IRC with the use of RECIST v1.1 (data cutoff 
date, 2 April 2014).  The data in Table 2 have not changed since the previous data cutoff date, 
14 February 2014 (Chugai data on file).  The maximum median PFS CI interval could not be 
estimated because the maximum was not reached.  
 
In Study NP28761/AF-002JG (patients with ALK-positive NSCLC who had experienced 
crizotinib therapy failure), the Part 1 portion has completed enrollment.  Two “bridging” 
cohorts of patients that received alectinib 600 and 900 mg BID, with the use of a 
150-mg capsule, were included in Study NP28761/AF-002JG to transition and facilitate 
the planned formulation for the Phase II studies.  A total of 47 patients were enrolled in 
Part 1.  There was no substantial difference in pharmacokinetics between the 
two formulations (20 or 40-mg capsule and the 150-mg capsule) at the 600-mg BID 
dosage on the basis of the available data. 
The radiological imaging analysis that was performed in 44 evaluable patients who had a 
baseline scan and at least one follow-up scan (data cutoff date, 12 September 2013) 
showed that 2 of 7 patients in the 300-mg BID dosage cohort, 5 of 7 patients in the 
460-mg BID dosage cohort, 4 of 10 patients in the 600-mg BID dosage cohort, and 
4 of 13 patients (including 1 patient with CR) in the 900-mg BID dosage cohort had 
achieved a confirmed partial response (PR), as assessed by the investigator.  
Three of 10 patients in the 600-mg BID dosage cohort, 2 of 7 patients in the 760-mg BID 
dosage cohort, and 4 of 13 patients in the 900-mg BID dosage cohort had achieved a 
PR as assessed by the investigator; these results have yet to be confirmed by a second 
tumor assessment.  Three patients (all in the 600-mg BID dosage cohort) were 
unevaluable (tumors could not be evaluated at baseline).  The ORR was 54.5% 
(i.e., 24 of 44 evaluable patients who had a baseline scan and at least one 
post-treatment scan available to determine overall response, or who had a best overall 
response of progressive disease [PD] determined by the investigator, on the basis of 
symptomatic progression [3 patients]), including unconfirmed responses across all dose 
cohorts.  Thirty-three of the 47 treated patients (70%) were still receiving study treatment.  
The durations of dosing by cohort are shown in Figure 1. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
39/Protocol YO29449, Version 3 
 
Figure 1 Duration of Dosing by Cohort for Patients in Part 1 
of Study NP28761/AF-002JG 
 
Note:  Data cutoff date, 12 September 2013. 
 
The waterfall plot for the 42 patients who had a radiological tumor assessment 
performed after baseline is shown in Figure 2; 27 patients experienced tumor shrinkage 
of > 30%, of whom 23 patients were assessed as experiencing a PR (9 of these PRs had 
yet to be confirmed by a second tumor assessment). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
40/Protocol YO29449, Version 3 
 
Figure 2 Maximum Percent Change from Baseline in Target Lesion Size 
as Assessed by the Investigator for Patients in Part 1 of 
Study NP28761/AF-002JG 
 
Note:  Data cutoff date, 12 September 2013. 
 
Study NP28673 began enrolling patients on 20 June 2013, and the efficacy/safety data 
was published on 2015 American Society of Clinical Oncology (ASCO) annual meeting 
(see Alectinib Investigator's Brochure for more details). 
The benefit of alectinib, with regard to CNS activity, has been described by the DOT 
(before disease progression) or ORR in patients with brain metastases at baseline in the 
two active studies:  Study AF-001JP, conducted in Japan and 
Study NP28761/AF-002JG conducted in North America.  In Part 2 of Study AF-001JP, 
14 of 46 crizotinib-naive patients (30%) had documented CNS lesions before being 
enrolled into the study.  Three of these 14 patients were asymptomatic and had not 
received any prior CNS radiation.  At the time of the clinical cutoff date of 
31 January 2014, 9 of 14 patients who had brain metastases at baseline remained in the 
study without disease progression in the CNS or systemic disease progression. 
Similar CNS responses were observed in Study NP28761/AF-002JG, although the data 
(n = 47 patients) are more limited due to the shorter follow-up duration implemented in 
this study.  Of the 47 patients for whom crizotinib therapy had failed who enrolled in the 
study (data cutoff date, 12 September 2013), 21 patients (45%) were known to have 
brain metastases at baseline, of whom 17 patients had received prior radiation before 
enrolling in the study and 4 had not received any prior radiation therapy.  Seventeen of 

 
Alectinib—F. Hoffmann-La Roche Ltd 
41/Protocol YO29449, Version 3 
 
the 21 patients are continuing on study treatment, and 4 patients discontinued study 
treatment due to progressive disease.  All 4 patients who did not have prior brain 
irradiation before enrolling in the study remain in the study with durations of 77, 77, 154 
and 196 days, as of 12 September 2013. 
Study BO28984 (ALEX) is the pivotal Phase III study to evaluate alectinib versus 
crizotinib in patients with treatment-naive advanced ALK-positive NSCLC.  This study is 
ongoing.  The results from Study BO28984 will determine whether alectinib treatment 
has superior efficacy compared with crizotinib. 
Study JO28928, with a design similar to Study BO28984 in patients with ALK-positive 
NSCLC who are treatment-naive or have received one line of standard chemotherapy, is 
ongoing in Japan. 
See the Alectinib Investigator's Brochure for additional details on nonclinical and clinical 
studies. 
1.3 
STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT 
Over the past 10 years, the treatment of NSCLC has become increasingly focused on 
guiding treatment based on the presence or absence of an actionable mutation.  
Numerous oncogenes have now been identified in NSCLC, including mutations in the 
genes that code for EGFR, KRAS, phosphoinositide-3-kinase, catalytic, α polypeptide, 
and human EGFR 2 (Pao and Girard 2011).  As described in previous sections, a 
translocation in the gene that encodes the receptor tyrosine kinase ALK that leads to the 
expression of ALK fusion proteins was identified as an oncogenic driver in a subset of 
patients with NSCLC (Soda et al. 2007).  ALK rearrangements are found in 
approximately 4.6% of unselected patients with NSCLC (Koivunen et al. 2008; 
Takeuchi et al. 2008; Boland et al. 2009; Wong et al. 2009; Bang 2011; Kim et al. 2011; 
Paik et al. 2011; Cardarella et al. 2012; Dai et al. 2012; Fukui et al. 2012). 
Crizotinib is the first ALK inhibitor that is currently approved, and it has been registered 
in multiple countries worldwide including China for the treatment of ALK-positive NSCLC.  
Crizotinib is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI) that 
targets ALK, MET, RON, and ROS1 tyrosine kinases (Sahu et al. 2013; 
Shaw et al. 2013a).  Study PROFILE 1014, a Phase III study of crizotinib compared with 
standard pemetrexed−platinum−based chemotherapy, was presented at the ASCO 2014 
congress (Mok et al. 2014).  The study met its primary objective of prolonging PFS in 
patients who were previously untreated with ALK-positive non-squamous NSCLC with a 
median PFS of 10.9 and 7.0 months (HR: 0.45; 95% CI: 0.35, 0.60; p< 0.0001) for 
crizotinib and pemetrexed-platinum-based chemotherapy, respectively 
(Solomon et al. 2014). 
Although substantial benefit has been observed with crizotinib therapy, relapse 
eventually occurs.  Two main reasons for this are the development of resistance 

 
Alectinib—F. Hoffmann-La Roche Ltd 
42/Protocol YO29449, Version 3 
 
because of secondary (e.g., gatekeeper) mutations or because of CNS relapse 
(Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013).  This could be because of 
the fact that crizotinib is a P-glycoprotein (P-gp) substrate and has a low penetration in 
the CNS.  Thus, patients with ALK-positive NSCLC that are treated with crizotinib 
experienced impaired control of brain metastases relative to other sites of systemic 
disease; 46% of progressive disease in patients who are treated with crizotinib involves 
the CNS (Costa et al. 2011).  The CNS becomes a sanctuary site for ALK positive 
NSCLC that is treated with crizotiniba physiologic and anatomic mechanism of drug 
resistance. 
The second approved treatment for ALK-positive NSCLC is ceritinib 
(ZYKADIA U.S. Package Insert), an inhibitor of receptor tyrosine kinases including ALK 
and IGF-1.  Ceritinib was granted accelerated approved by the FDA in 2014 for the 
treatment of patients with ALK-positive metastatic NSCLC who have had disease 
progression during treatment with crizotinib or are intolerant to crizotinib therapy. 
Alectinib was granted approval in Japan on 4 July 2014 for the treatment of patients with 
ALK fusion gene−positive, unresectable, recurrent or advanced NSCLC. 
Alectinib is a highly selective and potent, oral next-generation ALK inhibitor.  Clinical 
data from the Part 2 portion of ongoing Study AF-001JP assessing alectinib in patients 
with ALK-positive NSCLC who are crizotinib-naive and have disease progression after at 
least one line of chemotherapy reported that the median treatment duration in the study 
has passed 23 months (range: 1-33).  The ORR was 93.5% (95% CI: 82.1, 98.6) with a 
complete response rate of 19.6% (9 patients), and the 2-year PFS was 76% 
(95% CI: 60, 86) (Tamura et al. 2014). 
Moreover, alectinib is a lipophilic drug and not a P-gp substrate, which may support its 
accessibility through the blood-brain barrier.  This has been demonstrated in the 
nonclinical setting on the basis of the prolongation of survival in a mouse model with 
implanted CNS lesions and in a tissue-distribution study with a single oral dose of 
[14C]-alectinib of 1 mg/kg to albino rats (Ou et al. 2013).  Preliminary clinical data from 
the Phase I and II studies demonstrate the consistent therapeutic efficacy of alectinib in 
brain metastases. 
The clinical efficacy data are compelling, demonstrating that alectinib has a longer 
disease progression-free interval and improved activity with regard to the CNS, thus 
delaying the impact of CNS metastases on neurologic function and the morbidities 
associated with treatments required for disease control such as brain radiation, surgery, 
and corticosteroid use.  The currently available clinical safety data support an acceptable 
safety and tolerability profile for alectinib.  These data suggest the importance of 
comparing alectinib with crizotinib as a therapeutic option for ALK-positive advanced or 
advanced NSCLC. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
43/Protocol YO29449, Version 3 
 
In this proposed Phase III study, treatment-naive Asian patients with ALK-positive 
advanced NSCLC will be enrolled and randomized to receive either crizotinib or alectinib 
treatment.  The results of this study will determine whether alectinib treatment has 
similar efficacy to which was demonstrated in Study BO28984. 
The first Phase I dose-escalation study of alectinib was conducted in Japan 
(Study AF001-JP) and demonstrated that alectinib was generally well tolerated without 
dose-limiting toxicities at dosing regimens up to 300 mg BID.  Of the 58 patients who 
received treatment with the highest evaluated dosage, 300 mg BID alectinib in 
Study AF 001JP, 27 experienced Grade 3 adverse events and 9 experienced serious 
adverse events.  No deaths were reported during the study or during the 28 days after 
study drug treatment was discontinued.  There were 5 adverse events that led to 
treatment discontinuation in Part 2 of the study (brain edema, sclerosing cholangitis, 
interstitial lung disease [ILD], increased ALT, and tumor hemorrhage).  Alectinib was well 
tolerated at all doses investigated in this study.  Alectinib’s adverse event profile was 
consistent with the known adverse event profile associated with ALK inhibitors.  In Part 1 
of Study NP28761/AF-002JG, alectinib was well tolerated, with no DLTs or 
treatment-related dose modifications for doses through 600 mg BID.  Two DLTs were 
reported in a bridging cohort of patients treated at 900 mg BID.  Therefore, the 
recommended alectinib Phase II dosage of 600 mg BID was chosen as having the best 
balance among clinical safety, efficacy, and pharmacokinetic (PK) data observed in the 
Phase I and II studies (see Section 3.3.1). 
On the basis of available preliminary data, the estimated benefits of alectinib treatment 
outweigh the risks, specifically: 
• 
Available nonclinical and clinical data demonstrate that alectinib is active in patients 
with NSCLC who are either crizotinib-naive or have had disease progression during 
crizotinib therapy 
• 
Clinical safety data from patients treated with alectinib up to and including 900 mg 
BID demonstrated that safety profile of alectinib is consistent with the known safety 
profile associated with ALK inhibitors. 
 
Identified and potential risks associated with alectinib treatment will continue to be 
closely monitored throughout the clinical program.  Patient safety during the alectinib 
program is facilitated by targeting the most appropriate patient population and by using 
protocol-specified study drug interruption criteria. 
2. 
OBJECTIVES 
2.1 
EFFICACY OBJECTIVES 
The primary efficacy objective for this study is to evaluate and compare the efficacy of 
alectinib with that of crizotinib in Asian patients with treatment-naive ALK-positive 
advanced NSCLC, as measured by investigator-assessed PFS.  This objective is to 

 
Alectinib—F. Hoffmann-La Roche Ltd 
44/Protocol YO29449, Version 3 
 
reliably determine whether the benefit (in terms of PFS) of administrating alectinib in this 
study is consistent with the benefit observed in the global Study ALEX (BO28984). 
The secondary efficacy objectives for this study are as follows: 
• 
To evaluate and compare the ORR and DOR by treatment arm 
• 
To evaluate and compare the time to disease progression in the CNS on the basis 
of review of patient radiographs by an IRC with the use of Response Evaluation 
Criteria in Solid Tumors version 1.1 (RECIST v1.1) and Response Assessment in 
Neuro Oncology (RANO) criteria, as well as: 
To evaluate the CNS objective response rate (C-ORR) in patients with CNS 
metastases who have measurable disease in the CNS at baseline 
To assess the CNS duration of response (C-DOR) in patients who have a CNS 
objective response 
To assess CNS progression rates (C-PR) at 6, 12, 18, and 24 months on the 
basis of cumulative incidence 
• 
To evaluate and compare the PFS assessment by an IRC by treatment arm 
• 
To evaluate and compare the OS by treatment arm 
 
2.2 
SAFETY OBJECTIVE 
The safety objective for this study is to evaluate the safety and tolerability of alectinib 
compared with crizotinib. 
2.3 
PHARMACOKINETIC OBJECTIVE 
The PK objective for this study is to characterize the pharmacokinetics of alectinib (and 
metabolite[s], if appropriate). 
2.4 
PATIENT-REPORTED OUTCOME OBJECTIVES 
The patient-reported outcome (PRO) objectives for this study are as follows: 
• 
To evaluate and compare time to deterioration (TTD) with patient-reported lung 
cancer symptoms of cough, dyspnea (single item and multi-item subscales), chest 
pain, arm and/or shoulder pain, and fatigue as measured by the European 
Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life 
Questionnaire−Core (QLQ-C30, see Appendix 7), the supplemental EORTC 
Quality-of-Life Questionnaire−Lung Cancer module (QLQ-LC13, see Appendix 8), 
and a composite of the following three symptoms:  cough, dyspnea, and chest pain 
• 
To evaluate and compare PROs regarding health-related quality of life (HRQOL), 
daily functioning, and side effects of treatment as measured by the 
EORTC QLQ-C30 and EORTC QLQ-LC13 (see Appendix 7 and Appendix 8, 
respectively) 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
45/Protocol YO29449, Version 3 
 
2.5 
EXPLORATORY OBJECTIVES 
The exploratory objectives for this study are as follows: 
• 
To investigate molecular mechanisms of resistance to ALK inhibitors 
• 
To investigate detection of mutations in ALK and other genes, refer to Appendix 12 
for detailed information. 
 
3. 
STUDY DESIGN 
3.1 
DESCRIPTION OF STUDY 
This is a randomized, active-controlled, multicenter Phase III open-label study in Asian 
patients with treatment-naive ALK-positive advanced NSCLC.  All patients are required 
to provide a pretreatment tumor sample that will be used to confirm the presence of ALK 
rearrangement (by Ventana immunohistochemistry [IHC] test; D5F3 antibody, catalog 
reference number 790-4794, CE IVD: 06679072001, performed at a central laboratory).  
Patients will be randomized 2:1 into one of the two treatment arms to receive either 
alectinib or crizotinib, respectively. 
This study will be conducted in approximately three other countries in addition to China. 
The primary endpoint of the study is investigator-assessed PFS. 
Central randomization will be performed via an interactive voice/Web response system 
(IxRS) with stratification by Eastern Cooperative Oncology Group Performance Status 
(ECOG PS) (0/1 vs. 2) and CNS metastases at baseline (yes vs. no).  An IxRS 
information manual will be provided to each study site. 
The experimental arm will receive alectinib administered orally at 600 mg BID, taken with 
food.  The control arm will receive crizotinib administered orally at 250 mg BID, taken 
either with or without food.  The first dose of the study drug should be administered as 
soon as possible after randomization, preferably within 24 hours, and no later than 
48 hours after randomization. 
Patients will be treated until disease progression, unacceptable toxicity, withdrawal of 
consent, or death.  Patients should discontinue the study medication once progression of 
disease has been determined on the basis of RECIST v1.1, and subsequent treatment 
will be decided at the discretion of the investigator according to local practice.  
Information regarding the nature and the duration of subsequent therapies will be 
collected. 
In the case of isolated asymptomatic disease progression in the CNS (e.g., new CNS 
oligometastases), localized treatment (e.g., stereotactic radiotherapy or surgery) may be 
provided followed by the continuation of the patient’s study treatment (either alectinib or 
crizotinib) until systemic disease progression or symptomatic disease progression in the 
CNS.  The decision to continue the study treatment beyond the isolated, asymptomatic 

 
Alectinib—F. Hoffmann-La Roche Ltd 
46/Protocol YO29449, Version 3 
 
disease progression in the CNS is at the investigator’s discretion for patients who may 
continue to benefit from their respective study drug treatment. 
Patients who discontinue study drug treatment before disease progression 
(e.g., because of unacceptable toxicity) will continue to be followed to collect information 
regarding disease progression and OS information, regardless of whether the patient 
subsequently received any non-study anti-cancer therapy.  Data regarding subsequent 
anti-cancer therapy will be collected for the analysis of OS. 
Approximately 183 patients (122 in the alectinib treatment arm and 61 in the crizotinib 
treatment arm) will be enrolled into the study over a planned recruitment period of 
13 months.  Patients who are inappropriately randomized into the study will not be 
replaced.  With the current assumption that hazard ratio is 0.65, the primary 
analysis that will evaluate the primary endpoint of investigator-assessed PFS is 
expected to occur approximately 23 months after the first patient has been enrolled 
when approximately 97 PFS events have occurred.  Data collection will continue for 
each patient until death or study closure, whichever occurs first. 
A summary of the study design is shown in Figure 3, and a schedule of assessments is 
provided in Appendix 1. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
47/Protocol YO29449, Version 3 
 
Figure 3 Summary of Study Design 
 
BID = twice a day; NSCLC = non−small cell lung cancer. 
a Frequent blood sampling will be performed in a subset of 20 Chinese patients enrolled to 
receive alectinib treatment to facilitate the characterization of alectinib pharmacokinetics. 
 
3.1.1 
Independent Review Committee 
An IRC will be established to perform an independent review of all radiological scans for 
the primary analysis and to determine the response and disease progression on the 
basis of the RECIST v1.1 in addition to the local investigator’s review of radiographs.  
Only the results from the investigator’s review of radiographs will be used to determine 
whether patients should be enrolled or should remain in the study.  The IRC’s 
assessment will only be used in the primary analysis.  All decisions made during the 
performance of the study will be on the basis of the local investigator’s review and 
assessment of radiographs. 
Sites will submit radiological files to the centrally located IRC’s data review facility during 
the study on an ongoing basis or at the Sponsor’s request for primary analysis.  For the 
primary analysis, the IRC will perform an independent review of the computed 
Screening assessment 
2:1 Randomization  
with stratification 
(n = 183) 
600 mg BID 
alectinib a 
250 mg BID 
crizotinib 
Until disease progression, unacceptable 
toxicity, withdrawal of consent, or death 
Subsequent therapy for NSCLC and Survival follow-up 

 
Alectinib—F. Hoffmann-La Roche Ltd 
48/Protocol YO29449, Version 3 
 
tomography (CT) and magnetic resonance imaging (MRI) scans on the basis of a 
prespecified Charter to determine the response and disease progression on the basis of 
the RECIST v1.1.  Details are provided in the IRC Charter. 
For evaluation of the CNS endpoints, the IRC will perform an assessment of scans on 
the basis of RECIST and RANO criteria.  Details are provided in the IRC Charter. 
3.2 
END OF STUDY 
This is an event-driven study.  With the current assumption that the HR is 
0.65 and the recruitment period is 13 months, the required 97 PFS events for 
primary efficacy analysis is expected to occur 23 months after the first patient 
has been enrolled.  If the number of PFS events is not enough for the estimation 
of median PFS, an updated PFS analysis will be done when approximately 55% 
of patients have had PFS events.  A survival follow-up analysis will be 
performed when approximately 55% of patients have died, which is estimated to 
occur 41 months after the first patient has been enrolled. 
The study will formally end when the survival follow-up analysis is complete and the last 
patient has permanently discontinued treatment with alectinib and performed the Study 
Completion or Study Treatment Discontinuation assessments (Post-Treatment Visit). 
3.3 
RATIONALE FOR STUDY DESIGN 
3.3.1 
Rationale for Alectinib Dosage 
Selection of the alectinib dose used in this study is based on the clinical safety, 
efficacy, and PK data observed in the Phase I/II studies (Study AF-001JP and 
Study NP28761/AF-002JG) and the supportive nonclinical data for alectinib. 
The first-in-human study (Study AF-001JP) evaluated escalating doses of alectinib in 
Japanese patients in an accelerated titration scheme to rapidly identify the MTD.  All 
doses, including the highest evaluated dosage in the study (300 mg BID), were well 
tolerated, and no DLTs were observed.  The highest tested dosage, 300 mg BID, was 
further evaluated in the Part 2 portion of the study and demonstrated promising early 
efficacy and good safety with an ORR, as assessed by an IRC, of 93.5% (43/46 patients; 
95% CI: 82.1%, 98.6%). 
With no MTD determined in Study AF-001JP, dose escalation progressed in the North 
American Study NP28761/AF-002JG with the use of a modified 3 + 3 design, where 
3 patients were assessed for DLTs, and additional patients were enrolled for PK 
evaluation.  The starting dosage in Study NP28761/AF-002JG was 300 mg BID (the 
highest dosage evaluated in Study AF-001JP), and dose escalation progressed with 
evaluation of higher dosages of alectinib through 900 mg BID.  Following multiple 
dosages of alectinib at 300 mg BID in Study NP28761/AF-002JG, the median alectinib 
exposure (area under the concentration−time curve from 0 to 10 hours [AUC0-10]) 
appeared to be approximately 2-fold lower compared with that in patients from 

 
Alectinib—F. Hoffmann-La Roche Ltd 
49/Protocol YO29449, Version 3 
 
Study AF-001JP.  The mechanisms underlying the observed exposure differences are 
not entirely clear; however, they suggest that a proportion of patients may not achieve 
exposures that demonstrated robust efficacy and safety in Study AF-001JP. 
In Study NP28761/AF-002JG, no DLTs were observed in the dose escalation cohorts, 
up to a dosage-level of 900 mg BID.  However, 2 patients in the subsequent 900-mg BID 
bridging cohort experienced a DLT (1 patient experienced a Grade 3 headache, and 
1 patient Grade 3 neutropenia) and continued study drug treatment at a reduced dosage 
of 600 mg BID.  Overall, alectinib was well tolerated in the study population. 
Importantly, administration of alectinib at 600 mg BID provides systemic exposures that 
meet or exceed exposures that were achieved in patients receiving 300 mg BID in 
Study AF-001JP, demonstrating robust efficacy and safety in patients who are 
crizotinib-naive.  Further, in Study NP28761/AF-002JG, the 600-mg BID regimen has 
demonstrated promising activity in patients who are crizotinib-resistant and in patients 
who have CNS metastases; this regimen is also well tolerated in this patient population.  
Limited PK data from the 600-mg BID dose level are available from Study NP28673 
across populations and illustrate that the mean alectinib steady-state exposures are only 
approximately 30%−40% higher in Asian (Taiwanese/South Korean) patients compared 
with Caucasian (European) patients in the within-study evaluation of Study NP28673.  
During cross-study evaluations that were relative to Study NP28761/AF-002JG, mean 
exposure differences ranged from 30% to 100% between Asian and non-Asian patients.  
The underlying mechanism for the differences remains to be determined; however, 
analyses of clinical safety data from the ongoing Phase II Study NP28673 demonstrated 
that the safety and tolerability profiles of alectinib administered at 600 mg BID are 
comparable between Asian and non-Asian patients and show good tolerability in the 
Asian population receiving the 600 mg BID dosing regimen, indicating that the clinical 
relevance of any observed differences in PK are limited. 
On the basis of available nonclinical data, administration of alectinib 600 mg BID 
provides systemic exposures within the expected range (on the basis of regression of 
available data) for tumor regression observed in mouse xenograft models.  See the 
Alectinib Investigator’s Brochure. 
Thus, the available clinical efficacy, safety, and PK and PK/PD data from ongoing clinical 
studies along with the supportive nonclinical data support the dosing regimen of 600 mg 
BID of alectinib as the recommended dosing regimen for evaluation in this study. 
3.3.2 
Rationale for Patient Population 
The study population will be composed of patients with non-resectable, locally advanced 
and metastatic NSCLC who have been shown to be ALK-positive by an IHC test 
performed at central laboratories specially designated for the study.  Patients should not 
have received any previous treatment for advanced NSCLC (i.e., are treatment-naive). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
50/Protocol YO29449, Version 3 
 
Both experimental (alectinib) and control (crizotinib) treatments are ALK-targeted 
therapies.  The clinical practice guidelines recommend targeted treatment for patients 
with metastatic, oncogene-driven disease as first-line systemic therapy 
(i.e., EGFR-inhibitors for EGFR-positive NSCLC and ALK-inhibitors for ALK-positive 
NSCLC) (NCCN 2014). 
To be eligible to participate in this study, determination of ALK positivity will be 
performed at a central laboratory with the use of an IHC assay (see Appendix 10).  IHC 
is faster, easier to perform in local laboratories, and requires less equipment compared 
with the fluorescence in situ hybridization (FISH) assay.  In addition, IHC has high 
concordance with FISH and a lower false-negative rate (Kim et al. 2011), and Ventana 
Medical Systems has been approved in China 
(China Food and Drug Administration 2013, 2014). 
3.3.3 
Rationale for Control Group 
Targeted therapy (including ALK-targeted therapy) is likely to have a greater anti-tumor 
effect than standard chemotherapy, offering patients a higher response rate and longer 
durability of response with less toxicity compared with any potential chemotherapy 
options (Mok et al. 2009; Rosell et al. 2012; Sequist et al. 2013; Shaw et al. 2013a). 
Crizotinib is an oral small-molecule multi-targeted TKI targeting ALK, MET, RON, and 
ROS1 tyrosine kinases (Sahu et al. 2013; Shaw et al. 2013a).  It is the first-generation 
ALK inhibitor that has been approved in multiple countries worldwide for the treatment of 
ALK-positive NSCLC. 
In November 2013, crizotinib was granted regular approval in the United States for 
use in an ALK-positive NSCLC setting, regardless of treatment line 
(XALKORI U.S. Package Insert), whereas in Europe, crizotinib is currently approved 
conditionally for patients with previously treated ALK-positive NSCLC (Crizotinib SmPC). 
Crizotinib was also approved in China in February 2013 and became standard of 
treatment for ALK-positive NSCLC. 
The National Comprehensive Cancer Network (NCCN) guidelines recommend crizotinib 
as first-line therapy for patients with advanced ALK-positive NSCLC (NCCN 2014). 
The randomized Phase III Study PROFILE 1014 was conducted to assess the efficacy of 
crizotinib versus standard platinum-based chemotherapy (pemetrexed plus cisplatin or 
carboplatin) as first-line treatment for patients with ALK-positive, non-squamous NSCLC.  
The study met its primary objective of prolonging PFS in previously untreated patients 
with ALK-positive non-squamous NSCLC with median PFS of 10.9 and 7.0 months 
(HR: 0.45; 95% CI: 0.35, 0.60; p  < 0.0001) for crizotinib and pemetrexed-platinum-based 
chemotherapy, respectively (Solomon et al. 2014). The authors concluded that these 

 
Alectinib—F. Hoffmann-La Roche Ltd 
51/Protocol YO29449, Version 3 
 
findings establish crizotinib as the standard of care for patients with previously untreated 
advanced ALK-positive non-squamous NSCLC (Solomon et al. 2014). 
Crizotinib will be dosed as per standard dose recommendations from prescribing 
information—patients in the crizotinib arm will receive crizotinib at 250 mg orally BID with 
or without food until disease progression, unacceptable toxicity, withdrawal of consent, 
or death. 
3.3.4 
Rationale for Open-Label Design 
An open-label study design is more appropriate for patients enrolled in this particular 
study for a number of reasons defined below and with the ultimate goal to ensure patient 
compliance as much as possible. 
For a blinded study design, all enrolled patients would be required to take five large 
capsules BID.  This high pill count results from the difference in capsule size between 
crizotinib (size 0) and alectinib (size 1).  Each dose would consist of one-250 mg capsule 
of crizotinib or matching placebo, and four-150 mg capsules of alectinib or matching 
placebo.  In order to maintain blinding, crizotinib capsules would be required to be 
over-encapsulated which would increase the size of the capsule from size 0 to size 00 
(double zero).  The size 00 capsule is the largest capsule size administered orally to 
humans.  For some patients, the size 00 capsules are too large to swallow.  The high pill 
count per dose, combined with this large capsule size, is considered to be a significant 
burden to patients that increases the risk of non-compliance. 
Additionally, a blinded study design would increase the complexity of standard dose 
reductions.  Dose interruption or dose reduction may be required on the basis of 
individual safety and tolerability.  The standard crizotinib dose reduction is 200 mg BID, 
which would require a different capsule (size 1), followed by 250 mg QD.  However, 
dose reductions for alectinib would occur in 150 mg steps.  In a double-blind study, 
these multiple-step dose reductions introduce a high level of complexity and potential for 
error. 
To avoid a significant burden to patients associated with high pill count and increased 
risk of non-compliance because of capsule size and complexity of standard dose 
reductions, adequate steps have been taken to ensure the validity of the data in an 
open-label study design.  These include performing sensitivity analyses to demonstrate 
the robustness of the primary endpoint, defining disease progression with the use of 
established response evaluation criteria (RECIST v1.1), performing tumor assessment at 
the same frequency in both treatment arms, adhering to protocol-defined schedules, and 
finalizing the strategy for the primary analysis of the primary endpoint before initiating 
this study, which include predefined methods for handling missing data and censoring 
rules.  Efficacy analyses will be performed only at the prespecified analysis timepoints in 
the protocol (primary analysis will be performed when 97 PFS events have occurred, 
and survival follow-up analysis will be performed when 101 OS events have occurred). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
52/Protocol YO29449, Version 3 
 
3.3.5 
Rationale for Primary Endpoint Selection 
The investigator-assessed PFS is the primary endpoint for this study. 
PFS, as an endpoint, may reflect tumor growth and may be assessed before the 
determination of a survival benefit, and its determination is not generally confounded 
by subsequent therapies.  Whether an improvement in PFS represents a direct 
clinical benefit or a surrogate for clinical benefit depends on the magnitude of the 
effect and the benefit-risk of the new study drug treatment compared with available 
therapies (U.S. Department of Health and Human Services 2007; 
European Medicines Agency 2012).  A PFS HR of 0.65 will be targeted, which 
constitutes a clinically meaningful benefit in this patient population because it will delay 
the use of platinum-based chemotherapy and potentially reduce both the frequency of 
CNS relapse and the morbidity associated with treating CNS metastases. 
The assumed median PFS for patients in the alectinib treatment arm is 16.8 months, and 
an OS of more than 30 months is expected, which equates to a post-progression 
survival of at least 15 months.  Patients with ALK-positive NSCLC who were treated with 
crizotinib in the second-line setting had a median PFS of 7.7 months and an interim 
median OS of 20.3 months (Shaw et al. 2013a), which equated to a post-progression 
survival of 12.6 months.  This lengthy post-progression survival expected with alectinib 
treatment provides an opportunity for patients to receive subsequent treatments with 
other ALK inhibitors or several additional lines of chemotherapy or to participate in 
additional clinical studies. 
Patients in both study arms who experience disease progression during study treatment 
will likely be treated with other subsequent treatment options, including ALK inhibitors.  
The availability of crizotinib on the market, the likely availability of other next-generation 
ALK TKIs, and the availability of other investigational agents in clinical studies offer 
potential treatment options to patients in this study who will eventually have disease 
progression.  Subsequent therapies frequently confound the detection of an OS benefit, 
particularly in a setting with a long post-progression survival, such as ALK-positive 
NSCLC.  This has been observed in studies for EGFR TKIs, in which strong PFS 
benefits were observed without evidence of OS benefit (Rosell et al. 2009; 
Fukuoka et al. 2011). 
The anticipated long post-progression survival and the confounding effects of 
subsequent lines of therapy indicate that it may be difficult to detect an OS benefit in this 
setting.  Nevertheless, OS is one of the study’s secondary endpoints.  The crossover 
from crizotinib treatment to alectinib treatment will not be allowed in this study in order to 
preserve the study’s ability to potentially demonstrate some degree of treatment benefit 
of alectinib in regards to OS, but, upon progression, patients will be treated at the 
investigator’s discretion. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
53/Protocol YO29449, Version 3 
 
To ensure the consistency benefit with the global pivotal Study BO28984  (in terms of 
PFS), maintaining ≥50% of risk reduction from Study BO28984, a number of measures 
have been implemented, which include a substantial target magnitude of benefit 
(target HR = 0.65) and study assessments that allow for a robust evaluation of 
benefit-risk (standard RECIST criteria used to define disease progression at fixed 
assessment intervals that are identical in both treatment arms and a robust definition of 
PFS along with prospectively defined methods to assess, quantify, and analyze PFS, 
which include censoring methods and sensitivity analyses). 
3.3.6 
Rationale for Secondary Endpoint of Time to CNS Progression 
Lung cancer is the most common type of cancer to spread to the brain, with 
at least 40% of people with lung cancer developing brain metastases at some point 
during their disease.  ALK-positive NSCLC has a propensity to metastasize to the brain, 
and crizotinib has impaired control of brain metastases in comparison with other sites of 
systemic disease (Chun et al. 2012). 
Delaying or preventing the development of CNS metastases would provide patients with 
a clinically meaningful benefit by avoiding consequences of neurological deficits from 
brain metastasis or by delaying or preventing long-term side effects associated with 
steroid use and brain irradiation. 
Preliminary evidence of CNS benefit with alectinib has been observed in patients in the 
two ongoing Phase I/II studies.  See Section 1.2 and the Alectinib Investigator's 
Brochure for additional details. 
Time to CNS progression is defined as the time from randomization until radiographic 
evidence of CNS progression is documented.  The aim of the prespecified analysis will 
be to evaluate whether alectinib significantly delays or prevents the development of CNS 
metastases. 
Randomization of this Phase III study will be stratified by the presence or absence of 
CNS metastasis at baseline. 
Imaging analysis with the use of uniform image acquisition technique (MRI scans) will be 
performed routinely at baseline and at subsequent follow-up assessments along with 
every systemic imaging tumor assessment or whenever clinically indicated (i.e., clinical 
suspicion of CNS metastasis) in order to achieve an accurate determination of time to 
CNS progression.  This ensures that early brain metastatic lesions are detected and that 
assessment bias between the two treatment arms is avoided by having regularly 
scheduled MRI scans. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
54/Protocol YO29449, Version 3 
 
3.3.7 
Rationale for Alectinib Pharmacokinetic Sample Collection 
Schedule 
To date, the pharmacokinetics of alectinib has been characterized in Study AF-001JP in 
patients with NSCLC who are crizotinib-naive and have had chemotherapy treatment fail 
and in Study NP28761/AF-002JG and Study NP28673 in patients who had both 
chemotherapy and treatment with crizotinib fail.  In order to better understand the 
pharmacokinetics of alectinib in Chinese patients and to further support the development 
of a robust population PK model for alectinib, characterization of alectinib 
pharmacokinetics will be done in this study. 
This study will include PK assessment of alectinib in patients with ALK-positive 
advanced NSCLC who are ALK inhibitor treatment-naive by collecting sparse samples 
from all patients receiving alectinib.  Frequent blood sampling will be performed in a 
subset of 20 Chinese patients to facilitate the characterization of alectinib 
pharmacokinetics.  The PK profile of alectinib after a single dose and at steady-state will 
be evaluated to determine accumulation index, area under the concentration−time curve 
(AUC), maximum plasma concentration observed (Cmax), time to maximum concentration 
(tmax), etc. 
The data from this study will provide a more robust understanding of alectinib 
pharmacokinetics in the crizotinib-naive patient population, including investigation and 
potential identification of sources of variability influencing alectinib pharmacokinetics or 
response to alectinib therapy.  Results from the PK data collected in this study and 
analyses of these PK data may help support an optimal use of alectinib therapy. 
3.3.8 
Rationale for Biomarker Assessments 
There are several molecular mechanisms of resistance to crizotinib reported in the 
literature:  increased copy number of the ALK gene, increased expression of ALK mRNA, 
secondary mutations in ALK (e.g., gatekeeper mutation), and changes (e.g., increased 
copy number, increased phosphorylation, or point mutations) in escape genes such as 
EGFR, cKIT, or KRAS (Katayama et al. 2011; Doebele et al. 2012; Kim et al. 2013).  In 
order to investigate molecular mechanisms of resistance to ALK inhibitors and 
ALK-mutation status, tumor samples will be collected before treatment and at the time of 
disease progression with the goal of sequencing nucleic acids. 
Mutations in cancer genes appearing from drug resistance may be monitored in 
circulating nucleic acids in plasma (Forshew et al. 2012).  Tumor nucleic acids are shed 
into circulation in amounts that allow direct amplification by polymerase chain reaction 
and analysis by sequencing.  Plasma samples will be collected before treatment and at 
certain timepoints during treatment, to monitor mutations in ALK and other genes 
involved in resistance to ALK inhibitors.  Information from mutated genes in the tumor 
will be correlated with mutations in plasma nucleic acids. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
55/Protocol YO29449, Version 3 
 
3.3.9 
Rationale for Patient-Reported Outcome Assessments 
In the treatment of lung cancer, it is important to increase survival and palliate symptoms 
because disease symptoms have negative impacts on HRQOL (Hyde and Hyde 1974; 
Hopwood and Stephens 1995; Sarna et al. 2008).  This is especially true for studies that 
use PFS as a primary endpoint, where it is important to translate the delay in disease 
progression into an endpoint that is meaningful to patients. 
Pain (chest; arm/shoulder), dyspnea, cough, and fatigue have been regarded as the 
most frequent and clinically relevant disease-related symptoms experienced by patients 
with NSCLC.  Study BR.21 (erlotinib vs. chemotherapy in second- or third-line NSCLC) 
demonstrated that a longer TTD observed in the pain, dyspnea, and cough scales of the 
EORTC (QLQ-C30 and QLQ-LC13, see Appendix 7 and Appendix 8, respectively) was 
consistent with superior PFS, OS, and quality-of-life (QOL) benefits in the erlotinib 
treatment arm compared with the placebo treatment arm (Aaronson et al. 1993; 
Bergman et al. 1994; Bezjak et al. 2006).  Additionally, patients in crizotinib 
Study PROFILE 1005 reported clinically significant (10 points) improvement in the pain, 
cough, dyspnea, and fatigue symptom scales as early as 2 weeks after starting 
treatment (Crinò et al. 2011). 
The EORTC’s QLQ-C30 and QLQ-LC13 scales (see Appendix 7 and Appendix 8, 
respectively) were used in Study PROFILE 1007, a Phase III study that compared 
second-line crizotinib versus chemotherapy.  The study reported a significantly greater 
overall reduction from baseline in the symptoms of alopecia, cough, dyspnea, fatigue, 
chest pain, arm or shoulder pain, and pain in other parts of the body in patients treated 
with crizotinib compared with patients treated with chemotherapy (p < 0.001 for all 
comparisons, without adjustment for multiple testing).  Patients treated with crizotinib 
also had a significantly greater delay in the worsening of symptoms and significantly 
greater overall improvement from baseline in the global QOL versus those patients 
who received chemotherapy (p < 0.001).  In all domains measuring functioning, 
except for the domain measuring cognitive functioning, there was a significantly 
greater overall improvement from baseline among patients in the crizotinib 
treatment group versus patients in the chemotherapy group (Shaw et al. 2013a).  In 
Study PROFILE 1014, a Phase III study of crizotinib compared with standard 
pemetrexed−platinum-based chemotherapy, there was a significantly greater overall 
improvement from baseline in global quality of life among patients who received 
crizotinib than among those who received chemotherapy (P < 0.001).  Crizotinib was also 
associated with a significantly greater overall improvement from baseline in physical, 
social, emotional, and role-functioning domains (P < 0.001) (Solomon et al. 2014). 
Therefore, to assess the QOL of patients in this study, PRO data will be collected from 
patients enrolled in this study with the use of validated EORTC questionnaires 
(QLQ-C30 and QLQ-LC13, see Appendix 7 and Appendix 8, respectively). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
56/Protocol YO29449, Version 3 
 
3.4 
OUTCOME MEASURES 
3.4.1 
Efficacy Outcome Measures 
The efficacy outcome measures for this study are as follows: 
• 
PFS, defined as the time from randomization to the first documentation of disease 
progression, as determined by the investigators (primary endpoint) or IRC 
(secondary endpoint) with the use of RECIST v1.1, or death from any cause, 
whichever occurs first.  Patients without an event will be censored at the last tumor 
assessment, either during follow-up or during study treatment.  Patients without any 
assessments performed after baseline will be censored at the date of randomization. 
• 
ORR, defined as the percentage of patients who attain CR or PR as assessed by 
the investigators with the use of RECIST v1.1.  Patients without any assessments 
will be regarded as non-responders. 
• 
Time to progression of disease in the CNS, defined as the time from randomization 
to the first occurrence of disease progression in the CNS as determined by an IRC 
with the use of RECIST v1.1 and RANO (separate assessments and analyses), as 
well as C-ORR in patients with CNS metastases who have measurable disease in 
the CNS at baseline; C-DOR in patients who have a CNS Objective Response, and 
C-PR at 6, 12, 18, and 24 months. 
• 
DOR, defined as the time from the initial documentation of a response (CR or PR 
with the use of RECIST v1.1) to first documentation of disease progression with the 
use of RECIST V1.1, or death (whichever occurs first).  This will be calculated only 
for patients who have a best overall response of CR or PR.  Patients who do not 
have disease progression or who die after they have had a response will be 
censored at the date of their last tumor measurement. 
• 
OS, defined as the time from randomization to death from any cause.  Patients 
without an event will be censored at the last date they were known to be alive.  
Patients without any follow-up information will be censored at the date of 
randomization. 
 
3.4.2 
Safety Outcome Measures 
The safety outcome measures for this study are as follows: 
• 
Serious and non-serious adverse events 
• 
Safety laboratory test results 
• 
Vital signs (blood pressure, heart rate), ECG 
• 
Physical examination findings 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
57/Protocol YO29449, Version 3 
 
3.4.3 
Pharmacokinetic Outcome Measures 
The PK outcome measures for this study are as follows: 
• 
Sparse blood sampling will be performed in all patients receiving alectinib treatment 
to characterize the PK of alectinib (and metabolite[s], if appropriate).  See 
Appendix 1 and Appendix 2 for PK sampling times. 
• 
Frequent blood sampling will be performed in a subset of 20 consenting Chinese 
patients enrolled to receive alectinib treatment.  See Appendix 1 and Appendix 2 for 
PK sampling times. 
• 
PK parameters will be determined as appropriate and where data allow 
• 
NCA for alectinib (and metabolite[s], if appropriate) may be conducted in patients 
undergoing frequent blood sampling, as appropriate and where data allow. 
The sparse and frequent pharmacokinetics of alectinib (and metabolite[s], if 
appropriate) will be described and the between-patient variability will be 
estimated with the use of a population PK approach.  The potential influence of 
covariates that contribute significantly to the between-patient differences in PK 
parameters of alectinib will also be explored and quantified.  If necessary, data 
may be pooled with data from other studies. 
 
3.4.4 
Patient-Reported Outcome Questionnaires 
The PRO questionnaires included for this study are as follows and will be administered 
to patients every 4 weeks until disease progression and during disease progression 
while receiving study drug treatment in the case of isolated, asymptomatic disease 
progression in the CNS at the Post-Treatment Visit (4 weeks after treatment 
discontinuation) and at every follow-up visit (every 8 weeks) after the Post-Treatment 
Visit for 6 months: 
• 
The EORTC QLQ-C30 and EORTC QLQ-LC13 (see Appendix 7 and Appendix 8) 
will be used to determine the impact of alectinib compared with crizotinib as 
measured by TTD with patient-reported lung cancer symptoms (e.g., cough, 
dyspnea [single-item and multi-item scales], pain in chest, pain in arm/shoulder, 
fatigue). 
• 
The EORTC QLQ-C30 and EORTC QLQ-LC13 (see Appendix 7 and Appendix 8) 
will be used to measure PROs of HRQOL, patient functioning, and side effects of 
therapy compared between patients treated with alectinib and those treated with 
crizotinib. 
• 
For patients who discontinue treatment for reasons other than disease progression 
and who progress within the first 6 months of survival follow-up, PRO questionnaires 
will be administered every 4 weeks until disease progression.  Upon disease 
progression, PRO questionnaires will be provided every 8 weeks until 6 months 
post-treatment. 
• 
For patients who discontinue treatment for reasons other than disease progression 
and who have not yet progressed at 6 months post-treatment, PRO questionnaires 

 
Alectinib—F. Hoffmann-La Roche Ltd 
58/Protocol YO29449, Version 3 
 
will be administered every 4 weeks until disease progression and will no longer be 
required thereafter.  
 
3.4.5 
Exploratory Outcome Measures 
The exploratory outcome measures for this study are as follows: 
• 
Baseline and post-progression tumor mutation status to study molecular 
mechanisms of resistance to ALK inhibitors 
• 
ALK and other genes involved in cancer mutation and rearrangement status in 
plasma-circulating tumor nucleic acids to monitor efficacy, resistance, and disease 
progression 
 
4. 
MATERIALS AND METHODS 
4.1 
PATIENTS 
Target population is patients with treatment-naive ALK-positive non-resectable, locally 
advanced and metastatic NSCLC. 
4.1.1 
Inclusion Criteria 
Patients must meet the following criteria for study entry: 
• 
Histologically or cytologically confirmed diagnosis of advanced or recurrent 
(Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) 
NSCLC that is ALK-positive as assessed by the Ventana IHC test.  Sufficient tumor 
tissue available to perform ALK IHC is required.  The Ventana IHC test will be 
performed at the designated central laboratory. 
• 
Age ≥ 18 years 
• 
Life expectancy ≥ 12 weeks 
• 
ECOG PS of 0−2 
• 
No history of receiving systemic treatment for advanced, recurrent (Stage IIIB not 
amenable for multimodality treatment), or metastatic (Stage IV) NSCLC 
• 
Adequate hematologic function: 
Platelet count ≥ 100 × 109/L 
ANC ≥ 1500 cells/µL 
Hemoglobin ≥ 9.0 g/dL 
• 
Adequate renal function: 
An estimated glomerular filtration rate (eGFR) calculated using the Modification 
of Diet in Renal Disease (MDRD) formula of ≥ 45 mL/min/1.73 m2 
• 
Patients must have recovered from effects of any major surgery or significant 
traumatic injury at least 28 days before receiving the first dose of study treatment. 
• 
Measurable disease determined with the use of RECIST v1.1 before administration 
of study treatment 

 
Alectinib—F. Hoffmann-La Roche Ltd 
59/Protocol YO29449, Version 3 
 
• 
Previous brain or leptomeningeal metastases are allowed if the patient is 
asymptomatic (e.g., diagnosed incidentally at study baseline).  Asymptomatic CNS 
lesions may be treated at the discretion of the investigator as per local clinical 
practice.  If the patient has neurological symptoms or signs because of CNS 
metastasis, the patient must complete whole brain-radiation or gamma knife 
irradiation treatment.  In all cases, radiation treatment must be completed 
at ≥ 14 days before enrollment and be clinically stable. 
• 
For all females of childbearing potential, a negative serum pregnancy test result 
must be obtained within 3 days prior to starting study treatment. 
• 
For women who are not postmenopausal (≥ 12 months of non−therapy-induced 
amenorrhea) or surgically sterile (absence of ovaries and/or uterus), agreement to 
remain abstinent or use single or combined contraceptive methods that result in a 
failure rate of < 1% per year during the treatment period and for at least 3 months 
after the last dose of study drug.  Abstinence is acceptable only if it is in line with the 
preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, or postovulation methods) and withdrawal are not 
acceptable methods of contraception.  Examples of contraceptive methods with a 
failure rate of < 1% per year include tubal ligation, male sterilization, hormonal 
implants, established, proper use of combined oral or injected hormonal 
contraceptives, and certain intrauterine devices.  Alternatively, two methods 
(e.g., two barrier methods such as a condom and a cervical cap) may be combined 
to achieve a failure rate of < 1% per year.  Barrier methods must always be 
supplemented with the use of a spermicide. 
• 
For men, agreement to remain abstinent or use a condom plus an additional 
contraceptive method that together result in a failure rate of < 1% per year during the 
treatment period and for at least 3 months after the last dose of study drug.  
Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of 
the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or 
postovulation methods) and withdrawal are not acceptable methods of contraception. 
• 
Able and willing to provide written informed consent before performing any 
study-related procedures and to comply with the study protocol. 
 
4.1.2 
Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from study entry: 
• 
A malignancy within the past 3 years (other than curatively treated basal cell 
carcinoma of the skin, early gastrointestinal [GI] cancer by endoscopic resection, 
in situ carcinoma of the cervix, or any cured cancer that is considered to have no 
impact in PFS or OS for the current NSCLC) 
• 
Any GI disorder that may affect absorption of oral medications, such as 
malabsorption syndrome or status post-major bowel resection 

 
Alectinib—F. Hoffmann-La Roche Ltd 
60/Protocol YO29449, Version 3 
 
• 
Liver disease characterized by: 
ALT or AST > 3 × the upper limit of normal (ULN; ≥ 5 × ULN for patients with 
concurrent liver metastases) confirmed on two consecutive measurements 
OR 
Impaired excretory function (e.g., hyperbilirubinemia), synthetic function, or 
other conditions of decompensated liver disease, such as coagulopathy, 
hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from 
esophageal varices 
OR 
Acute viral or active autoimmune, alcoholic, or other types of hepatitis 
• 
National Cancer Institute Common Terminology Criteria for Adverse Events 
version 4.0 (NCI CTCAE v4.0) Grade 3 or higher toxicities due to any previous 
therapy (e.g., radiotherapy) (excluding alopecia) which have not shown 
improvement and are strictly considered to interfere with current study medication 
• 
History of organ transplant 
• 
Co-administration of anti-cancer therapies other than those administered in this 
study 
• 
Baseline QTc > 470 ms or symptomatic bradycardia 
• 
Administration of strong/potent cytochrome P450 (CYP) 3A inhibitors or inducers 
within 14 days prior to receiving the first dose of study treatment and during 
treatment with alectinib or crizotinib (see Appendix 3) 
• 
Administration of agents with potential QT-prolonging effects within 14 days prior to 
receiving the first dose of study drug (see Section 4.4.2 for further details) 
• 
History of hypersensitivity to any of the additives in the alectinib drug formulation 
(see Section 4.3.1.1 for further details) 
• 
History of hypersensitivity to any of the additives in the crizotinib drug formulation 
(see Section 4.3.1.2 for further details) 
• 
Pregnant or lactating women 
• 
Known HIV positivity or AIDS-related illness 
• 
Any clinically significant concomitant disease or condition that could interfere 
with, or for which the treatment might interfere with, the conduct of the study or the 
absorption of oral medications or that would, in the opinion of the 
Principal Investigator, pose an unacceptable risk to the patient in this study 
• 
Any psychological, familial, sociological, or geographical condition that potentially 
hampers compliance with the study protocol requirements or follow-up procedures; 
those conditions should be discussed with the patient before study entry 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
61/Protocol YO29449, Version 3 
 
4.2 
METHOD OF TREATMENT ASSIGNMENT AND BLINDING 
This is an open-label study, for which the rationale is described in Section 3.3.4. 
Approximately 183 patients will be randomly assigned in a 2:1 allocation ratio to the 
two treatment arms (122 in the alectinib treatment arm and 61 in the crizotinib treatment 
arm) via a block-stratified randomization procedure and over a planned recruitment 
period of 14 months. 
Randomization will guard against systematic selection bias and should ensure the 
comparability of treatment groups.  To assist the balance of important prognostic factors, 
randomization will be stratified by ECOG PS (0/1 vs. 2) and CNS metastases at baseline 
(yes vs. no). 
Central randomization and drug pack number allocations will be performed and 
managed by an IxRS.  Further details will be provided in an IxRS manual. 
4.3 
STUDY TREATMENT 
4.3.1 
Formulation, Packaging, and Handling 
4.3.1.1 
Alectinib 
Alectinib is supplied in a hard capsule dosage form containing the following active 
ingredient: 
Chemical name:  9-Ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl) 
piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile 
hydrochloride 
Each capsule contains 150 mg of alectinib (as free base) along with lactose 
monohydrate, carmellose calcium, hydroxypropyl cellulose, SLS, and magnesium 
stearate as excipients. 
Alectinib capsules should be stored in accordance with the storage instructions on the 
label. 
The formulation contains SLS as a surfactant excipient.  This excipient is known to be 
associated potentially with GI adverse events such as nausea, vomiting, diarrhea, and 
abdominal pain. 
For further details, see the Alectinib Investigator's Brochure. 
4.3.1.2 
Crizotinib 
Crizotinib comes in a hard capsule dosage form.  Each capsule contains 250 mg or 
200 mg crizotinib.  Crizotinib hard capsules should be stored in accordance with the 
storage instructions on the label.  Crizotinib capsules should be administered orally BID. 
For further details, see the local prescribing information for crizotinib. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
62/Protocol YO29449, Version 3 
 
4.3.2 
Dosage, Administration, and Compliance 
4.3.2.1 
Alectinib 
Alectinib 600 mg (four 150-mg capsules) should be administered orally BID with food in 
the morning and evening. 
If a planned dose of alectinib is missed, patients can make up that dose unless the next 
dose is due within 6 hours. If vomiting occurs after taking a dose of alectinib, patients 
should take the next dose at the scheduled time. 
Guidelines for dosage modifications and treatment interruptions or discontinuation 
because of specified adverse events are provided in Section 5.3.1. 
Any overdose or incorrect administration of study drug should be noted on the 
Study Drug Administration electronic Case Report Form (eCRF).  Adverse events 
associated with an overdose or incorrect administration of study drug should be 
recorded on the Adverse Event eCRF. 
4.3.2.2 
Crizotinib 
Crizotinib 250 mg (one 250-mg capsule) should be administered orally BID (in the 
morning and evening) with or without food. 
If a dose is missed, the missed dose should be taken as soon as the patient remembers 
unless it is < 6 hours until the next scheduled dose, in which case the patient should not 
take the missed dose.  Patients should not take 2 doses at the same time to make up a 
missed for a missed dose.  If vomiting occurs after taking a dose of crizotinib, the next 
dose should be taken as scheduled. 
If dose reduction is necessary, then the dose of crizotinib should be reduced to 
200 mg BID.  If further dose reduction is necessary, then the dose should be modified to 
250 mg taken QD.  Guidelines for dosage modification and treatment interruption or 
discontinuation are provided in Section 5.1.4.  Any overdose or incorrect administration 
of crizotinib should be noted on the crizotinib Administration eCRF.  Adverse events 
associated with an overdose or incorrect administration of crizotinib should be recorded 
on the Adverse Event eCRF. 
4.3.3 
Investigational Medicinal Product Accountability 
All investigational medicinal products (IMPs) required for completion of this study 
(alectinib and crizotinib) will be provided by the Sponsor where required by local health 
authority regulations.  The study site will acknowledge receipt of IMPs and confirm the 
shipment condition and content.  Any damaged shipments will be replaced. 
IMPs will either be disposed of at the study site according to the study site’s institutional 
standard operating procedure or be returned to the Sponsor with the appropriate 
documentation.  The site's method of IMP destruction must be agreed upon by the 

 
Alectinib—F. Hoffmann-La Roche Ltd 
63/Protocol YO29449, Version 3 
 
Sponsor.  The site must obtain written authorization from the Sponsor before any IMP is 
destroyed, and IMP destruction must be documented on the appropriate form. 
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
the study site should be recorded on the Drug Inventory Log. 
4.3.4 
Post-Study Access to Alectinib 
The Sponsor will offer post-study access to the study drug alectinib free of charge to 
eligible patients in accordance with the Roche Global Policy on Continued Access to 
Investigational Medicinal Product, as outlined below. 
A patient will be eligible to receive study drug after the end of the study if all of the 
following conditions are met: 
• 
The patient has a life-threatening or severe medical condition and requires 
continued study drug treatment for his or her well-being. 
• 
There are no appropriate alternative treatments available to the patient. 
• 
The patient and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them. 
 
A patient will not be eligible to receive study drug after the end of the study if any of the 
following conditions are met: 
• 
The study drug is commercially marketed in the patient's country and is reasonably 
accessible to the patient (e.g., is covered by the patient's insurance or would not 
otherwise create a financial hardship for the patient). 
• 
The Sponsor has discontinued development of the study drug or data suggest that 
the study drug is not effective for ALK-positive NSCLC. 
• 
The Sponsor has reasonable safety concerns regarding the study drug as treatment 
for ALK-positive NSCLC. 
• 
Provision of study drug is not permitted under the laws and regulations of the 
patient's country. 
 
The Roche Global Policy on Continued Access to Investigational Medicinal Product is 
available at the following Web site: 
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf 
4.4 
CONCOMITANT THERAPY 
4.4.1 
Permitted Therapy 
Concomitant therapy includes any medication (e.g., prescription drugs, over-the-counter 
drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from 
28 days prior to screening to the Study Completion and Study Treatment Discontinuation 
Visit.  All concomitant medications should be reported to the investigator and recorded 
on the Concomitant Medications eCRF. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
64/Protocol YO29449, Version 3 
 
All therapy and medication administered to manage adverse events should be recorded 
on the Concomitant Medications eCRF. 
Permitted medications and treatments are listed below: 
• 
Anticoagulants and anti-thrombotic agents (i.e., warfarin-derived anticoagulants, 
unfractionated heparin or low-molecular heparins, aspirin [≤ 325 mg/day], and 
clopidogrel) 
• 
Acetaminophen up to 2 g/day 
• 
Gastric pH-elevating medications (such as proton pump inhibitors, H2 blockers, or 
antacids) 
• 
Local therapy (e.g., stereotactic radiotherapy or surgery) may be given to patients 
with isolated asymptomatic CNS progression (e.g., new CNS oligometastases). 
 
Caution should be exercised when the following are co-administered with alectinib: 
• 
For medications that are substrates of P-gp transporter or breast cancer resistance 
protein transporter, the investigator should use caution and monitoring when 
considering concomitant use of alectinib.  Alectinib has been shown to have 
potential for inhibition of these transporters.  Substrates with a narrow therapeutic 
index (e.g., methotrexate, digoxin) should be avoided.  If co-administration cannot 
be avoided, it is recommended that signs for toxicity are carefully monitored 
(see Appendix 3). 
 
Caution should be exercised when the following are co-administered with crizotinib: 
• 
Crizotinib has been shown to be a moderate inhibitor of CYP3A.  Dose reduction 
may be needed for co-administered drugs that are predominantly metabolized by 
CYP3A in patients receiving crizotinib.  Concurrent use of CYP3A substrates with 
narrow therapeutic indices should be avoided (see Appendix 3). 
• 
On the basis of an in vitro study, crizotinib is predicted to inhibit intestinal P-gp.  
Therefore, administration of crizotinib with medicinal products that are substrates of 
P-gp (e.g., digoxin, dabigatran, colchicine, pravastatin) may increase their 
therapeutic effect and adverse reactions (see Appendix 3).  Close clinical 
surveillance is recommended when crizotinib is administered with these medicinal 
products. 
• 
Bradycardia has been reported during clinical studies; therefore, the use of crizotinib 
in combination with other agents known to cause bradycardia (e.g., beta-blockers, 
non-dihydropyridine calcium channel blockers, clonidine, and digoxin) should be 
avoided to the extent possible. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
65/Protocol YO29449, Version 3 
 
• 
In vitro studies in human hepatocytes indicated that crizotinib may induce 
pregnane X receptor and constitutive androstane receptor–regulated enzymes 
(e.g., CYP3A4, CYP2B6, CYP2C8, CYP2C9, UGT1A1).  However, there was no 
observed induction in vivo when crizotinib was co-administered with the CYP3A 
probe substrate midazolam.  Caution should be exercised in administering crizotinib 
in combination with medicinal products that are metabolized predominantly by these 
enzymes.  Of note, the effectiveness of concomitant administration of oral 
contraceptives may be altered. 
• 
In vitro studies indicated that crizotinib is an inhibitor of CYP2B6.  Therefore, 
crizotinib may have the potential to increase plasma concentrations of 
co-administered drugs that are metabolized by CYP2B6 (e.g., bupropion, efavirenz). 
 
4.4.2 
Prohibited Therapy 
Use of the following therapies (e.g., prescription drugs, over-the-counter drugs, herbal or 
homeopathic remedies, nutritional supplements) is prohibited during the study and for at 
least 14 days prior to initiation of study drug treatment (either alectinib or crizotinib), 
unless otherwise specified below.  Exceptions to the below listed concomitant therapies 
restrictions (e.g., prescription drugs, over-the-counter drugs, herbal or homeopathic 
remedies, nutritional supplements) may be made only if the rationale is discussed and 
documented between the investigator and the Sponsor’s Clinical Pharmacologist. 
• 
Potent inducers of CYP3A (e.g., rifampin, rifabutin, phenobarbital, phenytoin, 
carbamazepine, and St John’s wort [Hypericum perforatum]) within 2 weeks or 
5 half-lives (whichever is longer) prior to the first dose of study drug treatment and 
during treatment with study drugs (see Appendix 3) 
• 
Potent inhibitors of CYP3A (e.g., ketoconazole) within 2 weeks or 5 half-lives 
(whichever is longer) prior to the first dose of study drug treatment and during 
treatment with study drug (see Appendix 3) 
• 
Any concomitant medications known to affect QT interval duration, including but not 
limited to the following drugs:  amiodarone, cisapride, clarithromycin, methadone, 
and quinidine within 2 weeks prior to the first dose of study drug treatment for all 
patients, and while on treatment through the end of the study for crizotinib-treated 
patients only 
• 
Systemic immunosuppressive drugs, cytotoxic or chemotherapeutic agents 
(other than study drug treatment), ergot derivatives, probenecid, and bile 
acid-binding resins during study treatment 
• 
Systemic chemotherapy 
• 
Radiotherapy/radionuclide therapy except for palliative radiotherapy to bone lesions 
or for pain control.  If palliative radiation is indicated for bone metastases, palliative 
radiation may start within 24 hours after the last dose of alectinib unless, in the 
judgment of the investigator, patient safety will require a longer washout period 
before initiating palliative therapy.  Alectinib dosing may resume after resolution of 
any radiation toxicity to a Grade ≤ 1. 
• 
Additional investigational drug (except during the follow-up period) 

 
Alectinib—F. Hoffmann-La Roche Ltd 
66/Protocol YO29449, Version 3 
 
 
The above lists of medications are not necessarily comprehensive.  Thus, the 
investigator should consult the prescribing information for any concomitant medication 
as well as the Internet references provided below when determining whether a certain 
medication strongly inhibits or induces CYP3A.  In addition, the investigator should 
contact the Medical Monitor if questions arise regarding medications that are not listed 
above. 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM292362.pdf 
http://medicine.iupui.edu/clinpharm/ddis/table.aspx 
 
4.4.3 
Prohibited Food 
Ingestion of grapefruit or grapefruit juice should be avoided during the study and for at 
least 14 days prior to the initiation of study drug treatment (either alectinib or crizotinib) 
because it is a potent CYP3A inhibitor and may increase plasma concentration of either 
alectinib or crizotinib. 
4.5 
STUDY ASSESSMENTS 
See Appendix 1 for the schedule of assessments performed during the study. 
4.5.1 
Informed Consent Forms and Screening Log 
Written informed consent for participation in the study must be obtained before 
performing any study-specific screening tests or evaluations.  Informed Consent Forms 
for enrolled patients and for patients who are not subsequently enrolled will be 
maintained at the study site. 
All screening evaluations must be completed and reviewed to confirm the patient meets 
all eligibility criteria before randomization.  The investigator will maintain a screening log 
to record details of all patients screened and to confirm eligibility or record reasons for 
screening failure, as applicable. 
4.5.2 
Medical History and Demographic Data 
Medical history includes clinically significant diseases, surgeries, cancer history 
(including previous cancer therapies and procedures), reproductive status, smoking 
history, and all medications (e.g., prescription drugs, over-the-counter drugs, herbal or 
homeopathic remedies, nutritional supplements) used by the patient within 28 days 
prior to the screening visit. 
Demographic data will include age, sex, and self-reported race/ethnicity. 
4.5.3 
Corticosteroid Use for CNS Metastases 
For patients with CNS metastases requiring corticosteroid use, the corticosteroid intake 
should be captured at all tumor assessment visits and compared with the corticosteroid 
intake at the time of the last disease assessment.  The changes will be recorded as 

 
Alectinib—F. Hoffmann-La Roche Ltd 
67/Protocol YO29449, Version 3 
 
increased, unchanged, or decreased.  Increases and decreases in corticosteroid intake 
should be clinically justified.  Increases in corticosteroid dose for reasons other than for 
CNS metastases control do not need to be taken into consideration when making this 
comparison. 
4.5.4 
Physical Examinations 
A complete physical examination performed at screening and baseline should include an 
evaluation of the head, eyes, ears, nose, and throat and the cardiovascular, 
dermatological, musculoskeletal, respiratory, GI, genitourinary, and neurological systems 
as well as height and weight.  Any abnormality identified at baseline should be recorded 
on the General Medical History and Baseline Conditions eCRF. 
At subsequent visits (or as clinically indicated), limited, symptom-directed physical 
examinations should be performed.  Changes from baseline abnormalities should be 
recorded in patient notes.  New or worsened clinically significant abnormalities should be 
recorded as adverse events on the Adverse Event eCRF. 
Note:  For patients with known CNS metastases, a neurological examination must be 
performed at each tumor assessment visit and be compared with the neurological 
examination performed at the time of the last disease assessment.  Definition of clear 
neurological worsening is difficult to describe because progression in the CNS can 
present in numerous ways.  Accordingly, evaluation of neurological function at each 
disease assessment will be made purely on the basis of the investigator’s assessment of 
the patient’s neurological state compared with the neurological function at the time of the 
last disease assessment.  Neurological status will be recorded as improved, stable, or 
worsened. 
4.5.5 
Vital Signs 
Vital signs will include measurements of respiratory rate, oxygen saturation, heart rate, 
and systolic and diastolic blood pressure (while the patient is in a seated position), and 
temperature. 
4.5.6 
Eastern Cooperative Oncology Group Performance Status 
PS will be measured with use of the ECOG PS Scale (see Appendix 6).  It is 
recommended, where possible, that a patient’s PS be assessed by the same person 
throughout the study. 
4.5.7 
Tumor and Response Evaluations 
Disease burden must be documented at screening and re-assessed at each subsequent 
tumor evaluation.  Response will be assessed by the investigator based on physical 
examinations, radiographic imaging, and other modalities, and documented by color 
photography (with caliper measurement for measurable lesions) or measurements by CT 
scans and other modalities (e.g., MRI, brain scans), with the use of RECIST v1.1 (see 
Appendix 4).   

 
Alectinib—F. Hoffmann-La Roche Ltd 
68/Protocol YO29449, Version 3 
 
To assess response in patients with measurable disease, the preferred radiologic tumor 
response assessment is CT scan with intravenous contrast.  If intravenous contrast is 
contraindicated, a non−contrast-enhanced chest CT scan will be acceptable for chest 
lesions, and MRI may be used for non-chest lesions.  If contrast-enhanced MRI is 
contraindicated, then non−contrast-enhanced MRI will suffice.  Positron emission 
tomography (PET) scan, bone scan, and ultrasound cannot be used to measure lesions 
as per RECIST v1.1 (see Appendix 4). 
The same radiographic procedure used to define measurable disease sites at screening 
must be used throughout the study (e.g., the same contrast protocol for CT scans).  
Assessments should be performed by the same evaluator to ensure internal consistency 
across visits. 
CT and/or MRI scans of chest and abdomen and MRI scans of the brain should be 
performed for all patients as described in Schedule of Assessments (see Appendix 1) at 
screening, then every 8 weeks subsequently until disease progression and during post-
progression on treatment visit in the case of isolated, asymptomatic progression of 
disease in the CNS, and at the Post-Treatment Visit (4 weeks after permanent treatment 
discontinuation).  CT and/or MRI scans of the neck bones and pelvis should be included 
if clinically indicated.  At the investigator’s discretion, CT and/or MRI scans may be 
repeated at any time if PD is suspected. 
Note:  Brain imaging should be performed with the use of MRI with the following image 
acquisition requirements: 
• 
Minimum sequences required: 
Pre-contrast T1, T2/FLAIR 
Post-contrast T1, with two orthogonal planes (or a volume acquisition) 
recommended 
• 
Recommended slice thickness ≤ 5 mm with no gap 
 
Patients with known or suspected bone metastases should undergo a radionuclide bone 
scan at screening.  Bone scan, PET scan, or plain films are not considered to be 
adequate imaging techniques to measure bone lesions and do not need to be repeated 
routinely, but they can be used to confirm the presence or disappearance of bone 
lesions.  Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue 
components, that can be evaluated by cross-sectional imaging techniques such as CT or 
MRI may be considered measurable lesions of the soft tissue component and meets the 
definition of measurability; these should be followed by cross-sectional imaging. 
According to RECIST criteria, measurable skin metastases should be clinically assessed 
with caliper measurement.  Documentation by color photography, including a ruler to 
estimate the size of the lesion, should be performed at screening then repeated at the 
scheduled tumor evaluations. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
69/Protocol YO29449, Version 3 
 
4.5.8 
Laboratory, Biomarker, and Other Biological Samples 
4.5.8.1 
Laboratory Assessments 
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis: 
• 
Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, 
absolute differential count or percentage [neutrophils, eosinophils, lymphocytes, 
monocytes, basophils, other cells, etc.]) 
• 
Coagulation (PT [or INR] and aPTT) 
• 
Serum chemistry (sodium, potassium, chloride, bicarbonate or total CO2, fasting 
glucose, BUN or urea, creatinine [including an estimated eGFR calculated with the 
use of the MDRD formula; see Appendix 9], CPK, gamma-glutamyl transferase 
[GGT], calcium, total and direct bilirubin, total protein, albumin, ALT, AST, alkaline 
phosphatase [ALP], phosphorus, magnesium, and thyroid-stimulating hormone. 
• 
Urinalysis:  Urine samples will be collected according to the schedule of 
assessments (see Appendix 1) (first morning urine sample for baseline and 
end-of-treatment/withdrawal visit spot urine sample for rest of the visits).  Urine 
protein will be measured by dipstick test. 
• 
Pregnancy test.  All women who are not postmenopausal (≥ 12 months of 
non-therapy induced amenorrhea) or surgically sterile will have a serum pregnancy 
test performed at screening (i.e., within 3 days prior to receiving first dose of study 
drug).  Urine pregnancy tests will be performed anytime during the course of the 
study, as per investigator’s discretion.  If a urine pregnancy test result is positive, it 
must be confirmed by a serum pregnancy test. 
 
4.5.8.2 
Pretreatment Tumor Samples (Mandatory) 
Mandatory pretreatment tumor samples will be collected to centrally examine ALK status 
by IHC (eligibility criteria).  Tumor blocks (formalin-fixed, preferred 10% neutral-buffered 
formalin) are the preferred source, but if blocks are not available, 7 unstained 
5-µm slides cut < 3 months before screening are acceptable for ALK IHC testing.   
For cases where tumor blocks have been submitted, an additional 6 slides will be cut 
from blocks submitted for randomized patients.  For cases where slides have been 
submitted for screening, an additional 6 slides are desired. Pretreatment tumor samples 
may be used for DNA and/or RNA extraction to enable Next Generation Sequencing 
(NGS) to identify somatic mutations that are associated with disease progression or 
acquired resistance to alectinib and to add to researchers' understanding of disease 
pathobiology.  These samples will not be collected in countries /sites where the 
regulatory agency or the Institutional Review Board (IRB) does not allow this testing.  
Any remaining tumor blocks from screen-failed patients will be returned to the sites 
within 3− 4 months of receipt at Sponsor-designated central laboratory, and any 
remaining tumor blocks from randomized patients will be returned to the sites before the 
final closure of the clinical database; slides will not be returned. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
70/Protocol YO29449, Version 3 
 
For fresh tumor biopsy samples (guided by ultrasound or CT scan), acceptable methods 
include core biopsy samples for lung and liver lesions and bronchoscopic biopsy 
samples for lung lesions.  The minimum size recommended for the biopsy needle is 20G. 
For enrollment in the study, central ALK testing to determine or confirm patients’ ALK 
status will be performed at a Sponsor-designated central laboratory with use of a 
Ventana ALK test by IHC (see Appendix 10). 
For sample handling procedures, storage conditions and shipment instructions, see the 
laboratory manual. 
4.5.8.3 
Post-Treatment Tumor Samples (Optional) 
Post-treatment tumor samples (preferably formalin-fixed blocks, but if not available a 
minimum of 9 unstained 5 µm slides) at the time of disease progression or permanent 
treatment discontinuation (at the last treatment or post-progression visit) may be 
collected, with proper informed consent.  These samples may allow a greater 
understanding of the molecular mechanisms of resistance to ALK inhibitors and genes 
involved in cancer.  Any remaining tumor blocks of randomized patients will be 
returned to the sites before the final closure of the clinical database.  Slides will not be 
returned. 
NGS may be performed by Foundation Medicine (ex-China) or a designated laboratory 
in China.  If performed by Foundation Medicine or a designated lab in China, the 
investigator can obtain results from the samples collected at the time of disease 
progression in the form of an NGS report, which is available upon request directly from 
Foundation Medicine.  The investigator may share and discuss the results with the 
patient, unless the patient chooses otherwise.  The Foundation Medicine NGS assay 
has not been cleared or approved by the FDA; results from these investigational tests 
should not be used to guide future treatment decisions. 
On the basis of continual analysis of the data in this study and other studies, or on the 
basis of data from literature, collection of optional tumor samples with exploratory 
purposes may be stopped at any time if the data from the samples collected do not 
produce useful information. 
4.5.8.4 
Blood and Plasma Samples 
Mandatory plasma samples for biomarker analysis will be obtained to determine: 
• 
ALK rearrangement determination by plasma ALK quantitative reverse transcription 
polymerase chain reaction.  This will require 20 mL of blood at screening from all 
screened patients. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
71/Protocol YO29449, Version 3 
 
• 
Mutation status in ALK and other escape genes (e.g., EGFR, KRAS).  This will 
require 20 mL of blood (two tubes of 10 mL each) to be collected at baseline, at 
Treatment Visit 7 (Week 16), and subsequently at every second treatment visit 
(every 16 weeks) [see Appendix 1 for detailed information] until and at disease 
progression (CNS and/or systemic disease progression) or treatment 
discontinuation for any reasons.  
• 
These samples will not be collected in countries/or sites where the regulatory 
agency or the IRB does not allow genetic testing. 
 
Details of sample handling procedures, sample storage, and shipment will be described 
in a separate laboratory manual. 
On the basis of continual analysis of the data in this study and in other studies or on the 
basis of data from literature, the collection of plasma samples for exploratory purposes 
may be stopped at any time, if the data from the samples collected do not produce 
useful information. 
All the biomarker samples described in Sections 4.5.8.2, 4.5.8.3, and 4.5.8.4 will be 
stored for 5 years after the date of final closure of the associated clinical database. 
4.5.8.5 
Samples for Alectinib Pharmacokinetic Assessments 
Blood samples (approximately 2 mL of venous blood) collected from all patients treated 
with alectinib will be used for assessment of alectinib pharmacokinetics and major 
metabolites M4 (RO5468924) and other metabolites if appropriate (provided that assays 
for detection are available).  Plasma concentrations for alectinib (and metabolite[s], if 
appropriate) will be measured by specific and validated liquid chromatography tandem 
mass spectrometry methods.  These samples will be destroyed when the final clinical 
study report is complete. 
Frequent blood sampling will be performed in a subset of 20 consenting Chinese 
patients randomized to alectinib treatment to ensure there are at least 16 patients with 
evaluable PK profiles on Visit 0 (baseline, after the first dose) and Visit 2 (Week 4) at the 
timepoints specified in Appendix 2 for the non-compartmental PK analyses, as 
appropriate and where data allow. 
Sparse blood samples will be collected from all patients receiving alectinib treatment and 
subsequently used for popPK analyses, as appropriate and where data allow.  
See Appendix 2 for the blood sample collection schedule.  Residual samples following 
the PK analysis may be used to further evaluate the profile of alectinib metabolites. 
All predose blood samples collected for PK analysis should be collected within 2 hours 
BEFORE the morning dose of any study medication. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
72/Protocol YO29449, Version 3 
 
Patients who permanently discontinue study drug treatment will also be discontinued 
from all PK assessments.  The procedures for the collection, handling, storage, and 
shipping of plasma samples for the PK analysis are specified in the laboratory manual. 
These samples will be destroyed when the final clinical study report is complete. 
On the basis of continual analysis of the data in this study and other studies, collection of 
any sample type may be stopped at any time, if the data from the samples collected do 
not produce useful information or at the discretion of the Sponsor. 
4.5.9 
Electrocardiograms 
An ECG will be recorded at specified timepoints as outlined in the schedule of 
assessments (Appendix 1) at screening, at Visit 0 (baseline), at Visit 2 (Week 4), at 
Visit 8 (Week 24), at Visit 12 (Week 56), and at the end of treatment/withdrawal visit and 
as clinically indicated throughout the study.  All ECG recordings must be performed with 
the use of a standard high-quality, high-fidelity digital electrocardiograph machine 
equipped with computer-based interval measurements.  All ECGs are to be obtained 
before other procedures, as well as meals, that are scheduled at that same visit 
(e.g., vital sign measurements, blood draws, study drug administration).  Circumstances 
that may induce changes in heart rate, including environmental distractions (e.g., 
television, radio, conversation), should be avoided during the pre-ECG resting period 
and during ECG recording. 
Patients must have been in a supine or semi-supine position for at least 5 minutes 
before the ECG recording is obtained.  The same recording position (supine or 
semi-supine) and the same equipment should be used for each patient throughout the 
study.  The ECG printout must be 1) reviewed by a medically qualified member of the 
study team at the site, 2) annotated to indicate any clinical finding, and 3) dated and 
signed by this person and filed in the patient notes.  ECG parameters will be entered on 
the ECG eCRF.  The following parameters should be captured on the ECG eCRF:  heart 
rate; PQ, QRS, and QT duration; and QT interval corrected with the use of 
Fridericia’s formula (QTcF).  In the event that the ECG machine does not directly provide 
results for RR and/or QTcF, these parameters can be derived using the formulae 
provided in Appendix 11.  
To have a consistent approach for the RR and QTcF, it was decided that the calculation 
of RR and QTcF will be done by the Sponsor using the formulae provided in 
Appendix 11.  The results will be populated in the eCRF for use by the investigator. 
If any ECG abnormality is associated with an adverse event, it must be recorded and 
managed as described in Section 5.   
If considered appropriate by the Sponsor, ECG recordings may be analyzed 
retrospectively at a central laboratory.   

 
Alectinib—F. Hoffmann-La Roche Ltd 
73/Protocol YO29449, Version 3 
 
4.5.10 
Patient-Reported Outcomes 
PROs (EORTC QLQ-C30 and EORTC QLQ-L13, see Appendix 7 and Appendix 8, 
respectively) will be collected to more fully characterize the clinical profile of alectinib.  
These instruments (questionnaires) will be translated as required, in the local language.  
To ensure instrument validity and to ensure that data standards meet health authority 
requirements, the PROs scheduled for administration during a clinic visit (EORTC 
QLQ-C30 and EORTC QLQ-L13, see Appendix 7 and Appendix 8, respectively) should 
be completed before the performance of non-PRO assessments and the administration 
of study treatment.  Patients will also need to maintain a diary of daily drug intake 
(crizotinib arm)/drug intake with food (alectinib arm).  
4.6 
PATIENT, TREATMENT, STUDY, AND SITE DISCONTINUATION 
4.6.1 
Patient Discontinuation 
Patients have the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include but are not limited to the following: 
• 
Patient withdrawal of consent at any time 
• 
Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient’s safety if he or she continues in the study 
• 
Investigator or Sponsor determines it is in the best interest of the patient 
 
Every effort should be made to obtain information on patients who withdraw from the 
study.  The primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  Patients who withdraw consent for treatment should continue to be 
followed for tumor assessments until disease progression and for OS information, 
provided they have not withdrawn consent for the study.  However, patients will not be 
followed for any reason after consent for the study has been withdrawn.  Patients who 
withdraw from the study will not be replaced. 
4.6.2 
Study Treatment Discontinuation 
Patients must discontinue study treatment if they experience any of the following: 
• 
Pregnancy 
• 
Inability to tolerate the study medication on the basis of the investigator’s judgment 
 
See guidelines for managing adverse events and for comprehensive guidance regarding 
study drug discontinuation in Section 5.1.3. 
Patients who discontinue study drug prematurely will be asked to return to the clinic for 
tumor assessments until disease progression as per the study schedule (see 
Appendix 1). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
74/Protocol YO29449, Version 3 
 
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  Patients who discontinue study drug prematurely will not be replaced. 
4.6.3 
Study and Site Discontinuation 
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include but are not limited to the following: 
• 
The incidence or severity of adverse events in this or other related studies indicates 
a potential health hazard to patients. 
• 
Patient enrollment is unsatisfactory. 
 
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study. 
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include but are not limited to the following: 
• 
Excessively slow recruitment 
• 
Poor protocol adherence 
• 
Inaccurate or incomplete data recording 
• 
Non-compliance with the International Conference on Harmonisation (ICH) guideline 
for Good Clinical Practice 
• 
No study activity (i.e., all patients have completed and all obligations have been 
fulfilled) 
 
5. 
ASSESSMENT OF SAFETY 
5.1 
SAFETY PLAN 
5.1.1 
Adverse Events Collection 
After informed consent has been obtained and before initiation of study drug treatment, 
only serious adverse events caused by a protocol-mandated intervention should be 
reported (e.g., serious adverse events related to invasive procedures such as biopsy 
sample collections).   
After the first dose of study treatment and through the 4-week follow-up after the last 
dose of study treatment, all adverse events will be collected regardless of seriousness, 
causality assessment, or actions taken and reported by the investigator or designated 
medically qualified study site personnel, as described below.  At each visit, the 
investigator or designated medically qualified study personnel will ask the patient if any 
untoward medical event had occurred since the last visit.  It is the investigator’s 
responsibility to record all adverse events in the patient’s medical records. 
All serious and non-serious adverse events will be reported on the standard Adverse 
Event/Serious Adverse Event eCRF. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
75/Protocol YO29449, Version 3 
 
5.1.2 
Adverse Events Relating to ALK Inhibitors and/or the Tyrosine 
Kinase Inhibitor Class and Alectinib Data 
Events described in Sections 5.1.2.1 through 5.1.2.10 will be closely monitored and will 
represent selected adverse events for this study. 
A more detailed safety profile of alectinib is provided in the Alectinib Investigator's 
Brochure. 
5.1.2.1 
Interstitial Lung Disease 
TKIs, including the ALK inhibitors crizotinib and ceritinib, have been associated with the 
occurrence of treatment-related ILD (including fatalities). 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.2 
Hepatotoxicity 
Hepatobiliary findings were observed in both the rat and monkey in 4- and 13-week 
toxicity studies with alectinib.  The findings in the 13-week studies were similar to those 
of the 4-week studies.  The findings were at or were close to clinically relevant 
exposures.  Hepatobiliary effects included increased hepatic ALP, direct bilirubin, GGT, 
and liver weight; vacuolation/degeneration/necrosis of bile duct epithelium; inflammatory 
cell infiltration in Glisson’s sheath; enlargement/focal necrosis of hepatocytes; and 
enlargement of Kupffer cells. 
Abnormal hepatobiliary laboratory test values, such as increased ALT, AST, or bilirubin 
levels, have been observed after alectinib administration.  AST, ALT, and total bilirubin 
levels temporarily increased in the initial stages of treatment and then improved (i.e., 
levels decreased or returned to normal).  In patients with Grade 3-4 AST/ALT elevations, 
documented drug induced liver injury by liver biopsy was reported with uncommon 
frequency.  Concurrent elevations in ALT or AST greater than or equal to three times the 
upper limit of normal (ULN) and total bilirubin greater than or equal to two times the ULN, 
with normal alkaline phosphatase, occurred with uncommon frequency in patients 
treated in alectinib clinical trials. 
In patients treated with other ALK inhibitor drugs, abnormal liver function tests and 
drug-induced hepatotoxicity, including cases with fatal outcome have been reported. 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.3 
Anemia 
Hematologic findings were observed in both the rat and monkey 4- and 13-week toxicity 
studies with alectinib.  The findings in the 13-week studies were similar to those of the 
4-week studies.  Findings were at or close to clinically relevant exposures.  Hematologic 
adverse effects such as anemia, thrombocytopenia, bleeding, and neutropenia have 
been observed with most TKIs, including ALK inhibitors crizotinib and ceritinib. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
76/Protocol YO29449, Version 3 
 
Cases of anemia have been reported in patients treated with alectinib; the majority of 
the events were Grade 1 or 2. 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.4 
Gastrointestinal Disorders 
GI disorders such as nausea, vomiting, constipation, and diarrhea have been reported 
with alectinib.  Similar GI disorders have been observed with other TKIs, including the 
ALK inhibitors crizotinib and ceritinib. 
SLS (or the synthetic equivalent: sodium dodecyl sulfate) is a surfactant excipient in the 
clinical formulation at a concentration of 50% (w/w SLS to active pharmaceutical 
ingredient).  This excipient is a known GI irritant and may be associated with GI adverse 
events including nausea, vomiting, diarrhea, and abdominal pain.  Of note, GI tract 
toxicity as the safety determinant of SLS does not occur because of systemic toxicity, 
but is a consequence of local irritation to the GI tract.  In general, when taken with food, 
higher levels of SLSa known GI tract mucosal irritantare tolerated versus gavage 
administrations. 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.5 
Skin Disorders 
Results of an in vitro phototoxicity study indicated that alectinib may have a phototoxic 
potential. 
Skin rash has been reported with the majority of TKIs, including those that target the 
ALK receptor (Hartmann et al. 2009). 
Cases of skin rash and photosensitivity have been reported with alectinib and were 
generally of Grade 1 or 2. 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.6 
Vision Disorders 
In the rat quantitative whole body autoradiography study, tissue radioactivity 
disappeared over time, following a time course comparable to that of plasma 
radioactivity, with the exception of melanin-containing tissues such as the uveal tract of 
the eyes, which had a much higher and more sustained exposure in pigmented rats.  
This is consistent with what is commonly observed for lipophilic basic drugs. 
Vision disorders, including diplopia, photopsia, blurred vision, visual impairment, and 
vitreous floaters have been reported with several TKIs, including ALK inhibitors 
(crizotinib and ceritinib) (Shaw et al. 2013a; ZYKADIA U.S. Package Insert). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
77/Protocol YO29449, Version 3 
 
Vision disorders, such as dry eye, blepharitis, conjunctivitis, blurred vision, and impaired 
vision have been reported with alectinib and were generally of Grades 1 and 2. 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.7 
Edema 
Most TKIs, including the ALK inhibitors crizotinib and ceritinib, have been associated 
with edema.  Events of edema have been reported with alectinib, mostly of Grade 1 or 2. 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.8 
Bradycardia 
In the monkey telemetry study, there were no effects on the ECG or any of the other 
cardiovascular parameters or body temperature at doses of up to 15 mg/kg (mean Cmax: 
279 ng/mL). 
In a preliminary telemetry study in conscious cynomolgus monkeys, a slight hypotensive 
effect (approximately 10 mmHg) was observed when alectinib was administered at 
20 and 60 mg/kg orally with no effects on ECG or heart rate.  The hypotensive effect of 
alectinib observed in monkeys was considered likely to have been caused by 
vasodilatation that was induced by L-type Ca2+ channel inhibition. 
Events of bradycardia have been reported with alectinib.  Preliminary heart rate data 
(based on ECG and pulse measurements) from the ongoing alectinib clinical studies 
show a decrease in heart rate during alectinib treatment, which is mainly asymptomatic.  
In patients treated with other ALK inhibitors (crizotinib and ceritinib), bradycardia adverse 
events, and decreases in heart rate based on ECG and pulse measurements, have also 
been reported. 
In case of bradycardia, concomitant medications must be evaluated to identify those that 
are known to cause bradycardia, as well as anti-hypertensive medications; 
discontinuation or dose reduction of these concomitant medications must be considered. 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.9 
Abnormal Renal Function 
In a 2-week non-human primate study, alectinib was administered at 60 mg/kg.  An 
increase in creatinine was observed but no changes were observed in histopathology.  
In all other non-human primate studies, no changes in creatinine were observed. 
In a retrospective analysis conducted by the Chronic Kidney Disease Epidemiology 
Collaboration prediction equation, eGFR is reduced by treatment with crizotinib, but the 
majority of patients will recover their eGFR after the cessation of therapy.  The early 
onset, size of the change, minimal cumulative effect, and rapid reversibility raise the 

 
Alectinib—F. Hoffmann-La Roche Ltd 
78/Protocol YO29449, Version 3 
 
possibility that this may be a pharmacological and/or tubular creatinine secretion 
effect rather than a direct nephrotoxic effect (Brosnan et al. 2014). 
Serum creatinine increases have been reported with ceritinib treatment and were 
generally of Grades 1 and 2 (ZYKADIA U.S. Package Insert).  Serum creatinine 
increases have been reported with alectinib treatment and were generally of 
Grades 1 and 2. 
See Section 5.1.3 for management and follow-up procedures. 
5.1.2.10 
Severe Myalgia and CPK Elevations 
Postmarketing experience with some TKIs includes reports of myopathy and 
rhabdomyolysis (Hohenegger 2012). 
Blood CPK increases, generally of Grades 1 and 2, and muscular adverse events have 
been reported with alectinib treatment.  Grade 3 myalgia and CPK elevations have been 
reported with alectinib treatment and were reversible upon dose reduction and 
interruption. 
See Section 5.1.3 for management and follow-up procedures and Table 3 for guidelines 
for managing adverse events. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
79/Protocol YO29449, Version 3 
 
5.1.3 
Management of Specific Adverse Events with Alectinib 
Table 3 
Guidelines for Management of Specific Adverse Events with Alectinib 
Event 
Action to Be Taken 
Interstitial lung disease 
• 
Patients should be monitored for pulmonary symptoms that are indicative of pneumonitis. 
• 
Study drug should be permanently discontinued in patients who are diagnosed with interstitial lung disease. 
Hepatotoxicity 
Liver test laboratory abnormalities are to be reported as AEs only if they fulfill the criteria listed in Section 5.3.5.4 and 
Section 5.3.5.6. 
• 
If ALT or AST > 3 × baseline, repeat testing of ALT, AST, ALP, and total bilirubin within 48–72 hours, with inquiry 
about symptoms.  If upon repeat testing, the transaminases remain > 3 × baseline, but are not > 5 × baseline or not 
accompanied with bilirubin increases or do not match any other rule for permanent discontinuation, then dose 
modification is not necessary and monitoring can continue as per investigator judgment. 
• 
At any time during the study treatment, if symptoms that are compatible with liver injury are observed, liver enzymes 
should be measured as soon as possible. 
• 
Study drug treatment must be permanently discontinued if any of the following occurs: 
First observation of ALT or AST > 8 × ULN 
ALT or AST > 5 × ULN for > 2 weeks 
First observation of ALT or AST > 3 × ULN and total bilirubin > 2 × ULN  
First observation of ALT or AST > 3 × ULN and the appearance of jaundice or signs of hepatic dysfunction or 
other symptoms (such as fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or 
eosinophilia [> 5%]). 
• 
Following study drug discontinuation, weekly monitoring of laboratory test values should continue until the abnormal 
test values have normalized to pretreatment levels and/or an adequate explanation of the abnormal test value is 
found. 
• 
Resumption of study drug is not allowed in patients who discontinue because of any of the above criteria. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
80/Protocol YO29449, Version 3 
 
Table 3 
Guidelines for Management of Specific Adverse Events with Alectinib (cont.)  
Event 
Action to Be Taken 
Gastrointestinal tract 
AEs (e.g., nausea, 
vomiting, diarrhea) 
The events are expected to be minimized by taking the study drug with a meal.  If GI events occur, appropriate 
measures should be taken in accordance with local clinical practice guidelines.  If GI toxicities are observed and are not 
tolerable, treatment with study drug should be temporarily interrupted until recovery to Grade 1 or lower. 
Skin disorder AEs 
(e.g., phototoxicity, 
rash) 
Patients should be advised to avoid prolonged sun exposure while taking alectinib and for at least 7 days after study 
drug discontinuation.  Patients should also be advised to use a broad-spectrum sun screen and lip balm of at least 
SPF 50 to help protect against potential sunburn. 
Vision disorders 
Investigators should consider referring the patients for an ophthalmological evaluation according to local clinical practice 
guidelines, if vision disorders persist or worsen in severity. 
Edema 
Physical examinations will be performed routinely during the study.  In case edema events occur, appropriate measures 
should be taken in accordance with local clinical practice guidelines 

 
Alectinib—F. Hoffmann-La Roche Ltd 
81/Protocol YO29449, Version 3 
 
Table 3 
Guidelines for Management of Specific Adverse Events with Alectinib (cont.)  
Event 
Action to Be Taken 
Abnormal kidney 
function AEs 
Kidney function laboratory abnormalities are to be reported as AEs only if they fulfill the criteria listed in Section 5.3.5.4. 
• 
If, at any time during the study treatment, eGFR decreases more than 50% over the baseline visit value, the patient 
must be carefully monitored.  All of the underlying factors that may have acutely impacted serum creatinine levels 
must be evaluated and corrected (e.g., dehydration, recent exposure to contrast media, increased amount of 
cooked meat in diet, concomitant medications affecting renal function as appropriate, etc.). 
• 
Any eGFR decrease more than 50% over the baseline visit value requires repeat testing.  If, at the repeat test, the 
eGFR decrease remains > 50%remainsover the baseline visit value, the treatment with alectinib should be 
interrupted. 
• 
Alectinib treatment may be resumed with caution if the eGFR value has increased to the approximate baseline visit 
value. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
82/Protocol YO29449, Version 3 
 
Table 3 
Guidelines for Management of Specific Adverse Events with Alectinib (cont.)  
Event 
Action to Be Taken 
Severe myalgia and 
CPK elevations 
CPK laboratory abnormalities are to be reported as AEs only if they fulfill the criteria listed in Section 5.3.5.4. 
• 
Myopathy should be considered in any patient with diffuse myalgia, muscle tenderness or weakness, or marked 
elevations of CPK levels.  Patients should promptly report unexplained muscle pain, tenderness, or weakness, 
particularly if it is accompanied by malaise or fever.  CPK levels should be assessed in patients who report these 
symptoms. 
• 
At the first occurrence of any of asymptomatic CPK values (> 10 × ULN), symptomatic CPK > 5 × ULN, or in the 
presence of severe muscular symptoms with CPK > ULN but ≤ 5 × ULN) at any time during the study treatment, the 
patient will require monitoring of the CPK values until the values are normalized to pretreatment levels or a 
reasonable explanation for the CPK elevation and the symptoms is established. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
83/Protocol YO29449, Version 3 
 
Table 3 
Guidelines for Management of Specific Adverse Events with Alectinib (cont.) 
Event 
Action to Be Taken 
Other AEs (including 
bradycardia, anemia, 
and CPK elevation) or 
laboratory 
abnormalities: 
• 
Grade 3 or 4: 
Temporarily interrupt alectinib for a maximum of 3 weeks. 
If improvement to Grade ≤ 1 or baseline does not occur within 3 weeks, permanently discontinue alectinib. 
First episode:  If improvement to Grade ≤ 1 or baseline within 21 days, decrease the current dose of alectinib by 
150 mg (1 capsule) BID (decrease to 450 mg BID). 
Second episode:  If improvement to Grade ≤ 1 or baseline occurs within 21 days, decrease the current dose of 
alectinib by another 150 mg (1 capsule) BID (decrease to 300 mg BID). 
Third episode:  Permanently discontinue alectinib. 
• 
Grade 2 (except for any symptoms and signs that may be corrected with supportive care): 
Temporarily interrupt alectinib and resume if recover to Grade ≤ 1 or baseline if clinically indicated. 
First episode:  If improvement to Grade ≤ 1 or baseline occurs within 10 days, continue the same dose of 
alectinib.  If improvement occurs after 10 days, decrease the current dose of alectinib by 150 mg (1 capsule) 
BID when resuming treatment (decrease to 450 mg BID). 
Second episode:  If improvement to Grade ≤ 1 or baseline occurs within 10 days, decrease the current dose of 
alectinib by 150 mg (1 capsule) BID (decrease to 450 mg BID, or 300 mg BID if the dose was reduced to 
450 mg BID after the first episode.  If improvement occurs after 10 days, decrease the current dose of alectinib 
by 300 mg (2 capsules) when resuming treatment (decrease to 300 mg BID or 150 mg BID if the dose was 
reduced to 450 mg BID after the first episode). 
Third episode:  Permanently discontinue alectinib. 
• 
Grade 1:  no action required 
AE = adverse event; ALP = alkaline phosphate; BID twice daily; GI = gastrointestinal; SPF = sun protection factor; ULN = upper limit of normal. 
Note:  Diarrhea, nausea, and vomiting should be handled with supportive care practices before considering dose modification.  Preexisting pleural 
effusion will not be considered an adverse event. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
84/Protocol YO29449, Version 3 
 
5.1.4 
Safety of Crizotinib and Management of Adverse Events 
Dosing interruption and/or dose reduction may be required on the basis of individual 
safety and tolerability.  If dose reduction is necessary, then the dose of crizotinib should 
be reduced to 200 mg taken BID.  If further dose reduction is necessary, then the dose 
should be modified to 250 mg taken QD on the basis of individual safety and tolerability 
(XALKORI U.S. Package Insert; Crizotinib SmPC).  Dose reduction guidelines for 
hematologic and non-hematologic toxicities are provided in Table 4 and Table 5. 
Table 4 
Crizotinib Dose ModificationHematologic Toxicities (Except 
Lymphopenia) 
NCI CTCAE 
Grade 
Crizotinib Treatment 
3 
Withhold until recovery to Grade ≤ 2, then resume at the same dose schedule. 
4 
Withhold until recovery to Grade ≤ 2, then resume at 200 mg twice daily a. 
NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events. 
Note:  Based on the most recent version of NCI CTCAE (v4.0), which can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
a In the case of second episode, dosing should be withheld until recovery to Grade ≤ 2, then 
dosing should be resumed at 250 mg once daily.  Crizotinib must be permanently 
discontinued in the case of a third episode of Grade 4 hematologic toxicity. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
85/Protocol YO29449, Version 3 
 
Table 5 
Crizotinib Dose ModificationNon-Hematologic Toxicities 
NCI CTCAE Grade 
Crizotinib Treatment 
ALT or AST elevation > 5 × ULN with total bilirubin 
≤ 1.5 × ULN 
Withhold until recovery to baseline or 
≤ 3 × ULN, then resume at reduced dose. 
Crizotinib must be permanently 
discontinued in case of recurrence. 
ALT or AST elevation > 3 × ULN with concurrent 
total bilirubin elevation > 1.5 × ULN (in the 
absence of cholestasis or hemolysis) 
Permanently discontinue 
Any grade drug-related pneumonitis a 
Permanently discontinue 
QTc > 500 ms on at least 2 separate ECGs 
Withhold until recovery to baseline or 
< 481ms, then resume at reduced dose.  
Crizotinib must be permanently 
discontinued in case of recurrence 
(i.e., QTc > 500ms on at least 2 separate 
ECGs). 
QTc > 500 ms or ≥ 60 ms change from baseline 
with torsade de pointes or polymorphic 
ventricular tachycardia or signs/symptoms of 
serious arrhythmia 
Permanently discontinue 
Bradycardia (heart rate < 60 bpm, symptomatic, 
may be severe and medically significant, medical 
intervention indicated) 
Withhold until recovery to asymptomatic 
bradycardia or to a heart rate ≥ 60 bpm.  
Evaluate concomitant medications known 
to cause bradycardia, as well as 
anti-hypertensive medications.  If a 
contributing concomitant medication is 
identified and discontinued or its dose is 
adjusted, resume crizotinib at previous 
dose upon recovery to asymptomatic 
bradycardia or to a heart rate ≥ 60 bpm.   
If no contributing concomitant medication 
is identified, or if contributing concomitant 
medication is identified but not 
discontinued or its dose was not modified, 
resume crizotinib at reduced dose upon 
recovery to asymptomatic bradycardia or 
to a heart rate of ≥ 60 bpm. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
86/Protocol YO29449, Version 3 
 
Table 5 
Crizotinib Dose ModificationNon-Hematologic Toxicities (cont.) 
NCI CTCAE Grade 
Crizotinib Treatment 
Bradycardia (heart rate < 60 bpm, life-threatening 
consequences, urgent intervention indicated) 
Permanently discontinue If no contributing 
concomitant medication is identified or if 
contributing concomitant medication is 
identified but not discontinued, or its dose 
is adjusted, resume at 250 mg once daily 
upon recovery to asymptomatic 
bradycardia or to a heart rate > 60 bpm, 
with frequent monitoring.  Crizotinib must 
be permanently discontinued in case of 
recurrence. 
bpm = beats per minute; NCI CTCAE = National Cancer Institute Common Terminology Criteria 
for Adverse Events; NSCLC = non–small cell lung cancer; QD = once daily. 
Note:  Based on the most recent version of NCI CTCAE (v4.0), which can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
a Not attributable to NSCLC progression, other pulmonary disease, infection, or radiation 
effect.  Crizotinib should be withheld if pneumonitis is suspected and must be permanently 
discontinued if treatment-related pneumonitis is diagnosed. 
 
GI events were commonly reported with crizotinib in clinical studies.  Nausea, 
diarrhea, vomiting, and constipation were the most commonly reported GI events and 
were primarily Grade 1 in severity.  Supportive care for GI events may include 
standard anti-emetic or anti-diarrheal or laxative medicinal products 
(XALKORI U.S. Package Insert; Crizotinib SmPC).  In clinical studies with crizotinib, 
events of gastrointestinal perforations were also reported (XALKORI U.S. Package 
Insert; Crizotinib SmPC). 
Blood counts and liver function tests including ALT, AST, and total bilirubin should be 
monitored as per the local prescribing information for crizotinib. 
See local prescribing information for further crizotinib safety information. 
5.2 
SAFETY PARAMETERS AND DEFINITIONS 
Safety assessments will consist of monitoring and recording adverse events, including 
serious adverse events and non-serious adverse events of special interest; performing 
of protocol-specified safety laboratory assessments; measuring of protocol-specified vital 
signs; and conducting other protocol-specified tests that are deemed critical to the safety 
evaluation of the study. 
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
87/Protocol YO29449, Version 3 
 
5.2.1 
Adverse Events 
According to the ICH guideline for Good Clinical Practice, an adverse event is any 
untoward medical occurrence in a clinical investigation patient that is administered a 
pharmaceutical product, regardless of causal attribution.  An adverse event may 
therefore be any of the following: 
• 
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether considered related to the medicinal product 
• 
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition) 
• 
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline 
• 
Any deterioration in a laboratory test value or other clinical test (e.g., ECG, X-ray) 
that is associated with symptoms or leads to a change in study treatment or 
concomitant treatment or discontinuation from study drug 
• 
Adverse events that are related to a protocol-mandated intervention, including those 
that occur before assignment of study treatment (e.g., screening invasive 
procedures such as biopsy sample collections) 
‘ 
5.2.2 
Serious Adverse Events (Immediately Reportable to the 
Sponsor) 
A serious adverse event is any adverse event that meets any of the following criteria: 
• 
Fatal (i.e., the adverse event actually causes or leads to death) 
• 
Life threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death) 
This does not include any adverse event that might have caused death had it 
occurred in a more severe form or was allowed to continue. 
• 
Requires or prolongs inpatient hospitalization (see Section 5.3.5.9) 
• 
Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal life 
functions) 
• 
Congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug 
• 
Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above) 
 
The terms "severe" and "serious" are not synonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to NCI CTCAE; 

 
Alectinib—F. Hoffmann-La Roche Ltd 
88/Protocol YO29449, Version 3 
 
see Section 5.3.3); the event itself may be of relatively minor medical significance (such 
as severe headache without any further findings). 
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the Adverse Event eCRF. 
Serious adverse events are required to be reported by the investigator to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions). 
5.2.3 
Non-Serious Adverse Events of Special Interest (Immediately 
Reportable to the Sponsor) 
Non-serious adverse events of special interest are required to be reported by the 
investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2 for reporting instructions).  Adverse events of special interest 
for this study are the following: 
• 
Cases of potential drug-induced liver injury which include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
Hy’s law (see Section 5.3.5.6) 
• 
Suspected transmission of an infectious agent by the study drug, as defined below: 
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product.  This term applies only 
when a contamination of the study drug is suspected. 
 
5.3 
METHODS AND TIMING FOR CAPTURING AND ASSESSING 
SAFETY PARAMETERS 
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Section 5.4−Section 5.6.  For 
each adverse event recorded on the Adverse Event eCRF, the investigator will make an 
assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see 
Section 5.3.3), and causality (see Section 5.3.4). 
5.3.1 
Adverse Event Reporting Period 
Investigators will seek information on adverse events at each patient contact.  All 
adverse events, whether reported by the patient or noted by study personnel, will be 
recorded in the patient’s medical record and on the Adverse Event eCRF. 
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention (e.g., invasive 

 
Alectinib—F. Hoffmann-La Roche Ltd 
89/Protocol YO29449, Version 3 
 
procedures such as biopsy sample collections, discontinuation of medications) should be 
reported (see Section 5.4.2 for instructions for reporting serious adverse events). 
After initiation of study drug, all adverse events will be reported until 4 weeks after the 
last dose of study drug.  After this period, the investigator should report any serious 
adverse events that are believed to be related to prior study drug treatment (see 
Section 5.6). 
5.3.2 
Eliciting Adverse Event Information 
A consistent methodology of non-directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non-directive 
questions include the following: 
"How have you felt since your last clinic visit?" 
"Have you had any new or changed health problems since you were last here?" 
 
5.3.3 
Assessment of Severity of Adverse Events 
The adverse event severity grading scale for the NCI CTCAE v4.0 will be used for 
assessing adverse event severity.  Table 6 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
90/Protocol YO29449, Version 3 
 
Table 6 
Adverse Event Severity Grading Scale for Events Not Specifically 
Listed in the NCI CTCAE 
Grade 
Severity 
1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or 
intervention not indicated 
2 
Moderate; minimal, local, or non-invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily living a 
3 
Severe or medically significant, but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; or limiting 
self-care activities of daily living b, c 
4 
Life-threatening consequences or urgent intervention indicated d 
5 
Death related to adverse event d 
NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events. 
Note:  Based on the most recent version of NCI CTCAE (v4.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
a Instrumental activities of daily living refer to preparing meals, shopping for groceries or 
clothes, using the telephone, managing money, etc. 
b Examples of self-care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by patients who are 
not bedridden. 
c If an event is assessed as a "significant medical event," it must be reported as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.2. 
d Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2. 
 
5.3.4 
Assessment of Causality of Adverse Events 
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to the study drug, indicating "yes" or "no" 
accordingly.  The following guidance should be taken into consideration: 
• 
Temporal relationship of event onset to the initiation of study drug 
• 
Course of the event, with consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable) 
• 
Known association of the event with the study drug or with similar treatments 
• 
Known association of the event with the disease under study 
• 
Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event 
• 
Presence of non-treatment-related factors that are known to be associated with the 
occurrence of the event 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
91/Protocol YO29449, Version 3 
 
5.3.5 
Procedures for Recording Adverse Events 
Investigators should use correct medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Colloquialisms and abbreviations should be 
avoided. 
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF. 
5.3.5.1 
Diagnosis versus Signs and Symptoms 
A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather than 
jaundice, asterixis, and elevated transaminases).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a single diagnosis or syndrome 
at the time of reporting, each individual event should be recorded on the Adverse Event 
eCRF.  If a diagnosis is subsequently established, all previously reported adverse events 
based on signs and symptoms should be nullified and replaced by one adverse event 
report based on the single diagnosis, with a starting date that corresponds to the starting 
date of the first symptom of the eventual diagnosis. 
5.3.5.2 
Adverse Events That are Secondary to Other Events 
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by their primary cause, with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example: 
• 
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF. 
• 
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF. 
• 
If a severe GI hemorrhage leads to renal failure, both events should be reported 
separately on the eCRF. 
• 
If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF. 
• 
If neutropenia is accompanied by an infection, both events should be reported 
separately on the eCRF. 
 
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated. 
5.3.5.3 
Persistent or Recurrent Adverse Events 
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 

 
Alectinib—F. Hoffmann-La Roche Ltd 
92/Protocol YO29449, Version 3 
 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should also be recorded on the Adverse Event 
eCRF.  If the event becomes serious, it should be reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning that the event became serious; see 
Section 5.4.2 for reporting instructions).  The Adverse Event eCRF should be updated by 
changing the event from "non-serious" to "serious," providing the date that the event 
became serious, and completing all data fields related to serious adverse events. 
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF. 
5.3.5.4 
Abnormal Laboratory Values 
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria: 
• 
Accompanied by clinical symptoms 
• 
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation) 
• 
Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy 
• 
Clinically significant in the investigator’s judgment 
Note: For oncology studies, certain abnormal values may not qualify as adverse 
events. 
 
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event. 
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., ALP and bilirubin 5 × ULN associated with cholestasis), the diagnosis only 
(i.e., cholestasis) should be recorded on the Adverse Event eCRF. 
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating if the test result is above or below the normal range (e.g., "elevated 
potassium," as opposed to "abnormal potassium").  If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical term should 
be recorded as the adverse event.  For example, an elevated serum potassium level 
of 7.0 mEq/L should be recorded as "hyperkalemia." 

 
Alectinib—F. Hoffmann-La Roche Ltd 
93/Protocol YO29449, Version 3 
 
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for 
details on recording persistent adverse events). 
5.3.5.5 
Abnormal Vital Sign Values 
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criteria: 
• 
Is accompanied by clinical symptoms 
• 
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation) 
• 
Results in a medical intervention or a change in concomitant therapy 
• 
Is clinically significant in the investigator’s judgment 
 
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event. 
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF. 
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for 
details on recording persistent adverse events). 
5.3.5.6 
Abnormal Liver Function Tests 
The finding of an elevated ALT or AST (> 3 × baseline value) in combination with either 
an elevated total bilirubin (> 2 × ULN) or clinical jaundice in the absence of cholestasis or 
other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury.  
Therefore, investigators must report as an adverse event the occurrence of either of the 
following: 
• 
Treatment-emergent ALT or AST > 3 × baseline value in combination with total 
bilirubin > 2 × ULN (of which ≥ 35% is direct bilirubin) 
• 
Treatment-emergent ALT or AST > 3 × baseline value in combination with clinical 
jaundice 
 
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.1) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event) either as an serious adverse event or a non-serious adverse event of special 
interest (see Section 5.4.2). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
94/Protocol YO29449, Version 3 
 
5.3.5.7 
Deaths 
For this protocol, mortality is an efficacy endpoint.  Deaths that occur during the 
protocol-specified adverse event reporting period (see Section 5.3.1) that are attributed, 
by the investigator, solely to progression of NSCLC should be recorded only on the 
Study Completion/Early Discontinuation eCRF.  All other deaths that occur during the 
study, regardless of the relationship to study drug, must be recorded on the Adverse 
Event eCRF and immediately reported to the Sponsor (see Section 5.4.2). 
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death" should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should 
be replaced by the established cause of death.  The term "sudden death" should not 
be used unless combined with the presumed cause of death (e.g., "sudden cardiac 
death"). 
During survival follow-up, deaths attributed to progression of NSCLC should be recorded 
only on the Survival eCRF. 
5.3.5.8 
Preexisting Medical Conditions 
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF. 
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  When 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by including applicable descriptors 
(e.g., "more frequent headaches"). 
5.3.5.9 
Lack of Efficacy or Worsening of Non−Small Cell Lung Cancer 
Events that are clearly consistent with the expected pattern of progression of the 
underlying disease should not be recorded as adverse events.  These data will be 
captured as efficacy assessment data only.  In most cases, the expected pattern of 
progression will be based on RECIST v1.1 (see Appendix 4).  In rare cases, the 
determination of clinical progression will be made on the basis of symptomatic 
deterioration.  However, every effort should be made to document progression with use 
of objective criteria.  If there is any uncertainty as to whether an event occurs because of 
disease progression, it should be reported as an adverse event. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
95/Protocol YO29449, Version 3 
 
5.3.5.10 
Hospitalization or Prolonged Hospitalization 
Any adverse event that results in hospitalization (i.e., inpatient admission to a hospital) 
or prolonged hospitalization should be documented and reported as a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2), except as outlined 
below. 
An event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event: 
• 
Hospitalization for respite care 
• 
Planned hospitalization required by the protocol 
• 
Hospitalization for a preexisting condition, provided that all of the following criteria 
are met: 
The hospitalization was planned before the study or was scheduled during the 
study when elective surgery became necessary because of the expected 
normal progression of the disease. 
The patient has not experienced an adverse event. 
• 
Hospitalization due solely to progression of the underlying cancer 
 
An event that leads to hospitalization under the following circumstances is not 
considered to be a serious adverse event, but should be reported as an adverse event 
instead: 
• 
Hospitalization that was necessary because of patient requirement for outpatient 
care outside of normal outpatient clinic operating hours 
• 
Hospitalization to perform a planned measurement for the study 
 
5.3.5.11 
Adverse Events Associated with an Overdose or Error in Drug 
Administration 
An overdose is the accidental or intentional use of a drug in an amount higher than the 
dose being studied.  An overdose or incorrect administration of study treatment is not 
itself an adverse event, but it may result in an adverse event.  All adverse events 
associated with an overdose or incorrect administration of study drug should be 
recorded on the Adverse Event eCRF.  If the associated adverse event fulfills serious 
criteria, the event should be reported to the Sponsor immediately (i.e., no more than 
24 hours after learning of the event; see Section 5.4.2). 
5.3.5.12 
Patient-Reported Outcome Data 
Adverse event reports will not be derived from PRO data by the Sponsor, and safety 
analyses will not be performed with the use of PRO data.  However, if any PRO 
responses suggestive of a possible adverse event are identified during site review of the 
PRO data, the investigator will determine whether the criteria for an adverse event have 
been met and, if so, will report the event on the Adverse Event eCRF. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
96/Protocol YO29449, Version 3 
 
5.3.5.13 
Adverse Events in Individuals Not Enrolled in the Study 
If an adverse event inadvertently occurs in an individual not enrolled in the study, the 
Adverse Event Form provided to investigators should be completed and submitted to 
Roche or its designee, either by faxing or by scanning and emailing the form using the 
fax number or email address provided to investigators. 
5.4 
IMMEDIATE REPORTING REQUIREMENTS FROM 
INVESTIGATOR TO SPONSOR 
Certain events require immediate reporting to allow the Sponsor to take appropriate 
measures to address potential new risks in a clinical study.  The investigator must report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than 24 hours after the investigator learns of the event.  The following is a list 
of events that the investigator must report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug: 
• 
Serious adverse events 
• 
Non-serious adverse events of special interest 
• 
Pregnancies 
 
The investigator must report new significant follow-up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following: 
• 
New signs or symptoms or a change in the diagnosis 
• 
Significant new diagnostic test results 
• 
Change in causality based on new information 
• 
Change in the event’s outcome, including recovery 
• 
Additional narrative information on the clinical course of the event 
 
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/Ethics Committee (EC). 
5.4.1 
Emergency Medical Contacts 
Medical Monitor (Roche Medical Responsible) Contact Information 
Medical Monitor: 
 M.D. 
Email:   
 
Telephone No.: 
Mobile Telephone No.: 
 
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the Roche Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a Roche Medical 

 
Alectinib—F. Hoffmann-La Roche Ltd 
97/Protocol YO29449, Version 3 
 
Monitor, and track all calls.  The Emergency Medical Call Center Help Desk will be 
available 24 hours per day, 7 days per week.  Toll-free numbers for the Help Desk and 
Medical Monitor contact information will be distributed to all investigators (see "Protocol 
Administrative and Contact Information & List of Investigators Form"). 
5.4.2 
Reporting Requirements for Serious Adverse Events and 
Non-Serious Adverse Events of Special Interest 
5.4.2.1 
Events That Occur before Study Drug Initiation 
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention should be reported.  
The Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided 
to investigators should be completed and submitted to Roche or its designee 
immediately (i.e., no more than 24 hours after learning of the event), either by faxing or 
by scanning and emailing the form with use of the fax number or email address provided 
to investigators. 
5.4.2.2 
Events That Occur after Study Drug Initiation 
After initiation of study drug, serious adverse events and non-serious adverse events of 
special interest will be reported until 4 weeks after the last dose of study drug.  
Investigators should record all case details that can be gathered immediately (i.e., within 
24 hours after learning of the event) on the Adverse Event eCRF and submit the report 
via the electronic data capture (EDC) system.  A report will be generated and sent to 
Roche Safety Risk Management by the EDC system. 
In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse 
Event of Special Interest Reporting Form provided to investigators should be completed 
and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours 
after learning of the event), either by faxing or by scanning and emailing the form with 
use of the fax number or email address provided to investigators (see "Protocol 
Administrative and Contact Information & List of Investigators").  Once the EDC system 
is available, all information will need to be entered and submitted via the EDC system. 
Instructions for reporting post-study adverse events are provided in Section 5.6. 
5.4.3 
Reporting Requirements for Pregnancies 
5.4.3.1 
Pregnancies 
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study or within 3 months after the last 
dose of study drug.  A Clinical Trial Pregnancy Reporting Form should be completed by 
the investigator and submitted to the sponsor within 24 hours after learning of the 
pregnancy.  Pregnancy should not be recorded on the Adverse Event eCRF.  The 
investigator should discontinue study drug and counsel the patient, discussing the risks 

 
Alectinib—F. Hoffmann-La Roche Ltd 
98/Protocol YO29449, Version 3 
 
of the pregnancy and the possible effects on the fetus.  Monitoring of the patient should 
continue until conclusion of the pregnancy. 
Any serious adverse events associated with the pregnancy (e.g., an event in the fetus, 
an event in the mother during or after the pregnancy, or a congenital anomaly/birth 
defect in the child) should be reported on the Adverse Event eCRF. 
5.4.3.2 
Pregnancies in Female Partners of Male Patients 
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
3 months after the last dose of study drug.  A Clinical Trial Pregnancy Reporting Form 
should be completed and submitted to the sponsor by the investigator immediately (i.e., 
no more than 24 hours after learning of the pregnancy).  Attempts should be made to 
collect and report details of the course and outcome of any pregnancy in the partner of a 
male patient exposed to study drug.  The pregnant partner will need to sign an 
Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow-
up on her pregnancy.  Once the authorization has been signed, the investigator will 
update the Clinical Trial Pregnancy Reporting Form with additional information on the 
course and outcome of the pregnancy.  An investigator who is contacted by the male 
patient or his pregnant partner may provide information on the risks of the pregnancy 
and the possible effects on the fetus, to support an informed decision in cooperation with 
the treating physician and/or obstetrician. 
5.4.3.3 
Abortions 
Any abortion should be classified as a serious adverse event (as the Sponsor considers 
abortions to be medically significant), recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2). 
5.4.3.4 
Congenital Anomalies/Birth Defects 
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adverse event, recorded on the Adverse Event eCRF, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2). 
5.5 
FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS 
5.5.1 
Investigator Follow-Up 
The investigator should follow each adverse event until the event has resolved to 
baseline grade or better, the event is assessed as stable by the investigator, the patient 
is lost to follow-up, or the patient withdraws consent.  Every effort should be made to 
follow all serious adverse events considered to be related to study drug or study-related 
procedures until a final outcome may be reported. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
99/Protocol YO29449, Version 3 
 
During the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification.  All pregnancies reported during the study should be followed until 
pregnancy outcome.  If the EDC system is not available at the time of pregnancy 
outcome, follow reporting instructions provided in Section 5.4.3.1. 
5.5.2 
Sponsor Follow-Up 
For serious adverse events, non-serious adverse events of special interest, and 
pregnancies, the Sponsor or a designee may follow up by telephone, fax, electronic mail, 
and/or a monitoring visit to obtain additional case details and outcome information 
(e.g., from hospital discharge summaries, consultant reports, autopsy reports) in order to 
perform an independent medical assessment of the reported case. 
5.6 
POST-STUDY ADVERSE EVENTS 
The Sponsor should be notified if the investigator becomes aware of any serious 
adverse event that occurs after the end of the adverse event reporting period (defined as 
4 weeks after the last dose of study drug), if the event is believed to be related to prior 
study drug treatment.  
The investigator should report these events directly to the Sponsor or its designee, either 
by faxing or by scanning and emailing the Serious Adverse Event/Adverse Event of 
Special Interest Reporting Form using the fax number or email address provided to 
investigators. 
5.7 
EXPEDITED REPORTING TO HEALTH AUTHORITIES, 
INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND 
ETHICS COMMITTEES 
The Sponsor will promptly evaluate all serious adverse events and non-serious adverse 
events of special interest against cumulative product experience to identify and 
expeditiously communicate possible new safety findings to investigators, IRBs, ECs, and 
applicable health authorities based on applicable legislation. 
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events with the use of the following reference 
documents: 
• 
Alectinib Investigator's Brochure 
• 
Local prescribing information for crizotinib 
 
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
100/Protocol YO29449, Version 3 
 
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by the Sponsor as needed. 
6. 
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN 
The primary analysis population for efficacy is the intent-to-treat (ITT) population, 
defined as all randomized patients.  Patients will be assigned to the treatment group to 
which they were randomized. 
The primary analysis population for safety is the Safety Analysis Population (SAP) 
defined as all patients who received at least one dose of study medication.  Patients will 
be assigned to treatment groups as treated, and all patients who received any dose of 
alectinib will be included in the alectinib treatment arm. 
The primary objective of the study is to determine whether the benefit (in terms of 
investigator-assessed PFS) of administrating alectinib in this study is consistent with 
the benefit observed in global study ALEX.   Consistency is defined as 
maintaining ≥ 50% of risk reduction from ALEX.  The number of PFS events required 
to show consistency depends on the HR observed in the ALEX trial.  The required 
number of PFS events to achieve approximate 87% probability to meet consistency 
criteria is listed as below.  
Table 7 
Required Number of PFS Events to Show Consistency 
HR Observed 
in ALEX 
Consistency Criteria (HR) 
No. of PFS Events Required  
0.65 
0.83 
97 
0.6 
0.8 
70 
0.55 
0.78 
50 
0.5 
0.75 
35 
HR = hazard ratio; PFS = progression-free survival. 
 
The primary analysis of PFS will occur when as early as required PFS events to show 
consistency have occurred. If the number of PFS events is not enough for the 
estimation of median PFS, an updated PFS analysis will be done when approximately 
55% of patients have had PFS events.   
The first survival analysis will be performed together with the primary PFS analysis.  A 
survival follow-up analysis will be performed when approximately 55% patients have 
died. 
Further details of all analyses will be provided in the Statistical Analysis Plan. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
101/Protocol YO29449, Version 3 
 
6.1 
DETERMINATION OF SAMPLE SIZE 
The primary endpoint of investigator-assessed PFS was used to determine the sample 
size of the study.  The primary objective of the study is to reliably determine whether the 
benefit (in terms of PFS) of administrating alectinib in this study is consistent with the 
benefit observed in the global Study ALEX.  Consistency is defined as 
maintaining ≥ 50% of risk reduction from Study ALEX.  That is, assuming the estimated 
PFS HR for the ALEX trial is 0.65 (i.e., 35% risk reduction), if the point estimate of HR 
from Study YO29449 is less than 0.83, then the study’s primary objective to 
demonstrate consistency is met. 
Based on the assumption of PFS HR = 0.65, a total of 97 PFS events are required to 
achieve approximately 87% probability to show consistency.  In this study, 183 patients 
will be enrolled in a 2:1 randomization allocation.  Based on the assumption that the 
median PFS is 10.9 months for the crizotinib arm and 16.8 months for the alectinib arm 
(HR = 0.65) and patients are to be enrolled over approximately 13 months; the final PFS 
analysis is expected to occur approximately 23 months after the first patient is enrolled. 
No interim analysis for efficacy or futility is planned. 
The first survival analysis will be performed together with the primary PFS analysis.  A 
survival follow-up analysis will be performed once approximately 55% of patients have 
died.  The median OS in the crizotinib arm is assumed to be 24 months, and the 
expected median OS in the alectinib treatment arm is 30 months, equating to an HR 
of 0.8.  The survival follow-up analysis is expected to occur approximately 41 months 
after the first patient has been enrolled. 
6.2 
SUMMARIES OF CONDUCT OF STUDY 
Study enrollment, study treatment administration, reasons for discontinuation from study 
treatment, and reasons for study termination will be summarized by treatment arm for all 
randomized patients.  Violations of inclusion and exclusion criteria will be reported and 
summarized by treatment arm. 
6.3 
SUMMARIES OF TREATMENT GROUP COMPARABILITY 
Summaries of treatment group comparability will be based on the ITT population. 
Demographic, baseline disease characteristics and lung cancer history will be 
summarized by treatment arm for all randomized patients, including the randomization 
stratification factors.  Descriptive baseline summaries of continuous data will present the 
group mean, standard deviation, median, minimum, and maximum.  Descriptive 
summaries of discrete data will present the category counts as frequency and 
percentages. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
102/Protocol YO29449, Version 3 
 
Previous and concomitant cancer therapy will also be summarized, as well as 
anti-cancer subsequent therapy.  Previous and concurrent diseases and medications will 
also be summarized. 
6.4 
EFFICACY ANALYSES 
The primary population for all primary and secondary efficacy analyses will be the ITT 
population. 
6.4.1 
Primary Efficacy Endpoint 
PFS is defined as the time from date of randomization to the date of first documented 
disease progression or death, whichever occurs first.  The primary endpoint of PFS will 
be determined on the basis of investigator assessment of progression according to 
RECIST v1.1.  Patients who have not experienced disease progression or death at the 
time of analysis will be censored at the last tumor assessment date either during study 
treatment or during follow-up.  Patients without tumor assessments after baseline will be 
censored at the date of randomization. 
Patients who discontinue treatment before disease progression (e.g., because of toxicity) 
will continue in the study and will be followed until disease progression and for OS 
regardless of whether they subsequently receive anti-cancer therapy. 
The Kaplan-Meier method will be used to estimate the median PFS for each treatment 
arm with 95% confidence limits, and a Kaplan-Meier curve will be constructed to provide 
a visual description of the difference between the treatment arms.  A stratified 
Cox proportional regression model will be used including treatment in order to provide an 
estimate of the treatment effect expressed as an HR (alectinib vs. crizotinib), as well as 
a 95% CI.  The stratification factors are the randomization stratification factors:  ECOG 
PS (0/1 vs. 2) and CNS metastases at baseline (yes vs. no), as recorded on the eCRF.  
Point estimate of the adjusted HR will be compared with the consistency threshold 
(observed HR in the ALEX trial). 
The treatment comparison of PFS will also be assessed and tested based on a stratified 
log-rank test to demonstrate the strength of consistent trend.  However, this hypothesis 
testing is limited because statistically negative outcomes do not necessarily rule out 
clinically significant treatment effects. 
6.4.2 
Secondary Efficacy Endpoints 
PFS by IRC 
An analysis of PFS on the basis of the IRC assessments will be performed using the 
same methodology as specified for PFS on the basis of investigator assessment. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
103/Protocol YO29449, Version 3 
 
Time to CNS Progression 
Time to progression of disease in the CNS is defined as the time from the randomization 
date until radiographic evidence of progression of disease in the CNS.  The analysis of 
progression of disease in the CNS or response will be based on the data from the IRC 
assessment.  All patients will be included in the analysis regardless of their baseline 
status of CNS metastases.  Progression of disease in the CNS is defined as progression 
due to newly developed CNS lesions or progression of preexisting baseline CNS lesions.  
On the basis of RECIST v1.1 and RANO, this is defined as a new post−baseline 
CNS/brain lesion(s) and/or an increase of ≥ 20% in the sum of longest diameters of the 
measurable baseline CNS lesions compared with nadir or unequivocal progression of 
non-measurable baseline CNS lesions. 
To account for the competing risks inherent in such an analysis, HRs, including 
statistical inference based on a two-sided log-rank test to compare the risk of 
progression of disease in the CNS between the alectinib and crizotinib treatment groups, 
will be computed on the basis of cause-specific hazard functions. 
The probability of CNS disease progression, non-CNS disease progression, and death 
will each be estimated with the use of cumulative incidence functions. 
For descriptive purposes, estimates of the CNS disease progression rates over time with 
95% CIs will be presented on the basis of cumulative incidence functions.  A Gray’s test 
to compare the risk of progression of disease in the CNS between alectinib and crizotinib 
will also be performed as a supportive analysis. 
In the subgroup of patients with measurable CNS lesions at baseline, an exploratory 
analysis of C-ORR, defined as the percentage of patients who achieve a best overall 
response of CR or PR in the CNS (defined by RECIST v1.1 as a 30% decrease in the 
sum of longest diameters of measurable CNS lesions referencing baseline), will also be 
performed.  Duration of CNS response will be listed and may be analyzed if there are a 
sufficient number of CNS responses. 
Objective Response Rate 
ORR, based on investigator assessment, is defined as the percentage of patients who 
attain a CR or PR based on RECIST v1.1.  Confirmation of an objective response is not 
required for this secondary endpoint.  Patients without a tumor assessment after 
baseline will be considered non-responders, as will patients with a best overall response 
of stable disease (SD), PD, or NE. 
An estimate of ORR and its two-sided 95% CI will be calculated with use of the 
Clopper-Pearson method for each treatment arm.  Response rates in the treatment 
groups will be compared with use of a stratified Mantel-Haenszel test on the basis of the 
randomization stratification factors.  The difference in ORR between the two treatment 

 
Alectinib—F. Hoffmann-La Roche Ltd 
104/Protocol YO29449, Version 3 
 
arms will be presented together with a two-sided 95% CI on the basis of a normal 
approximation to the binomial distribution. 
Duration of Response 
For patients who have experienced an objective response (CR or PR) during the study 
as assessed by the investigator, DOR is defined as the duration from the first tumor 
assessment that supports the patient’s objective response (CR or PR, whichever is first 
recorded) to first documented disease progression or death due to any cause, whichever 
occurred first.  Patients who have not progressed or died at the time of analysis will be 
censored at the last tumor assessment date.  DOR will be estimated with the use of 
Kaplan-Meier methodology, and a HR on the basis of a Cox proportional regression 
model will be calculated. 
CNS Objective Response Rate  
This is defined as the objective tumor response rate (CR + PR) in CNS lesions in patients 
who have measurable disease in the CNS at baseline.  An analysis by an IRC with the 
use of RECIST v1.1 and RANO criteria will be performed.  An exploratory analysis of C-
ORR in patients with measurable and/or non-measurable CNS disease at baseline will 
also be performed. 
CNS Duration of Response 
This is defined as the time from the first observation of a CNS response until first 
observation of CNS progression or death from any cause.  An analysis by an IRC with 
the use of RECIST v1.1 and RANO criteria will be performed.  Duration of CNS 
response will be listed and may be analyzed if there are a sufficient number of CNS 
responses. 
CNS Progression Rate 
The cumulative incidence of CNS progression will be plotted using a cumulative 
incidence curve and rates over time will be presented.  CNS progression is defined as a 
new CNS lesion or progression of preexisting CNS lesions.  An analysis by an IRC with 
the use of RECIST v1.1 and RANO criteria will be performed. 
Overall Survival 
OS is defined as the time from the date of randomization to the date of death due to any 
cause.  Patients who are not reported as having died at the time of analysis will be 
censored at the date when they were last known to be alive.  Patients who do not have 
information after baseline will be censored at the date of randomization.  OS will be 
analyzed with the use of the same methodology as specified for the primary endpoint.  A 
survival follow-up will be performed based on more mature data. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
105/Protocol YO29449, Version 3 
 
6.4.3 
Sensitivity Analyses 
The following sensitivity analysis will be performed on the primary endpoint of PFS: 
• 
The effect of non−protocol-specified anti-cancer therapy before progression will be 
assessed by censoring patients at the last adequate tumor assessment before the 
start of non−protocol-specified anti-cancer therapy. 
 
6.4.4 
Subgroup Analyses 
Subgroup analyses of PFS will be performed for patients with baseline CNS metastases 
and for patients without baseline CNS metastases.  In addition, a subgroup analysis of 
time to CNS progression will be performed, excluding patients who had pretreatment 
radiation therapy for CNS lesions. 
All other subgroup analyses will be specified in the statistical analysis plan. 
6.5 
SAFETY ANALYSES 
The primary population for all safety analyses will be the SAP as defined in Section 6. 
All safety parameters will be summarized in tables to evaluate and compare the safety 
profile of patients treated with alectinib versus crizotinib in terms of the following: 
• 
Adverse events including adverse events leading to dose modifications or 
interruptions, study drug withdrawal, and death 
• 
Severe, serious, and selected adverse events 
• 
Deaths 
• 
Laboratory parameters and abnormalities 
• 
Vital signs 
• 
ECGs 
• 
ECOG PS 
 
Adverse events will be coded with the use of MedDRA and will be summarized by 
mapped term and appropriate thesaurus level.  All adverse events and routine laboratory 
parameters will be assessed according to the NCI CTCAE v4.0 grading system.  
Adverse events will be described by individual listings, by body system, and by severity.  
In tables showing the overall incidence of adverse events, patients who experienced the 
same event on more than one occasion will be counted only once in the calculation of 
the event frequency. 
Laboratory values will be summarized by treatment arm, including summary tables for 
the shifts in grades from baseline to the worst grade observed during treatment. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
106/Protocol YO29449, Version 3 
 
Descriptive summary tables of change from baseline over time will be provided for vital 
signs, and descriptive statistics will be tabulated for ECOG PS.  ECG findings over time 
will be summarized. 
Study drug administration will be summarized by duration and cumulative dose.  In 
addition, treatment exposure will be summarized and will include the number of doses 
received, dose intensity, and the planned dose percentage. 
6.6 
PHARMACOKINETIC ANALYSES 
Standard NCA may be conducted for PK data collected from patients who participate in 
the frequent blood sampling, as appropriate and if data allow.  Blood samples will be 
used for PK analysis of relevant analytes, as data allow and where appropriate.  PK 
parameters including but not limited to AUC, Cmax, and tmax, will be calculated on the 
basis of the available data as appropriate and where data allow.  Additional PK 
parameters may be calculated as deemed appropriate. 
A popPK analysis will be performed to describe the time course of plasma 
concentrations of alectinib (and/or metabolite(s), if available and appropriate), as 
appropriate and where data allow.  The influence of covariates (e.g., body weight, age, 
sex, race, and concomitant medications) on PK parameters will be investigated, if 
necessary and appropriate.  If necessary, the data may be pooled with data from 
previous studies. 
Individual and mean plasma concentrations at each sampling timepoint and/or PK 
parameters for alectinib (and metabolite[s], if appropriate) will be listed. 
Summary statistics (e.g., means, standard deviation, coefficient of variation percentages, 
geometric means, medians, and ranges) for plasma concentrations and/or PK 
parameters for alectinib (metabolite[s], if appropriate) will be presented by treatment and 
nominal collection times (plasma concentrations only), as appropriate.  Additional plots 
or summary statistics may be constructed or calculated, as appropriate. 
Results of PK and/or any PK or PK/pharmacodynamic analyses may be reported outside 
the clinical study report. 
Nonlinear mixed-effects modeling (with software NONMEM) (Beal et al. 1999) will be 
used to analyze the sparse and/or and frequent plasma concentration-time data for 
alectinib.  The PK data from this study may be pooled with data from other studies.  
Population and individual PK parameters will be estimated and the influence of various 
covariates (such as age, sex, and body weight) on these parameters will be investigated. 
Details of any mixed-effects modeling and exploratory analyses will be reported in a 
document separate from the clinical study report of this study. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
107/Protocol YO29449, Version 3 
 
6.7 
PATIENT-REPORTED OUTCOME ANALYSES 
The following PRO endpoints will be analyzed and PRO data will be presented 
separately from adverse event data. 
6.7.1 
Time to Deterioration of Patient-Reported Lung Cancer 
Symptoms 
TTD from baseline will be assessed every 4 weeks until disease progression and during 
study treatment after disease progression in the case of isolated, asymptomatic 
progression of disease in the CNS; at Post-Treatment Visit (4 weeks after permanent 
treatment discontinuation); and at subsequent survival follow-up visits every 8 weeks for 
6 months, for the following lung cancer symptoms:  cough (Question 31 on the QLQ-
LC13), dyspnea single item (Question 8 on the QLQ-C30), dyspnea multi-item subscale 
(Questions 33-35 on the QLQ-LC13), chest pain (Question 40 on the QLQ-LC13), 
arm/shoulder pain (Question 41 on the QLQ-LC13), and fatigue multi-item subscale 
(Questions 10, 12, and 18 on the QLQ-C30) for patients in each arm.  Completion and 
compliance rates will be summarized at each timepoint by treatment arm with reasons 
for missing data.  TTD will be analyzed for the ITT population.  If a baseline or 
postbaseline PRO evaluation is not available, TTD will be censored at the date of 
randomization.  If they have not deteriorated, patients will be censored at the last time 
when they completed an assessment for cough, dyspnea (single item), dyspnea 
(subscale items), chest pain, arm/shoulder pain, and fatigue. 
Additional details regarding the TTD analyses will be included within the SAP. 
6.7.2 
Additional Patient-Reported Outcomes 
PROs of HRQOL, lung cancer−related symptoms, and health status will be measured 
with the use of the EORTC QLQ-C30 and EORTC QLQ-LC13 (see Appendix 7 and 
Appendix 8, respectively). 
Summary statistics (mean, standard deviation, median, and range) of linear transformed 
scores will be reported for all the items and subscales of the EORTC QLQ-C30 and the 
QLQ-LC13 according to the EORTC scoring manual guidelines (see Appendix 7 and 
Appendix 8, respectively).  Completion and compliance rates will be summarized at each 
timepoint by treatment arm with reasons for missing data.  Only patients with a baseline 
assessment and at least one post-treatment assessment will be included in the analyses. 
Additional details regarding the PRO analyses will be included within the SAP. 
6.8 
EXPLORATORY ANALYSES 
Results of exploratory analyses on post-progression tumor samples to measure 
molecular mechanisms of resistance to ALK inhibitors and plasma samples to measure 
ALK rearrangements and mutations in ALK and other genes involved in cancer will be 
communicated outside the main clinical study report. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
108/Protocol YO29449, Version 3 
 
6.9 
OPTIONAL INTERIM ANALYSES 
No interim analysis for efficacy or futility is planned. 
7. 
DATA COLLECTION AND MANAGEMENT 
7.1 
DATA QUALITY ASSURANCE 
The Sponsor will be responsible for data management of this study, including quality 
checking of the data.  Data entered manually will be collected via EDC with the use of 
eCRFs.  Sites will be responsible for data entry into the EDC system.  In the event of 
discrepant data, the Sponsor will request data clarification from the sites, which the sites 
will resolve electronically in the EDC system. 
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data or other electronic 
data will be sent directly to the Sponsor, with use of the Sponsor’s standard procedures 
to handle and process the electronic transfer of these data. 
eCRFs and correction documentation will be maintained in the EDC system’s audit trail.  
System backups for data stored by the Sponsor and records retention for the study data 
will be consistent with the Sponsor’s standard procedures. 
7.2 
ELECTRONIC CASE REPORT FORMS 
eCRFs are to be completed through use of a Sponsor-designated EDC system.  Sites 
will receive training and have access to a manual for appropriate eCRF completion.  
eCRFs will be submitted electronically to the Sponsor and should be handled in 
accordance with instructions from the Sponsor. 
All eCRFs should be completed by designated, trained site staff.  eCRFs should be 
reviewed and electronically signed and dated by the investigator or a designee. 
At the end of the study, the investigator will receive patient data for his or her site in a 
readable format on a compact disc that must be kept with the study records.  
Acknowledgement of receipt of the compact disc is required. 
7.3 
SOURCE DATA DOCUMENTATION 
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are 
accurate, complete, and verifiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, PROs, evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copies of 

 
Alectinib—F. Hoffmann-La Roche Ltd 
109/Protocol YO29449, Version 3 
 
transcriptions that are certified after verification as being accurate and complete, 
microfiche, photographic negatives, microfilm or magnetic media, X-rays, patient files, 
and records kept at pharmacies, laboratories, and medico-technical departments 
involved in a clinical study. 
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no previous written or electronic record of the data) 
and considered source data. 
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.5. 
To facilitate source data verification, the investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for study-related 
monitoring, Sponsor audits, and IRB/EC review.  The study site must also allow 
inspection by applicable health authorities. 
7.4 
USE OF COMPUTERIZED SYSTEMS 
When clinical observations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record may serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name of the person 
making the change, and date of the change. 
7.5 
RETENTION OF RECORDS 
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, including eCRFs, Informed Consent Forms, laboratory test results, and medication 
inventory records, must be retained by the Principal Investigator for at least 15 years 
after completion or discontinuation of the study, or for the length of time required by 
relevant national or local health authorities, whichever is longer.  After that period of time, 
the documents may be destroyed, subject to local regulations. 
No records may be disposed of without the written approval of the Sponsor.  Written 
notification should be provided to the Sponsor before transferring any records to another 
party or moving them to another location. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
110/Protocol YO29449, Version 3 
 
8. 
ETHICAL CONSIDERATIONS 
8.1 
COMPLIANCE WITH LAWS AND REGULATIONS 
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting). 
8.2 
INFORMED CONSENT 
The Sponsor’s sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a Child’s Assent or Caregiver's Informed Consent Form, if applicable) will 
be provided to each site.  If applicable, it will be provided in a certified translation of the 
local language.  The Sponsor or its designee must review and approve any proposed 
deviations from the Sponsor's sample Informed Consent Forms or any alternate consent 
forms proposed by the site (collectively, the "Consent Forms") before IRB/EC 
submission.  The final IRB/EC−approved Consent Forms must be provided to the 
Sponsor for health authority submission purposes according to local requirements. 
The Consent Forms must be signed and dated by the patient before his or her 
participation in the study.  The case history or clinical records for each patient shall 
document the informed consent process and that written informed consent was obtained 
before participation in the study. 
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC−approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes. 
Patients must be re-consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obtained with use of 
the updated/revised Consent Forms for continued participation in the study. 
A copy of each signed Consent Form must be provided to the patient or the patient’s 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient’s study file or in the site file and must be available for verification by study 
monitors at any time. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
111/Protocol YO29449, Version 3 
 
8.3 
INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE 
This protocol, the Informed Consent Forms, any information to be given to the patient, 
and relevant supporting information must be submitted to the IRB/EC by the Principal 
Investigator and reviewed and approved by the IRB/EC before the study is initiated.  In 
addition, any patient recruitment materials must be approved by the IRB/EC. 
The Principal Investigator is responsible for providing written summaries of the status of 
the study to the IRB/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by the IRB/EC.  Investigators are also responsible 
for promptly informing the IRB/EC of any protocol amendments (see Section 9.6). 
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written Investigational New 
Drug safety reports or other safety-related communications from the Sponsor.  
Investigators are responsible for ensuring that such reports are reviewed and processed 
in accordance with health authority requirements and the policies and procedures 
established by their IRB/EC, and archived in the site’s study file. 
8.4 
CONFIDENTIALITY 
The Sponsor maintains confidentiality standards by coding each patient enrolled in the 
study through assignment of a unique patient identification number.  This means that 
patient names are not included in data sets that are transmitted to any Sponsor location. 
Patient medical information obtained by this study is confidential and may be disclosed 
to third parties only as permitted by the Informed Consent Form (or separate 
authorization for use and disclosure of personal health information) signed by the patient, 
unless permitted or required by law. 
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare, for treatment purposes. 
Data generated by this study must be available for inspection upon request by 
representatives of the FDA and other national and local health authorities, Sponsor 
monitors, representatives, and collaborators, and the IRB/EC for each study site, as 
appropriate. 
8.5 
FINANCIAL DISCLOSURE 
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
112/Protocol YO29449, Version 3 
 
9. 
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION 
9.1 
STUDY DOCUMENTATION 
The investigator must maintain adequate and accurate records to enable the conduct of 
the study to be fully documented, including but not limited to the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, which includes an audit trail containing a complete record of all changes 
to data. 
9.2 
PROTOCOL VIOLATIONS 
The investigator should document and explain any protocol deviations.  The investigator 
should promptly report any deviations that might have an impact on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.  As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed. 
9.3 
SITE INSPECTIONS 
Site visits will be conducted by the Sponsor or an authorized representative for 
inspection of study data, patients’ medical records, and eCRFs.  The investigator will 
permit national and local health authorities, Sponsor monitors, representatives, and 
collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study. 
9.4 
ADMINISTRATIVE STRUCTURE 
A Steering Committee is established to provide the study Sponsor with 
recommendations related to any aspect of the study, specifically study design, data 
interpretation, exploratory analyses, or alternate changes to the study that may assist in 
patient accrual, data collection, analysis, and interpretation of the study results.  The 
Sponsor is ultimately responsible for all decisions regarding the study. 
The test for the study inclusion criteria of ALK-positive NSCLC will be performed at the 
Sponsor’s designated central laboratories and assessed by the Ventana IHC test. 
An IRC will review the tumor assessments to determine the secondary endpoints of the 
overall disease PFS and time to CNS progression, both on the basis of RECIST v1.1.  In 
addition to the secondary endpoint of time to CNS progression together with C-ORR, 
C-DOR, and CNS progression rate at 6, 12, 18, and 24 months, an IRC will review the 
tumor assessments on the basis of RANO criteria.  

 
Alectinib—F. Hoffmann-La Roche Ltd 
113/Protocol YO29449, Version 3 
 
The independent review of MRI and CT scans will NOT determine either eligibility OR 
patient treatment.  All treatment decisions will be made by the investigator using local 
assessments. 
9.5 
PUBLICATION OF DATA AND PROTECTION OF TRADE 
SECRETS 
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, both at scientific 
congresses and in peer-reviewed journals.  The Sponsor will comply with all 
requirements for publication of study results.  For more information, refer to the Roche 
Global Policy on Sharing of Clinical Trials Data at the following Web site: 
http://www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.
pdf 
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within 6 months after the availability of 
the respective clinical study report.  In addition, for all clinical trials in patients involving 
an IMP for which a marketing authorization application has been filed or approved in any 
country, the Sponsor aims to publish results from analyses of additional endpoints and 
exploratory data that are clinically meaningful and statistically sound. 
The investigator must agree to submit all manuscripts or abstracts to the Sponsor before 
submission for publication or presentation.  This allows the Sponsor to protect 
proprietary information and to provide comments based on information from other 
studies that may not yet be available to the investigator. 
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
center data.  In this case, a coordinating investigator will be designated by mutual 
agreement. 
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by the investigator and the 
appropriate Sponsor personnel. 
Any inventions and resulting patents, improvements, or know-how originating from the 
use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
114/Protocol YO29449, Version 3 
 
9.6 
PROTOCOL AMENDMENTS 
Any protocol amendments will be prepared by the Sponsor.  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements. 
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact information). 

 
Alectinib—F. Hoffmann-La Roche Ltd 
115/Protocol YO29449, Version 3 
 
10. 
REFERENCES 
Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research 
and treatment of cancer QLQ-C30: a quality-of-life instrument for use in 
international clinical trials in oncology. J Natl Cancer Inst 1993;85:365−76. 
American Lung Association. Lung cancer fact sheet [resource on the Internet]. [cited 
2014 Jan 20]. Available from: 
http://www.lung.org/lung-disease/lung-cancer/resources/facts-figures/lung-cancer-f
act-sheet.html#1. 
Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. 
Ther Adv Med Oncol 2011;3:279−91. 
Beal SL, Boeckmann AJ, Sheiner LB. NONMEM Project Group. NONMEM users guides. 
Version 5 ed. San Francisco, CA: University of California at San Francisco, 1999. 
Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular 
supplement to the EORTC core quality-of-life questionnaire (QLQ-C30) for use in 
lung cancer clinical trials. Eur Journal Cancer 1994;30A:635−42. 
Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated 
with erlotinib: quality of life analysis of the National Cancer Institute of Canada 
Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831−7. 
Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase 
immunoreactivity correlates with ALK gene rearrangement and transcriptional 
up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40:1152−8. 
Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular 
filtration rate in patients with ALK-positive non-small cell lung cancer treated with 
the ALK inhibitor crizotinib. Cancer 2014;120:664−74. 
Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with 
ALK-positive non−small-cell lung cancer: updated results from a Phase 1 study. 
Lancet Oncol 2012;13:1011−9. 
Cancer Therapy Evaluation Program, National Cancer Institute. Protocol development 
[resource from the Internet]. [cited 2014 Jan 20]. Available from: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
Cardarella S, Ortiz TM, Joshi VA, et al. The introduction of systematic genomic testing 
for patients with non−small-cell lung cancer. J Thorac Oncol 2012;7:1767−74. 
Chen W, Zhang S, Zheng R, et al. The incidence and mortalities of major cancers in 
China, 2009. Chin J Cancer, 2013;32:106−12. 
China Food and Drug Administration. Approval license number 3402824, 2013. Approval 
license  number 340115, 2014. Ventana Medical Systems. [resource on Internet]. 
Available from http://app1.sfda.gov.cn/datasearch/face3/base.jsp. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
116/Protocol YO29449, Version 3 
 
Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer 
resistance to ALK inhibitors. N Engl J Med 2010;363:1734−9. 
Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on 
crizotinib: an achilles heel of non−small cell lung cancer with EML4-ALK 
translocation? Cancer Biol Ther 2012;13:1376−83. 
Costa DB, Kobayashi S, Pandya SS, et al. CSF Concentration of the anaplastic 
lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443−5. 
Crinò L, Kim D, Rielyet GJ, et al. Initial Phase II results with crizotinib in advanced 
ALK-positive non−small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 
2011:29(suppl;abstr7514). 
Crizotinib Summary of Product Characteristics (SmPC) [resource on Internet]. [cited 
2014 Jan 20]. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/002489/WC500134759.pdf. 
Dai Z, Kelly JC, Meloni-Ehrig A, et al. Incidence and patterns of ALK FISH abnormalities 
seen in a large unselected series of lung carcinomas. Mol Cytogenet. 2012;5:44. 
Division of Clinical Pharmacology, Indiana University. P450 drug interaction table 
[resource on Internet]. [cited 2014 Jan 20]. Available from: 
http://medicine.iupui.edu/clinpharm/ddis/table.aspx. 
Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in 
patients with ALK gene rearranged non−small cell lung cancer. Clin Cancer Res 
2012;18:1472−82. 
European Medicines Agency. Guideline on the evaluation of anticancer products in man. 
2012 Dec 13 [cited 2014 Jan 20]. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/201
3/01/WC500137128.pdf. 
Felip E, Kimm DW, Mehra R, et al. Efficacy and safety of ceritinib in patients with 
advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK +) non−small-cell 
lung cancer (NSCLC): an update of ASCEND-1. Presented at the 2014 European 
Society for Medical Oncology (ESMO) Annual Congress, Madrid, Spain. Abstract 
#1295P. 
Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of 
cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 
2012;4:136ra68. 
Fukui T, Yatabe Y, Kobayashi Y, et al. Clinicoradiologic characteristics of patients with 
lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 
2012;77:319−25. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
117/Protocol YO29449, Version 3 
 
Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival 
results from a Phase III, randomized, open-label, first-line study of gefitinib versus 
carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell 
lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866−74. 
Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors−a review on 
pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470−81. 
Hohenegger M. Drug induced rhabdomyolysis. Curr Opin Pharmacol 2012;12:335−9. 
Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung 
cancer: implications for the evaluation of palliative treatment. The Medical 
Research Council (MRC) Lung Cancer Working Party. Br J Cancer 
1995;71:633−36. 
Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974;65:299−306. 
Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological 
characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13−17. 
Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by 
rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. 
Mod Pathol 2009;22:508−15. 
Inoue A, Nishio M, Kiura K, et al. One year follow-up of a Phase I/II study of a highly 
selective ALK inhibitor CH5424802/RO5424802 in ALK-rearranged advanced 
non−small cell lung cancer (NSCLC). J Thorac Oncol 2013;8(Suppl 2). 
Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib 
resistance in non−small cell lung cancers harboring the fusion oncogene EML4-
ALK. Proc Natl Acad Sci USA 2011;108:7535−40. 
Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non−small cell 
lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in 
situ hybridization with correlation of ALK protein expression. J Thorac Oncol 
2011;6:1359−66. 
Kim DW, Ahn MJ, Shi Y, et al. Results of a global Phase II study with crizotinib in 
advanced ALK-positive non−small cell lung cancer. J Clin Oncol 2012 
30:488s(Suppl; abstr7533). 
Kim S, Kim TM, Kim DW, et al. Heterogeneity of genetic changes associated with 
acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 
2013;8:415−22. 
Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an 
ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275−83. 
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary 
adenocarcinoma. N Engl J Med 2009;361:947−57. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
118/Protocol YO29449, Version 3 
 
Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed–cisplatin or 
pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-
squamous non-small cell lung cancer (NSCLC): results of a phase III study 
(PROFILE 1014). J Clin Oncol 2014 32:5s, (suppl; abstr 8002). 
National Cancer Institute. FDA approval for crizotinib [resource on Internet]. [updated 
2013 Nov 22; cited 2014 Jan 20]. Available from: 
http://www.cancer.gov/cancertopics/druginfo/fda-crizotinib. 
[NCCN] National Comprehensive Cancer Network 2014. Clinical Practice Guidelines in 
Oncology. Non−small Cell Lung Cancer Version 1 2014. NCCN.org. 
Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of 
ALK-rearranged non−small cell lung cancer: a success story to usher in the 
second decade of molecular targeted therapy in oncology. Oncologist 
2012;17:1351−75. 
Ou SH, Gadgeel S, Chiappori AA, et al. Consistent therapuetic efficacy of 
CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-
positive non−small cell lung cancer (NSCLC) patients in an ongoing Phase I/II 
study (AF-002JG/NP28761, NCT01588028). J Thorac Oncol 2013:8(Suppl2). 
Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement 
by immunohistochemistry in non−small cell lung cancer: correlation with 
fluorescence in situ hybridization. Thorac Oncol 2011;6:466−72. 
Pao W, Girard N. New driver mutations in non−small-cell lung cancer. Lancet Oncol 
2011;12:175−80. 
Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) 
and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic 
cells with the monoclonal antibody ALK1. Blood 1997;89:1394−404. 
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor 
mutations in lung cancer. N Engl J Med 2009;361:958−67. 
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as 
first-line treatment for European patients with advanced EGFR mutation-positive 
non−small-cell lung cancer (EURTAC): a multicentre, open-label, randomised 
Phase 3 trial. Lancet Oncol 2012;13:239−46. 
Sahu A, Prabhash K, Noronha V, et al. Crizotinib: a comprehensive review. South Asian 
J Cancer 2013;2:91−7. 
Sarna L, Swann S, Langer C, et al. Clinically meaningful differences in patient-reported 
outcomes with amifostine in combination with chemoradiation for locally advanced 
non−small cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol 
Phys 2008;3:1378−84. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
119/Protocol YO29449, Version 3 
 
Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus 
pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 
J Clin Oncol 2013;31:3327−34. 
Shah RR, Morganroth J, Shah DR, et al. Cardiovascular safety of tyrosine kinase 
inhibitors: with a special focus on cardiac repolarisation (QT Interval). Drug Saf 
2013;36:295−316. 
Shaw A, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced 
ALK-positive lung cancer. N Engl J Med 2013a;368:2385−94. 
Shaw AT, Mehra R, Kim DW, et al. Clinical activity of the ALK inhibitor LDK378 in 
advanced, ALK-positive NSCLC. J Clin Oncol 2013b;ASCO abstract 8010. 
Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. 
CA Cancer J Clin 2012;62:220−41. 
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion 
gene in non−small-cell lung cancer. Nature 2007;448:561−6. 
Solomon B, Mok T, Dong-Wan K, et al. First-line crizotinib versus chemotherapy in 
ALK-positive lung cancer. N Engl J Med 2014;371:2167−77. 
Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-pcr screening for 
eml4-alk fusion transcripts. Clin Cancer Res 2008;14:6618−24. 
Tamura T, Seto T, Nakagawa K, et al. Updated data of a phase I/II study (AF-001JP) of 
alectinib, a CNS penetrant, highly selective ALK inhibitor in ALK-rearranged 
advanced NSCLC. 2014 Multidisplinary Symposium in Thoracic Oncology: abstract 
2014-A-3282-ASTRO-TH. 
U.S. Department of Health and Human Services. Guidance for industry: clinical trial 
endpoints for the approval of cancer drugs and biologics [resource on Internet] 
2007 [cited 2014 Jan 20]. Available from: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm071590.pdf. 
Wong DWS, Leung ELH, So KKT, et al. The EML4-ALK fusion gene is involved in 
various histologic types of lung cancers from nonsmokers with wild-type EGFR and 
KRAS. Cancer 2009;115:1723−33. 
XALKORI U.S. Package Insert, Pfizer Inc. 2012 [cited 2014 Jan 20]. Available from: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s002lbl.pdf. 
ZYKADIA U.S. Package Insert, Novartis Pharmaceuticals [cited 2014 Apr 29] 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf. 

 
Alectinib—F. Hoffmann-La Roche Ltd 
120/Protocol YO29449, Version 3 
 
Appendix 1  
Schedule of Assessments 
Assessment 
Screening 
Treatment Period 
Post-Progression 
Visits during 
Treatment in the 
Case of Isolated, 
Asymptomatic 
Disease 
Progression in 
the CNS (Every 
8 Weeks) until 
Systemic 
Disease 
Progression or 
Symptomatic 
Disease 
Progression in 
the CNS 
End of 
Treatment/
Withdrawal 
Visit d 
Post-
Treatment 
Visit 
(4 Weeks 
after 
Permanent 
Treatment 
Discontinua
tion) 
Subsequent 
Therapy for 
NSCLC; 
Survival 
Follow-Up 
and PRO 
(EORTC 
QLQ-C30/ 
QLQ-LC13) 
Days − 28 to 0 
Days − 3 to 0 
Visit 0 (Baseline) 
Visit 1 (Week 2) a 
Visit 2 (Week 4) 
Visit 3 (Week 6) b 
Visit 4 (Week 8) 
Visit 5 (Week 10) 
and 
Visit 6 (Week 12) c 
All Subsequent Visits (Every 8 Weeks, from 
Week 8 onward) until PD, Death, or 
Withdrawal from the Study before PD 
Informed consent 
x 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
x 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
and baseline 
conditions 
x 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnancy test e 
x e 
x e 
To be repeated as necessary 
 
 
 
 
Physical 
examination f 
x 
 
x 
 
x 
 
x 
 
x 
x 
x 
 
 
Vital signs 
x 
 
x 
 
x 
 
x 
 
x 
x 
x 
 
 
ECOG PS 
x 
 
x 
 
x 
 
x 
 
x 
x 
x 
 
 
ECG g 
x 
 
x h 
 
x 
 
 
 
x 
 
x 
 
 

 
 
Appendix 1  
Schedule of Assessments (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
121/Protocol YO29449, Version 3 
 
Assessment 
Screening 
Treatment Period 
Post-Progression 
Visits during 
Treatment in the 
Case of Isolated, 
Asymptomatic 
Disease 
Progression in 
the CNS (Every 
8 Weeks) until 
Systemic 
Disease 
Progression or 
Symptomatic 
Disease 
Progression in 
the CNS 
End of 
Treatment/
Withdrawal 
Visit d 
Post-
Treatment 
Visit 
(4 Weeks 
after 
Permanent 
Treatment 
Discontinua
tion) 
Subsequent 
Therapy for 
NSCLC; 
Survival 
Follow-Up 
and PRO 
(EORTC 
QLQ-C30/ 
QLQ-LC13) 
Days − 28 to 0 
Days − 3 to 0 
Visit 0 (Baseline) 
Visit 1 (Week 2) a 
Visit 2 (Week 4) 
Visit 3 (Week 6) b 
Visit 4 (Week 8) 
Visit 5 (Week 10) 
and 
Visit 6 (Week 12) c 
All Subsequent Visits (Every 8 Weeks, from 
Week 8 onward) until PD, Death, or 
Withdrawal from the Study before PD 
Hematology, 
coagulation 
x 
 
x h 
 
x 
 
x 
 
x 
x 
x 
 
 
Biochemistry 
x 
 
x h 
x a 
x 
x b 
x 
x c 
x 
x 
x 
 
 
Urinalysis 
x 
 
x h 
 
x 
 
x 
 
x 
x 
x 
 
 
Concomitant 
medications 
x 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
 
Mandatory tumor 
sample for ALK 
testing i 
x 
 
 
 
 
 
 
 
 
 
 
 
 
Tumor sample 
for sequencing 
(NGS) 
 
 
x j 
 
 
 
 
 
 
x k 
x k 
 
 

 
 
Appendix 1  
Schedule of Assessments (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
122/Protocol YO29449, Version 3 
 
Assessment 
Screening 
Treatment Period 
Post-Progression 
Visits during 
Treatment in the 
Case of Isolated, 
Asymptomatic 
Disease 
Progression in 
the CNS (Every 
8 Weeks) until 
Systemic 
Disease 
Progression or 
Symptomatic 
Disease 
Progression in 
the CNS 
End of 
Treatment/
Withdrawal 
Visit d 
Post-
Treatment 
Visit 
(4 Weeks 
after 
Permanent 
Treatment 
Discontinua
tion) 
Subsequent 
Therapy for 
NSCLC; 
Survival 
Follow-Up 
and PRO 
(EORTC 
QLQ-C30/ 
QLQ-LC13) 
Days − 28 to 0 
Days − 3 to 0 
Visit 0 (Baseline) 
Visit 1 (Week 2) a 
Visit 2 (Week 4) 
Visit 3 (Week 6) b 
Visit 4 (Week 8) 
Visit 5 (Week 10) 
and 
Visit 6 (Week 12) c 
All Subsequent Visits (Every 8 Weeks, from 
Week 8 onward) until PD, Death, or 
Withdrawal from the Study before PD 
Plasma for 
detection of ALK 
rearrangements 
(20 mL, for all 
screened 
patients) 
x 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma for 
detection of ALK 
mutation status 
(20 mL of blood) 
 
 
x 
 
 
 
 
 
x l 
 
x l 
 
 
Tumor 
assessment m 
x n 
 
x n 
 
 
 
x 
 
x o 
x 
 
x p 
 

 
 
Appendix 1  
Schedule of Assessments (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
123/Protocol YO29449, Version 3 
 
Assessment 
Screening 
Treatment Period 
Post-Progression 
Visits during 
Treatment in the 
Case of Isolated, 
Asymptomatic 
Disease 
Progression in 
the CNS (Every 
8 Weeks) until 
Systemic 
Disease 
Progression or 
Symptomatic 
Disease 
Progression in 
the CNS 
End of 
Treatment/
Withdrawal 
Visit d 
Post-
Treatment 
Visit 
(4 Weeks 
after 
Permanent 
Treatment 
Discontinua
tion) 
Subsequent 
Therapy for 
NSCLC; 
Survival 
Follow-Up 
and PRO 
(EORTC 
QLQ-C30/ 
QLQ-LC13) 
Days − 28 to 0 
Days − 3 to 0 
Visit 0 (Baseline) 
Visit 1 (Week 2) a 
Visit 2 (Week 4) 
Visit 3 (Week 6) b 
Visit 4 (Week 8) 
Visit 5 (Week 10) 
and 
Visit 6 (Week 12) c 
All Subsequent Visits (Every 8 Weeks, from 
Week 8 onward) until PD, Death, or 
Withdrawal from the Study before PD 
MRI scan of the 
brain 
x n 
 
x n 
 
 
 
x 
 
x o 
x 
 
x p 
 
PK samples for 
alectinib (2 mL 
blood) q 
 
 
x 
 
x 
 
x 
 
x 
 
 
 
 
PRO 
(EORTC QLQ-C
30/QLQ-LC13) r 
 
 
x 
 
x 
 
x 
 
x 
x 
 
x 
x s 
Adverse events t 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Subsequent 
therapy for 
NSCLC 
 
 
 
 
 
 
 
 
 
x 
 
x 
x s 

 
 
Appendix 1  
Schedule of Assessments (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
124/Protocol YO29449, Version 3 
 
Assessment 
Screening 
Treatment Period 
Post-Progression 
Visits during 
Treatment in the 
Case of Isolated, 
Asymptomatic 
Disease 
Progression in 
the CNS (Every 
8 Weeks) until 
Systemic 
Disease 
Progression or 
Symptomatic 
Disease 
Progression in 
the CNS 
End of 
Treatment/
Withdrawal 
Visit d 
Post-
Treatment 
Visit 
(4 Weeks 
after 
Permanent 
Treatment 
Discontinua
tion) 
Subsequent 
Therapy for 
NSCLC; 
Survival 
Follow-Up 
and PRO 
(EORTC 
QLQ-C30/ 
QLQ-LC13) 
Days − 28 to 0 
Days − 3 to 0 
Visit 0 (Baseline) 
Visit 1 (Week 2) a 
Visit 2 (Week 4) 
Visit 3 (Week 6) b 
Visit 4 (Week 8) 
Visit 5 (Week 10) 
and 
Visit 6 (Week 12) c 
All Subsequent Visits (Every 8 Weeks, from 
Week 8 onward) until PD, Death, or 
Withdrawal from the Study before PD 
Drug dispensing 
and 
accountability u 
 
 
x 
 
x 
 
x 
 
x 
x 
 
x 
(accountabi
lity only) 
 
ALK = anaplastic lymphoma kinase; ALP = alkaline phosphatase; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECOG 
PS = Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30 = European Organization for the Research and Treatment of Cancer Quality-of-
Life Questionnaire−Core; EORTC QLQ-LC15 = European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire−Lung Cancer 
module; MRI = magnetic resonance imaging; NCI = National Cancer Institute; NGS = Next Generation Sequencing; NSCLC = non−small cell lung cancer; 
PD = progressive disease; PK = pharmacokinetic; PRO = patient-reported outcome; ULN = upper limit of normal. 
Notes:  First dose of study drug to be taken as soon as patient has been randomized and appropriate drug has been provided−within ≤ 24 hours.  Assessments 
performed after baseline are to be completed within ± 1 week for the first two 4 weekly and subsequent 8 weekly assessments. 

 
 
Appendix 1  
Schedule of Assessments (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
125/Protocol YO29449, Version 3 
 
a The visit on Week 2 is only required for the specific monitoring of liver function tests, including ALT, AST, total bilirubin, direct bilirubin, ALP, and 
CPK for patients in the alectinib treatment arm, and for the specific monitoring of ALT, AST, ALP, total bilirubin, and direct bilirubin for patients in 
the crizotinib treatment arm.  No other assessments are needed on this visit with the exception of any new records for adverse events and 
concomitant medications. 
b The visit on Week 6 is only required for the specific monitoring of liver function tests, including ALT, AST, total bilirubin, and direct bilirubin, ALP 
for patients in both the alectinib and crizotinib treatment arm.  No other assessments are needed on this visit with the exception of any new 
records for adverse events and concomitant medications. 
c The visits on Week 10 and Week 12 are only required for the specific monitoring of liver function tests, including ALT, AST, ALP, total bilirubin, 
and direct bilirubin for patients in the alectinib treatment arm only.  No other assessments are needed on this visit with the exception of any new 
records for adverse events and concomitant medications. 
d End of Treatment/Withdrawal:  The visit that the investigators or patients decide to stop/withdraw study treatment permanently for progression, 
AE, or any other reason.  Obtain these assessments, if not completed during the previous 4 weeks on study. 
e All women who are not postmenopausal (≥ 12 months of non−therapy induced amenorrhea) or surgically sterile will have a serum pregnancy test 
performed at screening (i.e., within 3 days prior to receiving first dose of study drug).  Urine pregnancy tests will be performed anytime during the 
course of the study, per the investigator’s discretion.  If a urine pregnancy test result is positive, it must be confirmed by a serum pregnancy test. 
f Includes an ophthalmologic examination if clinically indicated. 
g ECG should be performed in 12-lead in triplicate and obtained within approximately 2−5 minutes at each specified timepoint, and each 
measurement should be separated ≤ 2 minutes.  ECGs should be performed at screening, Visit 0 (baseline), Visit 2 (Week 4), Visit 8 (Week 24), 
Visit 12 (Week 56), end of treatment/withdrawal visit, and as clinically indicated throughout the study. 
h Screening laboratory assessment done within 3 days may be counted as the baseline assessment. 
i Preferably blocks fixed in neutral buffered formalin; if blocks are not available, a minimum of 7 unstained 5-µm slides cut less than 3 months 
before screening are required.  Tumor ALK status will be assessed by central laboratory before randomization. 
j Tumor sample could be taken from the tumor block obtained at screening and will be used for NGS.  If blocks are not available, 6 unstained 
5-µm slides are desired. 
k Only one optional tumor sample to be collected at the time of disease progression from progressive lesions.  Preferably blocks fixed in neutral 
buffered formalin; if blocks are not available, a minimum of 9 unstained 5-µm slides are required. 
l Blood samples (20 mL) will be collected to obtain plasma used to test for exploratory biomarkers.  Blood samples will be collected at Visit 0 
(baseline), at every 16 weeks during the study, until and at disease progression (CNS or systemic disease) or treatment discontinuation for 
any reasons. 

 
 
Appendix 1  
Schedule of Assessments (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
126/Protocol YO29449, Version 3 
 
m Tumor assessment consists at minimum of a CT and/or MRI scan of chest and abdomen (for imaging of liver and adrenal glands).  Patients who 
are known to have bone metastasis or who display clinical or laboratory signs (e.g., serum ALP > 1.5 × ULN) of bone metastasis should undergo 
radionuclide bone scan.  Skin metastases should be clinically assessed with caliper measurement and documented by color photography, 
including a ruler to estimate the size of the lesion.  Assessments performed after baseline must be completed within ± 1 week for the 8 weekly 
assessments.  If there is a suspicion of disease progression on the basis of clinical or laboratory findings, a tumor assessment should be 
performed as soon as possible and before the next scheduled evaluation. 
n Screening tumor assessment performed within 14 days will be considered the baseline assessment. 
o Tumor assessment may be performed whenever clinically indicated.  Brain assessment scans should be performed at every systemic imaging tumor assessment.  
Tumor assessment should continue until disease progression if a patient discontinues treatment before PD, regardless of whether they subsequently receive 
non-study anti-cancer therapy (a use of subsequent non-study, anti-cancer therapy before disease progression would be considered a protocol violation). 
p If treatment was permanently discontinued because of disease progression. 
q Predose PK (2 mL) sampling for all patients on alectinib treatment will be performed at each visit during the treatment period and at the final study visit.  The 
predose PK samples should be taken immediately before (within 2 hours) intake of study medication at all study visits.  Remind the patient not to take a daily 
dose at home on the day of scheduled study visit.  Frequent blood sampling will be performed in a subset of 20 Chinese patients consenting to frequent sampling 
to ensure that at least 16 patients will have evaluable PK profiles at Visit 0 (baseline) and Visit 2 (Week 4) at predose (within 2 hours before intake of study 
medication), and at 1, 2, 4, 6, 8, 10, and 12 hours postdose.  Sparse PK sampling will be collected from all patients enrolled onto alectinib treatment. See 
Appendix 2  for further detail on alectinib PK sampling times. 
r PRO questionnaires are to be completed every 4 weeks until disease progression and during disease progression during study treatment for the case of isolated, 
asymptomatic disease progression in the CNS; at the Post-Treatment Visit (4 weeks after treatment discontinuation); and at every follow-up visit (every 8 weeks) 
after Post-Treatment Visit for 6 months.  Further guidelines for the administration of the PRO questionnaires will be provided in the study manual. 
s Performed every 8 weeks after Post-Treatment Visit during the first 6 months and then every 12 weeks or performed as appropriate.  The PRO assessments 
should be performed during the first 6 months. 
t Graded according to the NCI CTCAE (v4.0).  Serious adverse event collection must start from the time of the first study-specific procedure. 
u For details on drug dispensing and accountability, see Section 4.3.3. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
127/Protocol YO29449, Version 3 
 
Appendix 2  
Schedule of Alectinib Pharmacokinetic Assessments 
Visit 
Timepoint 
Visit 0 (baseline) 
Predose (within 2 hours before morning dose) 
Visit 2 (Week 4) 
Predose (within 2 hours before morning dose) 
Visit 4 (Week 8) 
Predose (within 2 hours before intake of 
alectinib) 
Every 8 weeks until PD or death or 
withdrawal from the study before PD 
Visit 0 (baseline) and Visit 2 (Week 4) a 
Predose (within 2 hours before intake of 
alectinib) 
 
Predose (within 2 hours before morning dose), 
1, 2, 4, 6, 8, 10, and 12 b hours postdose 
PD = progressive disease; PK = Pharmacokinetic. 
Notes:  Blood samples (approximately 2 mL of venous blood) collected from all patients.   
a Only for the subset of 20 patients who participate in the frequent blood sample 
collections. 
b The 12 hour PK samples should be taken before the evening dose; a sample 
collection time window of ± 1 hour is only considered for the 12-hour PK sample. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
128/Protocol YO29449, Version 3 
 
Appendix 3  
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing 
Enzymes and Transporters 
This representative list is not intended to be an exhaustive list.  Each patient’s 
concomitant medications should be carefully considered by the investigator with regard 
to the benefit-risk for the particular patient and appropriate monitoring, including any 
concomitant medication, dose adjustment, or therapeutic alternatives, which should be 
determined by the investigator caring for the patient. 
CYP3A Inducers 
CYP3A Potent Inhibitors 
avasimibe, aminoglutethimide, barbiturates, 
carbamazepine, dexamethasone, efavirenz, 
ethosuximide, garlic supplements, 
glucocorticoids, glutethimide, griseofulvin, 
modafinil, nafcillin, nevirapine, oxcarbazepine, 
phenobarbital, phenytoin, pioglitazone, 
primidone, rifabutin, rifampin, rifapentine, 
St John’s wort, troglitazone 
aprepitant, atazanavir, boceprevir, 
ciprofloxacin, clarithromycin, conivaptan, 
diltiazem, erythromycin, fluconazole, 
grapefruit, grapefruit juice, indinavir, 
itraconazole, ketoconazole, lopinavir, 
mibefradil, nefazodone, nelfinavir, 
posaconazole, ritonavir, saquinavir, 
telaprevir, telithromycin, troleandomycin, 
verapamil, voriconazole 
P-gp 
Substrates 
Inducers 
aliskiren, ambrisentan, colchicine, dabigatran, 
digoxin, everolimus, fexofenadine, imatinib, 
lapatinib, maraviroc, nilotinib, posaconazole, 
pravastatin, ranolazine, saxagliptin, sirolimus, 
sitagliptin, talinolol, tolvaptan, topotecan 
avasimibe, carbmazepine, phenytoin, 
rifampin, St John’s wort, tipranavir 
Dual UGT1A1/CYP3A 
Substrates 
Inhibitors 
Inducers 
buprenorphine, raltegravir 
atazanavir 
rifampin 
 
This information in this appendix is adapted from Levien and Baker 20031, Zhang 20102, 
and FDA Guidance on Drug-Drug Interactions. 
Also see:  http://medicine.iupui.edu/clinpharm/ddis/table.aspx. 
                                            
1 Levien TL and Baker DE Cytochrome P450 Drug Interactions. Therapeutic Research Center 
Pharmacist’s Letter/Prescriber’s Letter [resource on the Internet]. 2003. Available from: 
www.pharmacistsletter.com and www.prescribersletter.com. 
2 Zhang L. Transporter Mediated Drug-Drug Interactions. FDA. Clinical Pharmacology Advisory 
Committee Meeting Topic 4: Transporter-Mediated Drug-Drug Interactions Atlanta, GA, 
17 March 2010. 

 
 
Appendix 3  
List of Substrates, Inhibitors, and Inducers of Drug-Metabolizing 
Enzymes and Transporters (cont.)  
Alectinib—F. Hoffmann-La Roche Ltd 
129/Protocol YO29449, Version 3 
 
 
Potent inhibitors of CYP3A are those considered to be “strong CYP3A inhibitors” 
previously shown to result in a ≥ 5−fold increase in the area under the 
concentration−time curve of a concomitantly administered CYP3A substrate.  These are 
based on the available published literature and, thus, are not considered exhaustive or 
inclusive.  See FDA Guidance on Drug-Drug Interactions for further detail. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
130/Protocol YO29449, Version 3 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication 
Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST), 
Version 1.1,1 are presented below, with slight modifications and the addition of 
explanatory text as needed for clarity.2 
MEASURABILITY OF TUMOR AT BASELINE 
DEFINITIONS 
At baseline, tumor lesions/lymph nodes will be categorized as measurable or 
non-measurable as described below. 
Measurable tumor lesions 
Tumor lesions 
Tumor lesions must be accurately measured in at least one dimension (longest diameter 
in the plane of measurement is to be recorded) with a minimum size as follows: 
• 
10 mm by computed tomography (CT) or magnetic resonance imaging (MRI) scan 
(CT and/or MRI scan slice thickness/interval no greater than 5 mm) 
• 
10-mm caliper measurement by clinical examination (lesions that cannot be 
accurately measured with calipers should be recorded as non-measurable) 
• 
20 mm by chest X-ray 
 
Malignant lymph nodes 
To be considered pathologically enlarged and measurable, a lymph node must 
be ≥ 15 mm in the short axis when assessed by CT scan (CT scan slice thickness is 
recommended to be no greater than 5 mm).  At baseline and follow-up, only the short 
axis will be measured and followed.  See also the notes below on “Baseline 
Documentation of Target and Non-Target Lesions” for information on lymph node 
measurement. 
Non-measurable tumor lesions 
Non-measurable tumor lesions encompass small lesions (longest diameter < 10 mm or 
pathological lymph nodes with ≥ 10 to < 15 mm short axis) as well as truly 
non-measurable lesions.  Lesions considered truly non-measurable include 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
                                            
1 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors:  revised 
RECIST guideline (Version 1.1). Eur J Cancer 2009;45:228–47. 
2 
For consistency within this document, the section numbers and cross-references to other 
sections within the article have been deleted and minor formatting changes have been made. 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
131/Protocol YO29449, Version 3 
 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
mass/abdominal organomegaly identified by physical examination that is not measurable 
by reproducible imaging techniques. 
Special considerations regarding lesion measurability 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below. 
Bone lesions 
Bone scan, positron emission tomography (PET) scan, or plain films are not considered 
to be adequate imaging techniques for measuring bone lesions.  However, these 
techniques may be used to confirm the presence or disappearance of bone lesions. 
Lytic bone lesions or mixed lytic−blastic lesions, with identifiable soft tissue components, 
that may be evaluated by cross-sectional imaging techniques, such as CT or MRI, may 
be considered measurable lesions if the soft tissue component meets the definition of 
measurability described above. 
Blastic bone lesions are non-measurable. 
Cystic lesions 
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) because they 
are, by definition, simple cysts. 
Cystic lesions thought to represent cystic metastases may be considered measurable 
lesions if they meet the definition of measurability described above.  However, if 
non-cystic lesions are present in the same patient, these are preferred for selection as 
target lesions. 
Lesions with prior local treatment 
Tumor lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  Study protocols should detail the conditions 
under which such lesions would be considered measurable. 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
132/Protocol YO29449, Version 3 
 
TARGET LESIONS: SPECIFICATIONS BY METHODS OF MEASUREMENTS 
Measurement of lesions 
All measurements should be recorded in metric notation, with use of calipers if clinically 
assessed.  All baseline evaluations should be performed as close as possible to the 
treatment start date and never more than 4 weeks before the beginning of the treatment. 
Method of assessment 
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during the study.  
Imaging-based evaluation should always be the preferred option. 
Clinical lesions 
Clinical lesions will only be considered measurable when they are superficial and 
≥ 10 mm in diameter as assessed with the use of calipers (e.g., skin nodules).  
Documentation of skin lesions by color photography, including a ruler to estimate the 
size of the lesion, is suggested. 
Chest X-ray 
Chest CT is preferred over chest X-ray, particularly when progression is an important 
endpoint, because CT is more sensitive than X-ray, particularly in identifying new 
lesions.  However, lesions on chest X-ray may be considered measurable if they are 
clearly defined and surrounded by aerated lung. 
Computed tomography scan and magnetic resonance imaging 
CT is the best currently available and reproducible method to measure lesions selected 
for response assessment.  This guideline has defined the measurability of lesions on CT 
scan on the basis of the assumption that CT slice thickness is ≤ 5 mm.  When CT scans 
have a slice thickness > 5 mm, the minimum size for a measurable lesion should be 
twice the slice thickness.  MRI is also acceptable. 
If, before enrollment, it is known that a patient is unable to undergo CT scans with 
intravenous (IV) contrast because of allergy or renal insufficiency, the decision whether a 
non-contrast CT or MRI (without IV contrast) will be used to evaluate the patient at 
baseline and during the study should be guided by the tumor type that is under 
investigation and the anatomic location of the disease.  For patients who develop 
contraindications to contrast after baseline contrast CT is performed, the decision 
whether non-contrast CT or MRI (enhanced or non-enhanced) will be performed should 
also be based on the tumor type and the anatomic location of the disease and should be 
optimized to allow for comparison with the previous studies if possible.  Each case 
should be discussed with the radiologist to determine if the substitution of these other 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
133/Protocol YO29449, Version 3 
 
approaches is possible and, if not, the patient should be considered not evaluable from 
that point forward.  Care must be taken in the measurement and interpretation of target 
lesions of non-target disease or new lesions on a different modality because the same 
lesion may appear to have a different size with use of a new modality. 
Ultrasound 
Ultrasound is not useful in the assessment of lesion size and should not be used as a 
method of measurement. 
Endoscopy, laparoscopy, tumor markers, cytology, and histology 
The utilization of these techniques for objective tumor evaluation cannot generally be 
advised. 
TUMOR RESPONSE EVALUATION 
ASSESSMENT OF OVERALL TUMOR BURDEN AND MEASURABLE 
DISEASE 
To assess objective response or future progression, it is necessary to estimate the 
overall tumor burden at baseline and use this as a comparator for subsequent 
measurements.  Measurable disease is defined by the presence of at least one 
measurable lesion, as detailed above. 
BASELINE DOCUMENTATION OF TARGET AND NON-TARGET LESIONS 
When more than one measurable lesion is present at baseline, all lesions, up to a 
maximum of five lesions total and a maximum of two lesions per organ, representative of 
all involved organs should be identified as target lesions and will be recorded and 
measured at baseline.  This means that, for instances in which patients have only one or 
two organ sites involved, a maximum of two lesions (one site) and four lesions 
(two sites), respectively, will be recorded.  Other lesions (even measurable lesions) in 
those organs will be recorded as non-measurable lesions (even if the size is > 10 mm by 
CT scan). 
Target lesions should be selected on the basis of their size (lesions with the longest 
diameter) and be representative of all involved organs, and the lesions should also be 
available for repeated measurements.  If measurement of the largest lesion is not 
reproducible, the next largest lesion that may be measured reproducibly should be 
selected. 
Lymph nodes merit special mention because they are normal anatomical structures that 
may be visible by imaging even if they are not involved by tumor.  As noted above, 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
134/Protocol YO29449, Version 3 
 
pathological nodes that are defined as measurable and may be identified as target 
lesions must meet the criterion of a short axis of ≥ 15 mm by CT scan.  Only the short 
axis of these nodes will contribute to the baseline sum.  The short axis of the node is the 
diameter normally used by radiologists to judge whether a node is involved by solid 
tumor.  Nodal size is normally reported as two dimensions in the plane in which the 
image is obtained (for CT this is almost always the axial plane; for MRI the plane of 
acquisition may be axial, sagittal, or coronal).  The smaller of these measures is the 
short axis.  For example, an abdominal node that is reported as being 20 mm × 30 mm 
has a short axis of 20 mm and qualifies as a malignant, measurable node.  In this 
example, 20 mm should be recorded as the node measurement.  All other pathological 
nodes (those with short axis ≥ 10 mm but < 15 mm) should be considered non-target 
lesions.  Nodes that have a short axis of < 10 mm are considered non-pathological and 
should not be recorded or followed. 
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum of diameters.  If lymph 
nodes are to be included in the sum, then, as noted above, only the short axis is added 
into the sum.  The baseline sum of diameters will be used as a reference to further 
characterize any objective tumor regression in the measurable dimension of the disease. 
All other lesions or sites of disease, including pathological lymph nodes, should be 
identified as non-target lesions and should also be recorded at baseline.  Measurements 
are not required, and these lesions should be followed as “present,” “absent,” or in rare 
cases “unequivocal progression.” 
In addition, it is possible to record multiple non-target lesions that involve the same 
organ as a single item on the electronic Case Report Form (eCRF) (e.g., “multiple 
enlarged pelvic lymph nodes” or “multiple liver metastases”). 
RESPONSE CRITERIA 
Evaluation of target lesions 
This section provides the definitions of the criteria used to determine objective tumor 
response for target lesions. 
• 
Complete response (CR):  Disappearance of all target lesions 
Any pathological lymph nodes (whether target or non-target) must have 
reduction in the short axis to < 10 mm. 
• 
Partial response (PR):  At least a 30% decrease in the sum of the diameters of the 
target lesions, using the baseline sum of diameters as a reference 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
135/Protocol YO29449, Version 3 
 
• 
Progressive disease (PD):  At least a 20% increase in the sum of the diameters of 
the target lesions using the smallest sum of the diameters during the study (nadir) 
as a reference, including baseline 
In addition to the relative increase of 20%, the sum of the diameters must also 
demonstrate an absolute increase of at least 5 mm. 
The appearance of one or more new lesions is also considered progression. 
• 
Stable disease (SD):  Neither sufficient decrease to qualify for PR nor sufficient 
increase to qualify for PD, using the smallest sum of the diameters during the study 
as a reference. 
 
Special notes on the assessment of target lesions 
Lymph nodes 
Lymph nodes that are identified as target lesions should always have the actual short 
axis measurement recorded (measured in the same anatomical plane as the baseline 
examination), even if the nodes regress to < 10 mm during the study.  This means that 
when lymph nodes are included as target lesions, the sum of the lesions may not be 
zero even if CR criteria are met, because a normal lymph node is defined as having a 
short axis of < 10 mm. 
Target lesions that become too small to measure 
During the study, all lesions (nodal and non-nodal) that are recorded at baseline should 
have their actual measurements recorded at each subsequent evaluation, even when 
they are very small (e.g., 2 mm).  However, sometimes lesions or lymph nodes that are 
recorded as target lesions at baseline become so faint on the CT scan that the 
radiologist may not feel comfortable assigning an exact measure and may report them 
as being too small to measure.  When this occurs, it is important that a value be 
recorded on the eCRF, as follows: 
• 
If it is the opinion of the radiologist that the lesion has likely disappeared, the 
measurement should be recorded as 0 mm. 
• 
If the lesion is believed to be present and is faintly seen but is too small to measure, 
a default value of 5 mm should be assigned, and the BML (below measurable limit) 
checkbox should not be checked.  (Note: It is less likely that this rule will be used for 
lymph nodes because they usually have a definable size when they are normal and 
are frequently surrounded by fat such as in the retroperitoneum; however, if a lymph 
node is believed to be present and is faintly seen but is too small to measure, a 
default value of 5 mm should be assigned in this circumstance as well, and BML 
should also be ticked). 
 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
136/Protocol YO29449, Version 3 
 
To reiterate:  if the radiologist is able to provide an actual measure, this 
measurement should be recorded even if it is below 5 mm, and, in that case, the BML 
checkbox should not be checked. 
Lesions that split or coalesce during treatment 
When non-nodal lesions fragment, the longest diameters of the fragmented portions 
should be added together to calculate the target lesion sum.  Similarly, as lesions 
coalesce, a plane between them may be maintained that would aid in obtaining maximal 
diameter measurements of each individual lesion.  If the lesions have truly coalesced 
such that they are no longer separable, the vector of the longest diameter in this 
instance should be the maximum longest diameter for the coalesced lesion. 
Evaluation of Non-Target Lesions 
This section provides the definitions of the criteria used to determine the tumor response 
for the group of non-target lesions.  Whereas some non-target lesions may actually be 
measurable, they need not be measured and instead should be assessed only 
qualitatively at the timepoints specified in the protocol. 
• 
CR:  Disappearance of all non-target lesions 
All lymph nodes must be non-pathological in size (< 10 mm short axis). 
• 
Non-CR/Non-PD:  Persistence of one or more non-target lesions  
• 
PD:  Unequivocal progression of existing non-target lesions 
The appearance of one or more new lesions is also considered progression. 
 
Special Notes on Assessment of Progression of Non-Target Disease 
When the patient also has measurable disease 
In this setting, to achieve unequivocal progression on the basis of the non-target 
disease, there must be an overall level of substantial worsening of non-target disease of 
a magnitude that, even in the presence of SD or PR in target disease, the overall tumor 
burden has increased sufficiently to merit discontinuation of therapy.  A modest increase 
in the size of one or more non-target lesions is usually not sufficient to qualify for 
unequivocal progression status.  The designation of overall progression solely on the 
basis of change in non-target disease in the face of SD or PR of target disease will 
therefore be extremely rare. 
When the patient has only non-measurable disease 
The circumstance arises in some Phase III studies in which it is not a criterion of study 
entry to have measurable disease.  The same general concepts apply here as noted 
above; however, in this instance, there is no measurable disease assessment to factor 
into the interpretation of an increase in non-measurable disease burden.  Because 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
137/Protocol YO29449, Version 3 
 
worsening in non-target disease cannot be easily quantified (by definition: if all lesions 
are truly non-measurable), a useful test that may be applied when assessing patients for 
unequivocal progression is to consider whether the increase in overall disease burden, 
on the basis of the change in non-measurable disease, is comparable in magnitude to 
the increase that would be required to declare PD for measurable disease.  That is, an 
increase in tumor burden represents an additional 73% increase in volume (which is 
equivalent to a 20% increase in diameter in a measurable lesion).  Examples include an 
increase in a pleural effusion from “trace” to “large” or an increase in lymphangitic 
disease from localized to widespread.  Examples may be described in protocols as  
“sufficient to require a change in therapy.”  If unequivocal progression is observed, the 
patient should be considered to have had overall PD at that point.  Though it would be 
ideal to have objective criteria to apply to non-measurable disease, the very nature of 
that disease makes it impossible to do so; therefore, the increase must be substantial. 
New lesions 
The appearance of new malignant lesions denotes disease progression; therefore, 
comments on detection of new lesions are important.  There are no specific criteria for 
the identification of new radiographic lesions; however, the finding of a new lesion 
should be unequivocal, that is, not attributable to differences in scanning technique, 
change in imaging modality, or findings thought to represent something other than tumor 
(e.g., some “new” bone lesions may be simply healing or flare of preexisting lesions).  
This is particularly important when the patient’s baseline lesions show PR or CR 
(e.g., necrosis of a liver lesion may be reported on a CT scan report as a “new” cystic 
lesion, which it is not). 
A lesion that is identified during the study in an anatomical location that was not scanned 
at baseline is considered a new lesion and will indicate disease progression. 
If a new lesion is equivocal (e.g., because of the small size) continued therapy and 
follow-up evaluation will clarify whether it represents truly new disease.  If repeat scans 
confirm that there is definitely a new lesion, then progression should be declared with 
use of the date of the initial scan. 
EVALUATION OF RESPONSE 
Timepoint response (overall response) 
It is assumed that at each protocol-specified timepoint, a response assessment occurs.  
Table 1 provides a summary of the overall response status calculation at each timepoint 
for patients who have measurable disease at baseline. 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
138/Protocol YO29449, Version 3 
 
When patients have non-measurable (therefore non-target) disease only, Table 2 is to 
be used. 
Table 1 
Timepoint Response:  Patients with Target Lesions (with or 
without Non-Target Lesions) 
Target Lesions 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not all evaluated 
No 
PR 
SD 
Non-PD or not all evaluated 
No 
SD 
Not all evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or no 
PD 
Any 
PD 
Yes or no 
PD 
Any 
Any 
Yes 
PD 
CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; 
SD = stable disease. 
 
Table 2 
Timepoint Response:  Patients with Non-Target Lesions Only 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
No 
CR 
Non-CR/non-PD 
No 
Non-CR/non-PD a 
Not all evaluated 
No 
NE 
Unequivocal PD 
Yes or no 
PD 
Any 
Yes 
PD 
CR = complete response; NE = not evaluable; PD = progressive disease. 
a “Non-CR/non-PD” is preferred over “stable disease” for non-target disease because stable 
disease is increasingly used as an endpoint for an assessment of efficacy in some studies; 
thus, assigning “stable disease” when no lesions may be measured is not advised. 
 
Missing assessments and not-evaluable designation 
When no imaging or measurement is performed at a particular timepoint, the patient is 
not evaluable at that timepoint.  If only a subset of lesion measurements is made at an 
assessment, the case is also usually considered not evaluable at that timepoint unless a 
convincing argument may be made that the contribution of the individual missing 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
139/Protocol YO29449, Version 3 
 
lesion(s) would not change the assigned timepoint response.  This would be most likely 
to happen in the case of PD (e.g., if a patient had a baseline sum of 50 mm with three 
measured lesions, and during the study, only two lesions were assessed but those gave 
a sum of 80 mm, the patient will have achieved PD status, regardless of the contribution 
of the missing lesion).  
If one or more target lesions was not assessed either because the scan was not 
performed or because the scan could not be assessed as a result of poor image quality 
or obstructed view, the response for target lesions should be “unable to assess” because 
the patient is not evaluable.  Similarly, if one or more non-target lesion is not assessed, 
the response for non-target lesions should be “unable to assess,” except for where there 
is clear progression.  Overall response would be “unable to assess” if either the target 
response or the non-target response is “unable to assess,” except for where there is 
clear evidence of progression, as this equates with the case being not evaluable at that 
timepoint. 

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
140/Protocol YO29449, Version 3 
 
Table 3 
Best Overall Response When Confirmation Is Required 
Overall 
Response at 
First Timepoint 
Overall Response 
at Subsequent 
Timepoint 
Best Overall Response 
CR 
CR 
CR 
CR 
PR 
SD, PD, or PR a 
CR 
SD 
SD, provided minimum duration for SD was met; otherwise, PD 
CR 
PD 
SD, provided minimum duration for SD was met; otherwise, PD 
CR 
NE 
SD, provided minimum duration for SD was met; otherwise, NE 
PR 
CR 
PR 
PR 
PR 
PR 
PR 
SD 
SD 
PR 
PD 
SD, provided minimum duration for SD was met; otherwise, PD 
PR 
NE 
SD, provided minimum duration for SD was met; otherwise, NE 
NE 
NE 
NE 
CR = complete response; NE = not evaluable; PD = progressive disease; PR = partial response; 
SD = stable disease. 
a If a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, even 
disease meeting PR criteria relative to baseline, qualifies as PD at that point (because disease 
must have reappeared after CR).  Best response would depend on whether the minimum 
duration for SD was met.  However, sometimes CR may be reported when subsequent scans 
suggest small lesions were likely still present and in fact the patient had PR, not CR, at the first 
timepoint.  Under these circumstances, the original CR should be changed to PR and the best 
response is PR. 
 
Special notes on response assessment 
When nodal disease is included in the sum of target lesions and the nodes decrease to 
“normal” size (< 10 mm), they may still have a measurement reported on scans.  This 
measurement should be recorded even though the nodes are normal to avoid 
overstating progression, should it be based on increase in size of the nodes.  As noted 
earlier, this means that patients with CR may not have a total sum of “zero” on the 
eCRF. 
Patients with a global deterioration of health status who require discontinuation of 
treatment without objective evidence of disease progression at that time should be 
reported as “symptomatic deterioration.”  Every effort should be made to document 
objective progression even after discontinuation of treatment.  Symptomatic deterioration 
is not a descriptor of an objective response; it is a reason for stopping study therapy.  

 
 
Appendix 4  
Response Evaluation Criteria in Solid Tumors (RECIST):  
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
141/Protocol YO29449, Version 3 
 
The objective response status of such patients is to be determined by evaluation of 
target and non-target disease as shown in Table 1−Table 3. 
For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic 
changes, or necrosis in existing lesions), treatment may continue until the 
next scheduled assessment.  If, at the next scheduled assessment, progression is 
confirmed, the date of progression should be the earlier date when progression was 
suspected. 
In studies for which patients with advanced disease are eligible (i.e., primary disease is 
still present or partially present), the primary tumor should also be captured as a target 
or non-target lesion, as appropriate.  This is to avoid an incorrect assessment of CR if 
the primary tumor is still present but not evaluated as a target or non-target lesion. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
142/Protocol YO29449, Version 3 
 
Appendix 5  
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication 
Selected sections from the manuscript by Wen et al. (2010)1 describing the Response 
Assessment in Neuro-Oncology (RANO) criteria are presented below, with slight 
modifications to the original text and the addition of explanatory text as needed for 
clarity. 
In 2010, the Response Assessment in Neuro-Oncology Working Group (RANO) 
published its consensus recommended criteria for evaluation of treatment in high-grade 
gliomas (Wen et al. 2010).  These criteria offered an improvement over the frequently 
adopted Macdonald criteria (Macdonald et al. 19902), based primarily on 
contrast-enhanced imaging (magnetic resonance imaging [MRI] or computed 
tomography [CT]) and the two-dimensional World Health Organization (WHO) oncology 
response criteria using enhancing tumor area (the product of the maximal cross-
sectional enhancing diameters) as the primary tumor measure.  The RANO criteria 
mitigate some risks of false positive/negative response particularly those associated with 
anti-angiogenic therapies.  The RANO criteria will be used in the current trial to assess 
tumor response. 
Specific lesions must be evaluated serially, and comparative analysis of changes in the 
area of contrast enhancement, as well as the non-enhancing component, should be 
performed.  As with the Macdonald Criteria (Macdonald et al. 1990), the product of the 
maximal cross-sectional enhancing diameters will be used to determine the size of the 
contrast-enhancing lesions. 
MEASUREABLE AND NON-MEASURABLE DISEASE FOR 
CONTRAST-ENHANCING LESIONS 
Measurable disease is defined as bi-dimensionally contrast-enhancing lesions with 
clearly defined margins by MRI scan, with two perpendicular diameters of at least 
10 mm, visible on two or more axial slices that are preferably, at most, 5 mm apart with 
0-mm skip.  As with Response Evaluation Criteria in Solid Tumors (RECIST), Version 
1.1, in the event the MRI is performed with thicker slices, the size of a measurable lesion 
at baseline should be 2 times the slice thickness.  In the event there are interslice gaps, 
this also needs to be considered in determining the size of measurable lesions at 
baseline.  Measurement of tumor around a cyst or surgical cavity represents a 
particularly difficult challenge.  Such lesions should be considered non-measurable 
unless there is a nodular component measuring ≥ 10 mm in diameter.  The cystic or 
surgical cavity should not be measured in determining response. 
1 
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for 
high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 
2010;28:1963–72. 
2 
Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies 
of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80. 
 

 
 
Appendix 5  
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
143/Protocol YO29449, Version 3 
 
Non-measurable disease is defined as either uni-dimensionally measurable lesions, 
masses with margins not clearly defined, or lesions with maximum perpendicular 
diameters of < 10 mm.  Patients with measurable disease are required for study eligibility 
in Stage 2. 
NUMBER OF LESIONS 
If there are multiple contrast-enhancing lesions, a minimum of the two largest lesions 
should be measured, and the sum of the products of the perpendicular diameters of 
these lesions should be determined, similar to the criteria proposed for systemic tumors 
in RECIST, v1.1.  However, given the heterogeneity of high-grade gliomas and the 
difficulty in measuring some lesions, a maximum of five of the largest lesions may be 
measured.  In general, the largest enlarging lesion(s) should be selected.  However, 
emphasis should also be placed on lesions that allow reproducible repeated 
measurements.  Occasionally, the largest lesions may not lend themselves to 
reproducible measurements, and the next largest lesions that can be measured 
reproducibly should be selected. 
For patients with recurrent disease who have multiple lesions of which only one or two 
are increasing in size, the enlarging lesions will be considered the target lesions for 
evaluation of response.  The other lesions will be considered non-target lesions and 
should also be recorded. Rarely, unequivocal progression of a non-target lesion 
requiring discontinuation of therapy or development of a new contrast-enhancing lesion 
may occur, even in the setting of stable disease or partial response in the target lesions.  
These changes will qualify as progression. 
About 20%–30% of patients develop pseudoprogression after chemoradiotherapy, 
especially within the first 3 months after completion of radiotherapy.  Given the difficulty 
of differentiating pseudoprogression from true progression in the first 12 weeks after 
irradiation, such patients will be excluded from the clinical trial. 
Patients are required to have a 25% increase in the sum of the products of the 
perpendicular diameters of the contrast-enhancing lesions, while on stable or increasing 
doses of corticosteroids, before they are considered to have progressive disease and 
are entered into a clinical trial for recurrent/progressive disease.  Patients with new 
contrast-enhancing non-measurable disease may be considered for clinical trials in 
which progression-free survival (PFS) is the primary endpoint.  Clinical deterioration or 
increase in corticosteroid dosing alone would not be sufficient to indicate progressive 
disease for entry in clinical studies. 

 
 
Appendix 5  
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
144/Protocol YO29449, Version 3 
 
A particularly difficult problem involves patients receiving first-line anti-angiogenic agents 
who develop predominantly non-enhancing disease at progression.  This can be difficult 
to differentiate from treatment effects.  If it seems clear that the non-enhancing changes 
represent tumor progression, these patients would also be eligible for enrollment in 
clinical trials for recurrent disease, although their tumor will be considered 
non-measurable.  As noted previously, although it would be preferable to have a more 
objective measure of progressive non-enhancing recurrent disease similar to 
contrast-enhancing disease, the RANO Working Group felt that this was not possible at 
present given the limitations of current technology. 
Radiographic response should be determined in comparison to the tumor measurement 
obtained at pretreatment baseline for determination of response, and the smallest tumor 
measurement either at pretreatment baseline or after initiation of therapy should be used 
for determination of progression.  Criteria for radiographic changes after therapy are 
listed below.  In the event that the radiographic changes are equivocal and it is unclear 
whether the patient is stable or has developed progressive disease, it is permissible to 
continue treatment and observe the patient closely, for example at 4-week intervals. 
If subsequent imaging studies demonstrate that progression has occurred, the date of 
progression should be the date of the scan at which this issue was first raised.  The 
determination of radiographic response after treatment with agents, such as 
anti-angiogenic therapies, that affect vascular permeability is particularly difficult. 
In these patients, consideration should be given to performing a second scan at 4 weeks 
to confirm the presence of response or stable disease. 
DETERMINATION OF FIRST PROGRESSION 
RANO criteria for determination of first progression are summarized in Table 11.  
Standard therapy for glioblastoma involves maximal safe tumor resection followed by 
radiotherapy with concurrent and adjuvant temozolomide.  Approximately 20%−30% of 
patients undergoing their first post-radiation MRI show increased contrast enhancement 
that eventually subsides without any change in therapy.  This phenomenon, termed 
pseudoprogression, likely results from transiently increased permeability of the tumor 
vasculature from irradiation, which may be enhanced by temozolomide, and complicates 
the determination of tumor progression immediately after completion of radiotherapy.  
Pseudoprogression may be accompanied by progressive clinical signs and symptoms 
and seems to be more frequent in patients with a methylated MGMT gene promoter. 
This treatment-related effect has implications for patient management and may result in 
premature discontinuation of effective adjuvant therapy.  This limits the validity of a PFS 

 
 
Appendix 5  
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
145/Protocol YO29449, Version 3 
 
endpoint unless tissue-based confirmation of tumor progression is obtained. It also has 
significant implications for selecting appropriate patients for participation in clinical trials 
for recurrent gliomas.  Failure to exclude patients with pseudoprogression from these 
studies will result in a falsely high response rate and PFS and the possibility that an 
agent will be incorrectly considered to be active. To address this issue, the RANO criteria 
provides that within the first 12 weeks of completion of radiotherapy, when 
pseudoprogression is most prevalent, progression can only be determined if the majority 
of the new enhancement is outside of the radiation field (for example, beyond the 
high-dose region or 80% isodose line) or if there is pathologic confirmation of 
progressive disease (see Table 11).  It is recognized that the proposed histologic criteria 
have important limitations, but they provide guidance on the type of findings that are 
suggestive of progressive disease.  For patients in whom pseudoprogression cannot be 
differentiated from true tumor progression, enrollment into trials for recurrent gliomas 
should not be permitted.  Patients who remain clinically stable and/or are suspected to 
have pseudoprogression based on metabolic or vascular imaging should continue with 
their current therapy. 

 
 
Appendix 5  
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
146/Protocol YO29449, Version 3 
 
Table 11 Criteria for Determining First Progression Depending on Time 
from Initial Chemoradiotherapy  
 First Progression 
Definition 
Progressive disease 
< 12 weeks after 
completion of 
chemoradiotherapy 
Progression can only be defined using diagnostic imaging if there is new 
enhancement outside of the radiation field (beyond the high-dose region or 
80% isodose line) or if there is unequivocal evidence of viable tumor on 
histopathologic sampling (e.g., solid tumor areas [i.e., > 70% tumor cell nuclei in 
areas], high or progressive increase in MI2-A proliferation index compared with 
prior biopsy, or evidence for histologic progression or increased anaplasia in 
tumor).  Note:  Given the difficulty of differentiating true progression from 
pseudoprogression, clinical decline alone, in the absence of radiographic or 
histologic confirmation of progression, will not be sufficient for definition of 
progressive disease in the first 12 weeks after completion of concurrent 
chemoradiotherapy. 
Progressive disease 
≥ 12 weeks after 
chemoradiotherapy 
completion 
1.  New contrast-enhancing lesion outside of radiation field on decreasing, 
stable, or increasing doses of corticosteroids. 
2.  Increase by ≥ 25% in the sum of the products of the perpendicular diameters 
between the first post-radiotherapy scan, or a subsequent scan with smaller 
tumor size, and the scan at 12 weeks or later on stable or increasing doses of 
corticosteroids. 
3.  Clinical deterioration not attributable to concurrent medication or co-morbid 
conditions is sufficient to declare progression on current treatment but not for 
entry into a clinical trial for recurrence. 
4.  For patients receiving anti-angiogenic therapy, significant increase in 
T2/FLAIR non-enhancing lesion may also be considered progressive disease. 
The increased T2/FLAIR must have occurred with the patient on stable or 
increasing doses of corticosteroids compared with baseline scan or best 
response after initiation of therapy and must not be a result of co-morbid events 
(e.g., effects of radiation therapy, demyelination, ischemic injury, infection, 
seizures, postoperative changes, or other treatment effects). 
FLAIR = fluid-attenuated inversion recovery. 
 
RESPONSE ASSESSMENT 
Criteria for response assessment are summarized in Table 12.  All measurable and 
non-measurable lesions should be assessed using the same techniques as at baseline. 
All patients should be imaged on the same MRI scanner, or at least with the same 
magnet strength, for the duration of the study to reduce difficulties in interpreting 
changes. 

 
 
Appendix 5  
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
147/Protocol YO29449, Version 3 
 
Table 12 Summary of RANO Response Criteria 
 
CR 
PR 
SD 
PD 
T1 gadolinium enhancing disease 
None 
≥ 50% ↓ 
< 50% ↓ but 
< 25% ↑ 
≥ 25% ↑ 
T2/FLAIR 
Stable or ↓ 
Stable or ↓ 
Stable or ↓ 
↑ 
a 
New lesion 
None 
None 
None 
Present a 
Corticosteroids 
None 
Stable or ↓ 
Stable or ↓ 
NA b 
Clinical status 
Stable or ↑ 
Stable or ↑ 
Stable or ↑ 
↑ 
a 
Requirement for response 
All 
All 
All 
Any a 
↓ = decreased; ↑ = increased; CR = complete response; FLAIR = fluid-attenuated inversion 
recovery; NA = not applicable; PD = progressive disease; PR = partial response; RANO = Response 
Assessment in Neuro-Oncology; SD = stable disease. 
a Progression occurs when this criterion is present. 
b Increase in corticosteroids alone will not be taken into account in determining progression in 
the absence of persistent clinical deterioration. 
 
COMPLETE RESPONSE 
Complete response requires all of the following:  complete disappearance of all 
enhancing measurable and non-measurable disease sustained for at least 4 weeks; no 
new lesions; stable or improved non-enhancing (T2/fluid-attenuated inversion recovery 
[FLAIR]) lesions; and the patient must be off corticosteroids or on physiologic 
replacement doses only, and stable or improved clinically.  In the absence of a 
confirming scan 4 weeks later, this response will be considered only stable disease. 
PARTIAL RESPONSE 
Partial response requires all of the following:  ≥ 50% decrease, compared with baseline, 
in the sum of the products of the perpendicular diameters of all measurable enhancing 
lesions sustained for at least 4 weeks; no progression of non-measurable disease; no 
new lesions; stable or improved non-enhancing (T2/FLAIR) lesions on same or lower 
dose of corticosteroids compared with baseline scan; and the patient must be on a 
corticosteroid dose not greater than the dose at the time of the baseline scan, and stable 
or improved clinically.  In the absence of a confirming scan 4 weeks later, this response 
will be considered only stable disease. 

 
 
Appendix 5  
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
148/Protocol YO29449, Version 3 
 
STABLE DISEASE 
Stable disease occurs if the patient does not qualify for complete response, partial 
response, or progression (see next section) and requires the following:  stable 
non-enhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared 
with baseline scan and clinically stable status.  In the event that the corticosteroid dose 
was increased for new symptoms and signs without confirmation of disease progression 
on neuroimaging, and subsequent follow-up imaging shows that this increase in 
corticosteroids was required because of disease progression, the last scan considered 
to show stable disease will be the scan obtained when the corticosteroid dose was 
equivalent to the baseline dose. 
PROGRESSION 
Progression is defined by any of the following:  ≥ 25% increase in the sum of the 
products of the perpendicular diameters of all enhancing lesions (compared with the 
smallest tumor measurement either at baseline [pretreatment] or after initiation of 
therapy [i.e., compared with baseline if no decrease]) on stable or increasing doses of 
corticosteroids; a significant increase in T2/FLAIR non-enhancing lesions on stable or 
increasing doses of corticosteroids compared with baseline scan or best response after 
initiation of therapy, not due to co-morbid events; the appearance of any new lesions; 
clear progression of non-measurable lesions; or definite clinical deterioration not 
attributable to other causes apart from the tumor, or to a decrease in corticosteroid dose. 
Failure to return for evaluation as a result of death or deteriorating condition should also 
be considered as progression. 
Increase in corticosteroid dose alone, in the absence of clinical deterioration related to 
tumor, will not be used as a determinant of progression.  Patients with stable imaging 
studies whose corticosteroid dose was increased for reasons other than clinical 
deterioration related to tumor do not qualify for stable disease or progression.  Such 
patients should be observed closely.  If their corticosteroid dose can be reduced back to 
baseline, they will be considered as having stable disease; if further clinical deterioration 
related to tumor becomes apparent, they will be considered to have progression.  The 
date of progression should be the first timepoint at which corticosteroid increase was 
necessary. 
The definition of clinical deterioration is left to the discretion of the treating physician, 
but it is recommended that a decline in Karnofsky Performance Status from 
100 or 90 to 70 or less, a decline in Karnofsky Performance Status of at least 20 from 
80 or less, or a decline in Karnofsky Performance Status from any baseline to 50 or less, 

 
 
Appendix 5  
Response Assessment in Neuro-Oncology (RANO): 
Modified Excerpt from Original Publication (cont.) 
Alectinib—F. Hoffmann-La Roche Ltd 
149/Protocol YO29449, Version 3 
 
for at least 7 days, be considered neurologic deterioration unless attributable to 
co-morbid events or changes in corticosteroid dose.  Similarly, a decline in the Eastern  
Cooperative Oncology Group and WHO performance scores from 0 or 1 to 2 or from 
2 to 3 would be considered neurologic deterioration. 
Patients with non-measurable enhancing disease whose lesions have significantly 
increased in size and become measurable (minimum bi-directional diameter of ≥ 10 mm 
and visible on at least two axial slices that are preferably, at most, 5 mm apart with 
0-mm skip) will also be considered to have experienced progression.  The transition from 
a non-measurable lesion to a measurable lesion resulting in progression can 
theoretically occur with relatively small increases in tumor size (e.g., a 9 × 9 mm lesion 
[non-measurable] increasing to a 10 × 11 mm lesion [measurable]).  Ideally, the change 
should be significant ≥ 5 mm increase in maximum diameter or ≥ 25% increase in the 
sum of the products of the perpendicular diameters of enhancing lesions).  In general, if 
there is doubt about whether the lesion has progressed, continued treatment and close 
follow-up evaluation will help clarify whether there is true progression. 
If there is uncertainty regarding whether there is progression, the patient may continue 
on treatment and remain under close observation (e.g., evaluated at 4-week intervals).  
If subsequent evaluations suggest that the patient is in fact experiencing progression, 
the date of progression should be the timepoint at which this issue was first raised. For 
multifocal lesions, progressive disease is defined as a ≥ 25% increase in the sum of the 
products of the perpendicular diameters of all measurable lesions compared with the 
smallest tumor measurements either at baseline or after initiation of therapy Table 12).  
The appearance of a new lesion or unequivocal progression of non-target lesions will 
also be considered progression.  Partial response is defined as a ≥ 50% decrease, 
compared with baseline, in the sum of the products of the perpendicular diameters of all 
measurable lesions sustained for at least 4 weeks with stable or decreasing 
corticosteroid doses. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
150/Protocol YO29449, Version 3 
 
Appendix 6  
Eastern Cooperative Oncology Group Performance Status Scale 
Grade 
Description 
0 
Fully active, able to carry on all pre-disease performance without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature (e.g., light housework or office work) 
2 
Ambulatory and capable of all self-care but unable to carry out any work activities.  
Up and about > 50% of waking hours 
3 
Capable of only limited self-care, confined to a bed or chair > 50% of waking hours 
4 
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or 
chair 
5 
Dead 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
151/Protocol YO29449, Version 3 
 
Appendix 7  
EORTC Quality-of-Life Questionnaire−Core 30 
 
 
EORTC QLQ-C30 (version 3) 
We are interested in some things about you and your health.  Please answer all of the 
questions yourself by circling the number that best applies to you.  There are no "right" 
or "wrong" answers.  The information that you provide will remain strictly confidential. 
Please fill in your initials: 
 
Your birthdate (Day, Month, Year): 
 
Today's date (Day, Month, Year):  31 
 
________________________________________________________________ 
 
 
Not at         A        Quite      Very 
All             Little     a Bit     Much 
 
1.  Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase?                             
1 
2 
3 
4 
2.  Do you have any trouble taking a long walk?                                     
1 
2 
3 
4 
3.  Do you have any trouble taking a short walk outside of the house?   
1 
2 
3 
4 
4.  Do you need to stay in bed or a chair during the day?                          1 
2 
3 
4 
5.  Do you need help with eating, dressing, washing 
yourself or using the toilet?                                                                   
1 
2 
3 
4 
During the past week: 
6.  Were you limited in doing either your work or other daily activities?     1 
2 
3 
4 
7.  Were you limited in pursuing your hobbies or other 
leisure time activities?                                                                          
1 
2 
3 
4 
8.  Were you short of breath?                                                                    
1 
2 
3 
4 
9.  Have you had pain?                                                                               1 
2 
3 
4 
10.  Did you need to rest?                                                                          
1 
2 
3 
4 
11.  Have you had trouble sleeping?                                                         
1 
2 
3 
4 
12.  Have you felt weak?                                                                            1 
2 
3 
4 
13.  Have you lacked appetite?                                                                   1 
2 
3 
4 
14.  Have you felt nauseated?                                                                     1 
2 
3 
4 
15.  Have you vomited?                                                                               1 
2 
3 
4 
16.  Have you been constipated?                                                                  1 
2 
3 
4 

 
 
Appendix 7  
EORTC Quality-of-Life Questionnaire−Core 30 (cont.) 
 
Alectinib—F. Hoffmann-La Roche Ltd 
152/Protocol YO29449, Version 3 
 
Please go on to the next page 
During the past week: 
Not at       A        Quite     Very 
All           Little     a Bit     Much 
17.  Have you had diarrhea?  
1 
2 
3 
4 
18.  Were you tired? 
1 
2 
3 
4 
19.  Did pain interfere with your daily activities? 
1 
2 
3 
4 
20.  Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 
1 
2 
3 
4 
21.  Did you feel tense? 
1 
2 
3 
4 
22.  Did you worry? 
1 
2 
3 
4 
23.  Did you feel irritable? 
1 
2 
3 
4 
24.  Did you feel depressed?  
1 
2 
3 
4 
25.  Have you had difficulty remembering things? 
1 
2 
3 
4 
26.  Has your physical condition or medical treatment 
interfered with your family life? 
1 
2 
3 
4 
27.  Has your physical condition or medical treatment 
interfered with your social activities? 
1 
2 
3 
4 
28.  Has your physical condition or medical treatment 
caused you financial difficulties? 
1 
2 
3 
4 
For the following questions please circle the number between 1 and 7 that best applies to you 
29.  How would you rate your overall health during the past week? 
 
1 
2 
3 
4 
5 
6 
7 
        Very poor 
Excellent 
30.  How would you rate your overall quality of life during the past week? 
 
1 
2 
3 
4 
5 
6 
7 
        Very poor 
Excellent 
 
 Copyright 1995 EORTC Quality of Life Group.  All rights reserved.  Version 3.0 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
153/Protocol YO29449, Version 3 
 
Appendix 8  
EORTC Quality-of-Life Questionnaire−Lung Cancer 13 Module 
ENGLISH 
 
 
EORTC QLQ - LC13 
Patients sometimes report that they have the following symptoms or problems.  
Please indicate the extent to which you have experienced these symptoms or 
problems during the past week.  Please answer by circling the number that best 
applies to you. 
 
During the past week: 
Not at           A        Quite       Very 
  All           Little      a Bit       Much 
 
31.     How much did you cough? 
 1 
2 
3 
4 
 
32.     Did you cough up blood? 
 1 
2 
3 
4 
 
33.     Were you short of breath when you rested?  
 1 
2 
3 
4 
 
34.     Were you short of breath when you walked?  
 1 
2 
3 
4 
 
35.     Were you short of breath when you climbed stairs?  
 1 
2 
3 
4 
 
36.     Have you had a sore mouth or tongue?  
 1 
2 
3 
4 
 
37.     Have you had trouble swallowing? 
 1 
2 
3 
4 
38.     Have you had tingling hands or feet? 
 1 
2 
3 
4 
39.     Have you had hair loss?  
 1 
2 
3 
4 
 
40.     Have you had pain in your chest? 
 1 
2 
3 
4 
 
41.     Have you had pain in your arm or shoulder? 
 1 
2 
3 
4 
 
42.     Have you had pain in other parts of your body? 
 1 
2 
3 
4 
If yes, where_____________________________ 
43.     Did you take any medicine for pain? 
 
1              No                                2             Yes 
 
If yes, how much did it help?  
 1 
2 
3 
4 
 
 
 
 QLQ-C30-LC13 Copyright 1994 EORTC Quality of life Group.  All rights reserved 

 
Alectinib—F. Hoffmann-La Roche Ltd 
154/Protocol YO29449, Version 3 
 
Appendix 9  
Modification of Diet in Renal Disease Formula 
The estimated glomerular filtration rate (eGFR) will be calculated on the basis of the 
following formula: 
eGFR [mL/min/1.73 m
2] = 175 × serum creatinine − 1.154
 × AGE − 0.203 [× 0.742 if female] 
[× 1.212 if African American] (conventional units) 
Where SCRT = serum creatinine in conventional units (i.e., mg/dL), the following 
conversion factor should be used in case the serum creatinine value is provided by the 
laboratory in µmol/L units: 
Serum creatinine [mg/dL] = Serum creatinine [μmol/L] × 0.0113 
 
Reference:  Miller WG. Estimating glomerular filtration rate. Clin Chem Lab Med 
2009;47:1017−9 
Heil W., Koberstein R, Zawta B. Reference Ranges for Adults and Children−Pre-
Analytical Considerations. Roche Diagnostics GmbH 2014, 8th edition, p.159 
.

 
Alectinib—F. Hoffmann-La Roche Ltd 
155/Protocol YO29449, Version 3 
 
Appendix 10  
Anaplastic Lymphoma Kinase Immunohistochemistry 
Overview 
The VENTANA anti-anaplastic lymphoma kinase (ALK) (D5F3) Rabbit Monoclonal 
Primary Antibody (VENTANA anti-ALK [D5F3]; catalog reference number 790-4794) 
immunohistochemistry (IHC) assay will be used to determine ALK IHC status and to 
select patients with positive ALK for enrollment in Study Y029449.  The anti-ALK (D5F3) 
rabbit monoclonal antibody IHC assay is currently being developed by Ventana Medical 
Systems as a companion diagnostic to Roche’s ALK inhibitor, alectinib.  For 
Study YO29449, the VENTANA anti-ALK (D5F3) assay will be used for investigational 
purposes only. 
VENTANA anti-ALK (D5F3) is intended for laboratory use in the detection of the ALK 
protein in formalin-fixed, paraffin-embedded (FFPE) non−small cell lung cancer (NSCLC) 
tissue stained with use of a VENTANA automated slide stainer.  It is indicated as an aid 
in identifying patients eligible for treatment with alectinib. 
Device Description 
The VENTANA anti-ALK (D5F3) IHC assay is an automated IHC staining assay system 
comprising a pre-diluted, ready to-use anti-ALK (D5F3) rabbit monoclonal primary 
antibody, the BenchMark automated slide staining platform, OptiView DAB detection kit, 
OptiView Amplification kit, Rabbit Monoclonal Negative Control Ig, and VENTANA 
anti-ALK 2-in-1 cell line control slides or other appropriate system run control. 
Scoring System 
The IHC scoring system evaluates specific VENTANA anti-ALK (D5F3) staining in 
NSCLC tumor cells by the presence of a strong, granular, cytoplasmic staining pattern.  
Pathologists must rely on the Negative Reagent Control (NRC) slides to distinguish 
non-specific staining from specific ALK positivity.  Samples must be assessed for 
morphological damage and the presence of viable tumor versus necrosis.  Light, 
granular, cytoplasmic stippling in alveolar macrophages may occur on anti-ALK (D5F3) 
and/or NRC slides as an artifact of the detection system.  This staining artifact should be 
noted on the Slide Evaluation Form comment field but should NOT be interpreted as 
ALK-positive staining.  Some background staining has also been observed on normal 
mucosa in NSCLC specimens, as well as in necrotic tumor areas; this staining also 
should not be interpreted as ALK-positive staining.  Case slide sets failing to show 
specific staining of the case tissue with VENTANA anti-ALK (D5F3) cannot be 
considered ALK-positive.  Refer to VENTANA ALK Scoring Interpretation Guide for 
NSCLC for additional information. 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
156/Protocol YO29449, Version 3 
Appendix 11  
Formulae for the Calculation of QTcF and RR 
 
QtcF − Fridericia’s correction for QTc measurement (if not provided directly by the ECG 
machine): 
 
RR Interval Formula (if not provided directly by the ECG machine): 
RR (ms) = 60000/heart rate (bpm) 
 

 
Alectinib—F. Hoffmann-La Roche Ltd 
157/Protocol YO29449, Version 3 
 
Appendix 12  
FoundationOne Gene Panel 
Genes 
 
 
 
 
 
 
 
 
 
ABL1 
BRAF 
CHEK1 
FANCC 
GATA3 
JAK2 
MITF 
PDCD1LG2 
RBM10 
STAT4 
ABL2 
BRCA1 
CHEK2 
FANCD2 
GATA4 
JAK3 
MLH1 
PDGFRA 
RET 
STK11 
ACVR1B 
BRCA2 
CIC 
FANCE 
GATA6 
JUN 
MPL 
PDGFRB 
RICTOR 
SUFU 
AKT1 
BRD4 
CREBBP 
FANCF 
GID4 
KAT6A 
MRE11A 
PDK1 
RNF43 
SYK 
AKT2 
BRIP1 
CRKL 
FANCG 
GLI1 
KDM5A 
MSH2 
PIK3C2B 
ROS1 
TAF1 
AKT3 
BTG1 
CRLF2 
FANCL 
GNA11 
KDM5C 
MSH6 
PIK3CA 
RPTOR 
TBX3 
ALK 
BTK 
CSF1R 
FAS 
GNA13 
KDM6A 
MTOR 
PIK3CB 
RUNX1 
TERC 
AMER1 
C11orf30 
CTCF 
FAT1 
GNAQ 
KDR 
MUTYH 
PIK3CG 
RUNX1T1 
TERT 
APC 
CARD11 
CTNNA1 
FBXW7 
GNAS 
KEAP1 
MYV 
PIK3R1 
SDHA 
TET2 
AR 
CBFB 
CTNNB1 
FGF10 
GPR124 
KEL 
MYCL 
PIK3R2 
SDHB 
TGFBR2 
ARAF 
CBL 
CUL3 
FGF14 
GRIN2A 
KIT 
MYCN 
PLCG2 
SDHC 
TNFAIP3 
ARFRP1 
CCND1 
CYLD 
FGF19 
GRM3 
KLHL6 
MYD88 
PMS2 
SDHD 
TNFRSF14 
ARID1A 
CCND2 
DAXX 
FGF23 
GSK3B 
KMT2A 
NF1 
POLD1 
SETD2 
TOP1 
ARID1B 
CCND3 
DDR2 
FGF3 
H3F3A 
KMT2C 
NF2 
POLE 
SF3B1 
TOP2A 
ARID2 
CCNE1 
DICER1 
FGF4 
HGF 
KMT2D 
NFE2L2 
PPP2R1A 
SLIT2 
TP53 
ASXL1 
CD274 
DNMT3A 
FGF6 
HNF1A 
KRAS 
NFKBIA 
PRDM1 
SMAD2 
TSC1 
ATM 
CD79A 
DOT1L 
FGFR1 
HRAS 
LMO1 
NKX2-1 
PREX2 
SMAD3 
TSC2 
ATR 
CD79B 
EGFR 
FGFR2 
HSD3B1 
LRP1B 
NOTCH1 
PRKAR1A 
SMAD4 
TSHR 
ATRX 
CDC73 
EP300 
FGFR3 
HSP90AA1 
LYN 
NOTCH2 
PRKCI 
SMARCA4 
U2AF1 
AURKA 
CDH1 
EPHA3 
FGFR4 
IDH1 
LZTR1 
NOTCH3 
PRKDC 
SMARCB1 
VEGFA 
AURKB 
CDK12 
EPHA5 
FH 
IDH2 
MAGI2 
NPM1 
PRSS8 
SMO 
VHL 

 
Alectinib—F. Hoffmann-La Roche Ltd 
158/Protocol YO29449, Version 3 
 
Appendix 12  
FoundationOne Gene Panel (cont.) 
AXIN1 
CDK4 
EPHA7 
FLCN 
IGF1R 
MAP2K1 
NRAS 
PTCH1 
SNCAIP 
WISP3 
AXL 
CDK6 
EPHB1 
FLT1 
IGF2 
MAP2K2 
NSD1 
PTEN 
SOCS1 
WT1 
BAP1 
CDK8 
ERBB2 
FLT3 
IKBKE 
MAP2K4 
NTRK1 
PTPN11 
SOX10 
XPO1 
BARD1 
CDKN1A 
ERBB3 
FLT4 
IKZF1 
MAP3K1 
NTRK2 
QKI 
SOX2 
ZBTB2 
BCL2 
CDKN1B 
ERBB4 
FOXL2 
IL7R 
MCL1 
NTRK3 
RAC1 
SOX9 
ZNF217 
BCL2L1 
CDKN2A 
ERG 
FOXP1 
INHBA 
MDM2 
NUP93 
RAD50 
SPEN 
ZNF703 
BCL2L2 
CDKN2B 
ERRFI1 
FRS2 
INPP4B 
MDM4 
PAK3 
RAD51 
SPOP 
 
BCL6 
CDKN2C 
ESR1 
FUBP1 
IRF2 
MED12 
PALB2 
RAF1 
SPTA1 
 
BCOR 
CEBPA 
EZH2 
GABRA6 
IRF4 
MEF2B 
PARK2 
RANBP2 
SRC 
 
BCORL1 
CHD2 
FAM46C 
GATA1 
IRS2 
MEN1 
PAX5 
RARA 
STAG2 
 
BLM 
CHD4 
FANCA 
GATA2 
JAK1 
MET 
PBRM1 
RB1 
STAT3 
 
Rearrangements 
 
 
 
 
 
 
 
 
ALK 
BRAF 
BRD4 
ETV4 
FGFR1 
KIT 
MYC 
NTRK2 
RARA 
TMPRSS2 
BCL2 
BRCA1 
EGFR 
ETV5 
FGFR2 
MSH2 
NOTCH2 
PDGFRA 
RET 
 
BCR 
BRCA2 
ETV1 
ETV6 
FGFR3 
MYB 
NTRK1 
RAF1 
ROS1